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LAY SUMMARY OF THESIS 
The link between vitamin D concentrations and various conditions and diseases has 
been assessed in a large and rapidly expanding literature. Although vitamin D can be 
synthesized in the skin with sun exposure, vitamin D deficiency is of high prevalence 
worldwide. It is estimated that around 1 billion people worldwide suffer from vitamin 
D deficiency or insufficiency. This led to intensive research activity in relation to 
vitamin D and multiple health outcomes.  
 
Existing evidence from previous studies is largely inconclusive. Therefore, in this 
thesis, I would like to explore the link between genetically determined vitamin D and 
the whole spectrum of health outcomes using a large study, called the UK Biobank. 
 
In this study, I first studied whether 6 genetic variants, which were found to be 
relevant to vitamin D level, were linked to all health outcomes. Then I explored 
whether vitamin D level could impact nine health outcomes biologically, including 
systolic blood pressure, diastolic blood pressure, body mass index, risk of 
hypertension, type 2 diabetes, ischemic heart disease, depression, non-vertebral 
fracture and all-cause mortality. Given the large sample size of UK Biobank we 
would be able to observe links between vitamin D and common diseases. When 
individual genetic mutations affecting vitamin D were tested, only one was found to 
be linked to calculus outcomes. Beyond that, in this study I did not find any 
moderate to large effect of vitamin D on any of the nine outcomes. Thus, my study 
did not support the hypothesis that vitamin D plays a role in any health outcomes. 
Further studies of even larger size are needed to explore whether smaller effects of 







Vitamin D status is an important public health issue due to the high prevalence of 
vitamin D insufficiency and deficiency, especially in high latitude areas. Furthermore, 
it has been reported to be associated with a number of diseases. In a previous umbrella 
review of meta-analyses of randomized clinical trials (RCTs) and of observational 
studies, it was found that plasma/ serum 25-hydroxyvitamin D (25(OH)D) or 
supplemental vitamin D has been linked to more than 130 unique health outcomes. 
However, the majority of the studies yielded conflicting results and no association was 
convincing. 
 
Aim and Objectives 
The aim of my PhD was to comprehensively explore the association between vitamin 
D and multiple outcomes. The specific objectives were to: 1) update the umbrella 
review of meta-analysis of observational studies or randomized controlled trials on 
associations between vitamin D and health outcomes published between 2014 and 
2018; 2) conduct a systematic literature review of previous Mendelian Randomization 
studies on causal associations between vitamin D and all outcomes; 3) conduct a 
systematic literature review of published phenome wide association studies, 
summarizing the methods, results and predictors; 4) create a polygenic risk score of 
vitamin D related genetic variants, weighted by their effect estimates from the most 
recent genome wide association study; 5) encode phenotype groups based on 
electronic medical records of participants; 6) study the associations between vitamin 
D related SNPs and the whole spectrum of health outcomes, defined by electronic 
medical records utilising the UK Biobank study; 7) explore the causal effect of 25-




First I updated the vitamin D umbrella review published in 2015, by summarizing the 
evidence from meta-analyses of observational studies and meta-analyses of RCTs 
published between 2014 and 2018. I also performed a systematic literature review of 

 
all previous Mendelian Randomizations studies on the effect of vitamin D on all health 
outcomes, as well as a systematic review of all published PheWAS studies and the 
methodology they applied. Then I conducted original data analysis in a large 
prospective population-based cohort, the UK Biobank, which includes more than 
500,000 participants. A 25(OH)D genetic risk score (weighted sum score of 6 serum 
25(OH)D-related SNPs: rs3755967, rs12785878, rs10741657, rs17216707, 
rs10745742 and rs8018720, as identified by the largest genome wide association study 
of 25(OH)D levels) was constructed to be used as the instrumental variable. I used a 
phenotyping algorithm to code the electronic medical records (EMR) of UK Biobank 
participants into 1853 distinct disease categories and I then ran the PheWAS analysis 
to test the associations between the 25(OH)D genetic risk score and 950 disease 
outcome groups (i.e. outcomes with more than 200 cases). For phenotypes found to 
show a statistically significant association with 25(OH)D levels in the PheWAS or 
phenotypes which were found to be convincing or highly suggestive in previous 
studies, I developed an extended case definition by incorporating self-reported data 
collected by UK Biobank baseline questionnaire and interview. The possible causal 
effect of vitamin D on those outcomes was then explored by the MR two-stage method, 




In the updated systematic literature review of meta-analyses of observational studies 
or RCTs, only studies on new outcomes which had not been covered by the previous 
umbrella review were included. A total of 95 meta-analyses met the inclusion criteria. 
Among the included studies there were 66 meta-analyses of observational studies, and 
29 meta-analyses of RCTs. Eighty-five new outcomes were explored by meta-analyses 
of observational studies, and 59 new outcomes were covered by meta-analyses of 
RCTs.  
 
In the systematic review of published Mendelian Randomization studies on vitamin D, 
a total of 29 studies were included. A causal role of 25(OH)D level was supported by 
MR analysis for the following outcomes: type 2 diabetes, total adiponectin, diastolic 

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blood pressure, risk of hypertension, multiple sclerosis, Alzheimer’s disease, all-cause 
mortality, cancer mortality, mortality excluding cancer and cardiovascular events, 
ovarian cancer, HDL-cholesterol, triglycerides and cognitive functions. 
 
For the systematic literature review of published PheWAS studies and their 
methodology, a total of 45 studies were included. The processes for implementing a 
PheWAS study include the following steps: sample selection, predictor selection, 
phenotyping, statistical analysis and result interpretation. One of the main challenges 
is the definitions of the phenotypes (i.e., the method of binning participants into 
different phenotype groups). In the phenotyping step, an ICD curated phenotyping was 
widely used by previous PheWAS, which I also used in my own analysis.  
By applying the ICD curated phenotyping, 1853 phenotype groups were defined in the 
participants I used. In PheWAS, only phenotype groups with more than 200 cases were 
analysed (920 phenotypes). In the PheWAS, only associations between rs17216707 
(CYP24A1) and “calculus of ureter” (beta = -0.219, se = 0.045, P = 1.14*10-6), “urinary 
calculus” (beta = -0.129, se = 0.027, P = 1.31*10-6), “alveolar and parietoalveolar 
pneumonopathy” (beta = 0.418, se = 0.101, P = 3.53*10-5) survived Bonferroni 
correction.  
 
Nine outcomes, including systolic blood pressure, diastolic blood pressure, body mass 
index, risk of hypertension, type 2 diabetes, ischemic heart disease, depression, non-
vertebral fracture and all-cause mortality were explored in MR analyses. The MR 
analysis had more than 80% power for detecting a true odds ratio of 1.2 or larger for 
binary outcomes. None of explored outcomes were statistically significant. Results 
from multiple MR methods and sensitivity analyses were consistent. 
 
Discussion 
Vitamin D and its association with multiple outcomes has been widely studied. More 
than 230 outcomes have been linked with vitamin D by meta-analyses of observational 
studies and RCTs. On the contrary, evidence from Mendelian Randomization studies 
is lacking. In particular I identified only 20 existing MR studies and only 13 outcomes 
were suggested to be causally related to vitamin D. In the systematic literature review 

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of previous PheWAS studies, I summarized the applied methods, predictors and results. 
Although phenotyping based on ICD codes provided good performance and was 
widely applied by previous PheWAS studies, phenotyping can be improved if lab data, 
imaging data and medical notes can be incorporated. Alternative algorithms, which 
takes advantage of deep learning and thus enable high precision phenotyping, needs to 
be developed.  
 
From the PheWAS analysis, the score of vitamin D related genetic variants was not 
statistically significantly associated with any of the 920 phenotypes tested. In the 
single variant analysis, only rs17216707 (CYP24A1) was shown to be associated with 
calculus outcomes statistically significantly. Previous studies reported associations 
between vitamin D and hypercalcemia, hypercalciuria, nephrolithiasis and 
nephrocalcinosis, may be due to the role of vitamin D in calcium homeostasis. 
In the MR analysis, I found no evidence of large to moderate (OR>1.2) causal 
associations of vitamin D on a very wide range of health outcomes. These included 
SBP, DBP, hypertension, T2D, IHD, BMI, depression, non-vertebral fracture and all-
cause mortality which have previously been proposed to be influenced by low vitamin 
D levels. Further, even larger studies, probably involving the joint analysis of data 
from several large biobanks with future IVs that explain a higher proportion of the trait 
variance, will be required to exclude smaller causal effects which could have public 
health importance because of the high population prevalence of low vitamin D levels 
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Chapter I: Introduction – Vitamin D 
1.1 Vitamin D 
1.1.1 Vitamin D and its source/synthesis 
Vitamin D is a group of fat-soluble secosteroids which help in enhancing intestinal 
absorption of calcium, iron, magnesium, phosphate and zinc. The most common forms 
of vitamin D are vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). The 
natural form of vitamin D in all animals, including human, is vitamin D3, while 
vitamin D2 is a synthetic product derived by irradiation of plant sterols/ergosterols (1). 
 
A few food types are good sources of vitamin D, including oily fish (e.g. salmon, 
sardines and mackerel), eggs, fortified fat spreads, fortified breakfast cereals and some 
powdered milks (2). Another food source is vitamin D supplements. Apart from 
dietary sources and supplements, the majority of vitamin D we need is synthesized in 








Table 1. Dietary and supplemental sources of Vitamin D. 
Source Vitamin D content 
Natural sources  
Salmon  
  Fresh, wild (3.5 oz) 600-1000 IU of Vitamin D3 
  Fresh, farmed (3.5 oz) 100-250 IU of vitamin D3 or D2 
  Canned (3.5 oz) 300-600 IU of vitamin D3 
Sardines, canned (3.5 oz) 300 IU of vitamin D3 
Mackerel, canned (3.5 oz) 250 IU of vitamin D3 
Tuna, canned (3.6 oz) 230 IU of vitamin D3 
Cod liver oil (1 tsp) 400-1000 IU of vitamin D3 
Shiitake mushrooms  
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  Fresh (3.5 oz) 100 IU of vitamin D3 
  Sun-dried (3.5 oz) 1600 IU of vitamin D3 
Egg yolk 20 IU of Vitamin D3 or D2 
Exposure to sunlight, 
ultraviolet B radiation (0.5 
minimal erythema dose) 
3000 IU of vitamin D3 
Fortified foods  
Fortified milk 100 IU/8 oz, usually vitamin D3 
Fortified orange juice 100 IU/8 oz vitamin D3 
Infant formulas 100 IU/8 oz vitamin D3 
Fortified yogurts 100 IU/8 oz, usually vitamin D3 
Fortified butter 50 IU/3.5 oz, usually vitamin D3 
Fortified cheese 100 IU/3 oz, usually vitamin D3 
Fortified breakfast cereals 100 IU/serving, usually vitamin D3 
Supplements  
Vitamin D2  50,000 IU/capsule 
Drisdol (vitamin D2) liquid 
supplements 
8000 IU/ml 
Multivitamin 400 IU vitamin D, D2, or D3 
Vitamin D3 400, 800, 1000, and 2000 IU 
IU, international unit (25 ng); oz, ounces (28.3 grams). 
Source: reproduced with permission from reference 267, Copyright Massachusetts Medical Society. 
 
Oxidation of cholesterol to 7-dehydrocholesterol (7-DHC) is the initial step in vitamin 
D synthesis. 7-DHC is then stored principally in the cell membranes of keratinocytes 
and fibroblasts in the epidermis of skin, and is incorporated within the fatty acid 
hydrocarbon side chain and polar head group of the triglycerides (3). When exposed 
to sunlight, ultraviolet B radiation (UVB) (290-315 nm) is absorbed by epidermal cells, 
causing an activation of double bonds of 7-DHC (rearrange and open up the B ring) to 
form pre-vitamin D3 through a photolysis procedure. Once formed, pre-vitamin D3 
rapidly converts to vitamin D3 via a 1-7 antarafacial sigma shift of a hydrogen from 
C-19 to C-9, which causes rearrangement of double bonds to form vitamin D3 (Figure 
1) (4). All of the above steps of vitamin D synthesis happen in living cells of skin. 
Vitamin D3 is then ejected out of the plasma membrane into the extracellular space, 
binds with vitamin D binding protein (DBP) for transport to the liver (3).  
 






Figure 1.  Synthesis of vitamin D. 
 
Several factors could hinder vitamin D synthesis. Any physical factors that attenuate 
UVB exposure significantly reduce vitamin D3 synthesis in skin (e.g., clothing, 
sunscreens, glass shielding) (5). In addition, certain biological factors also inhibit 
cutaneous vitamin D synthesis and bioavailability. Increased skin pigmentation cuts 
the number of photons that reach the lower living cellular layer, where vitamin D3 is 
synthesized, and thus impact its availability. It is reported that under same degree of 
UVB radiation, significant ethnic group serum 25-hydroxyvitamin D (25(OH)D) level 
differences were observed between participants of multiple ethnicity with similar base-
line 25(OH)D concentration (6). In recent study, obese subjects were found to have 
significantly lower basal 25(OH)D levels and higher parathyroid hormone 
concentrations compared with matched controls, which was caused by vitamin D’s 
deposition in body fat compartments (7). Fat malabsorption syndromes, such as 
Crohn’s disease, could possibility cause vitamin D insufficiency and deficiency (8). 
Age is another risk factor. With age increasing, the ability of the skin to synthesize 
vitamin D3 decreases and a shortage of intake vitamin D from food also exists. 
Compared with young adults, a 70-year-old produces approximately 4 times less 
vitamin D via cutaneous synthesis (9). 
 
1.1.2 Metabolism and Physiologic Functions  
To exert its biological function, vitamin D needs to be converted to its relevant active 
form first. Binding with DBP, vitamin D is transported to the liver in the serum. Then 
with cytochrome P450 enzyme 25-hydroxylase (CYP2R1), vitamin D is converted 
into 25(OH)D with a hydroxyl group adding on carbon 25 (10). Consequently, bound 
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to DBP, 25(OD)D is transferred to kidney tubules and with the aid of mitochondrial 
cytochrome P450 enzyme 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1), 
25(OH)D is converted to 1α,25-dihydroxyvitamin D (1,25(OH)2D, or calcitriol) with 
a hydroxylation at position 1α (11). 1,25(OH)2D is the active metabolite which is 
responsible for most biological functions of vitamin D (Figure 2). 
 
 
Figure 2. Activation of vitamin D 




The main biological function of vitamin D involves calcium and phosphorus 
homeostasis. It was found that without vitamin D, only 10% to 15% of dietary calcium 
and about 60% of phosphorus is absorbed, while with vitamin D, calcium and 
phosphorus intestinal absorption are increased to around 40% and 80% respectively 
(12). Three metabolic pathways mediated by vitamin D are responsible for 
maintenance of serum calcium concentration. First, vitamin D impacts the intestinal 
absorption of calcium. Second, in absence of diet calcium, vitamin D stimulates 
transfer of calcium from bone to serum by osteoclastogenesis and activation of resting 
osteoclasts together with parathyroid hormone (13). Third, interacting with 
parathyroid hormone, the two hormones together can stimulate the reabsorption of the 
last 1% of filtered load of calcium in distal the renal tubule (14). 
 
Apart from its role in calcium metabolism, vitamin D has also been identified to be 
involved in regulation of gene transcription, through its binding to the Vitamin D 
receptor (VDR). When vitamin D binds to VDR, it forms a heterodimer with the 
retinoid X receptor (RXR). This heterodimer binds to the vitamin D response element 
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(DRE) in the promoter of vitamin D response genes and interacts with other 
transcription factors (including co-activator proteins, such as SRC-1). As a 
consequence, DNA structure is remodeled through bend and phosphorylation on 
serine-205 occurs, and thus gene transcription could either be upregulated or 
downregulated (Figure 3) (13, 14). Expression of the VDR gene is not only found in 
calcium homeostasis related cells, such as enterocytes and distal renal tubule cells, but 
also in pro-myelocytes, lymphocytes, colon cells, pituitary gland cells and ovarian 
cells (13), which may implicate a regulatory function of vitamin D in many tissues and 
explain the impact of vitamin D on multiple health outcomes. Genes involved in 
calcium endocrinology were the first to be identified to have DRE regions, such as 
Parathyroid Hormone Gene (PTH) (15). However, DREs are also identified in a 
number of genes not linked to calcium metabolism. Cao X. et al. cloned the promoter 
of the avian beta 3 integrin gene, and identified the classic DRE sequence 756 to 770 
bases upstream of beta 3 transcriptional start point (16). DRE was also identified in 




Figure 3. Regulation of gene expression by vitamin D. 
1,25(OH)2D, acting through its receptor, VDR. The result of regulation may be either suppression or 
activation. RXR, retinoid X receptor; DRE, vitamin D responsive element; TFIIB, transcription factor 
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IIB; TFIID, transcription factor IID; RNAP, RNA polymerase.  
Source: reproduced from reference 13, with permission from Oxford University Press (reference 
number: 4377770613631). 
 
1.1.3 Vitamin D deficiency 
There is no consensus on optimal serum 25(OH)D concentrations, which is 
conventionally used to measure vitamin D status. Typically, vitamin D deficiency is 
considered when 25(OH)D concentration is lower than 20 ng/mL (50 nmol/L). 
Considering PTH levels and calcium absorption, a 25(OH) D level above 30 ng/mL 
(75 nmol/L) is considered to be sufficient (5), whereas a level between 20 ng/mL and 
30 ng/mL is considered as insufficient. Through a systematic review of literature, 
Bischoff-Ferrari HA et al. suggested that for a wide variety of health outcomes (e.g. 
bone mineral density, dental health, colorectal cancer), the advantageous 25(OH)D 
levels begin at 30 ng/mL, and a higher level between 36-40 ng/mL would control 
disease risk further (18).  
 
Although vitamin D can be synthesized by sun exposure, vitamin D deficiency is still 
highly prevalent all around the world, partly due to the factors which can hinder 
vitamin D synthesis, as have been detailed above. Overall, around 1 billion people 
worldwide were estimated to be vitamin D deficient or insufficient (12). For a view of 
vitamin D status around the world among adults, please see Figure 4 (19). In the US, 
the prevalence of 25(OH)D of less than 10 ng/mL was 6%, and only 67.2 % adults had 
25(OH)D of 20 ng/mL or more. In the same study the proportion of adults with 
25(OH)D concentration > 30ng/mL was only 23% (20, 21). Meanwhile, vitamin D 
deficiency is highly prevalent in Europe as well. In a study in French general adult 
population, 14% of participants were found to have a 25(OH)D concentration of lower 
than 12 ng/mL (22). In northwest Russia, the prevalence of vitamin D insufficiency 
and deficiency was estimated to be 37.5% and 45.7% respectively (23). Furthermore, 
in a British birth cohort of 7434 whites at 45 years old, the prevalence of 25(OH)D 
lower than 10 ng/mL (25 nmol/L), 16 ng/mL (40 nmol/L) and 30 ng/mL (75 nmol/L) 
was found to be 15.5%, 46.6% and 87.1% in winter and spring; while, the proportions 
were 3.2%, 15.4% and 60.9% during summer and fall (24).  
 




Figure 4. Vitamin D status in adults (> 18 years) around the world when available. 
Winter values were used to calculate the mean 25(OH)D levels.  
Source: reproduced from reference 19, with permission from Springer Nature (license number: 
4377770985262). 
 
1.2 Vitamin D in relation to health outcomes 
1.2.1 Overview of association between vitamin D and health outcomes 
Based on findings of previous systematic reviews and meta-analyses, my principal 
supervisor, Dr. Evropi Theodoratou, and colleagues conducted an umbrella review, 
which had been completed and published before my entry into the PhD project (25). 
Through 11 October 2013, they included 107 systematic literature reviews, 74 meta-
analyses of observational studies of plasma vitamin D concentrations and 87 meta-
analyses of RCTs of vitamin D supplementation. They found that associations between 
vitamin D and a total of 137 health outcomes had been explored by previous systematic 
reviews and meta-analyses which were published in the literature. They concluded that 
an association between vitamin D concentrations and birth weight, dental caries in 
children, maternal vitamin D concentrations at term, and parathyroid hormone 
concentrations in patients with chronic kidney disease requiring dialysis were probable. 
Furthermore, relationships between vitamin D and 22 health-related outcomes were
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 suggestive, including colorectal cancer, cardiovascular disease, stroke, cognition, 
type 2 diabetes and metabolic syndrome prevalence.  
 
In order to form a comprehensive idea of which health outcomes have been studied in 
association with vitamin D, I firstly updated the aforementioned umbrella review by 
Dr. Evropi Theodoratou, using similar literature search terms and inclusion/exclusion 
criteria. For the new outcomes, which were not covered by the old umbrella review, I 
will briefly describe the results from the newly included studies in section 1.2.2. For 
the outcomes that have been covered by the old umbrella review, I will describe 
evidence for several high prevalence outcomes based on the studies that were included 
in the old review in section 1.2.3. 
 
1.2.2 Association between vitamin D and health outcomes – an updated review 
1.2.2.1 Search strategy, inclusion/exclusion criteria 
I searched Medline and Embase for any systematic reviews or meta-analyses which 
studied the association between vitamin D and health outcomes and were published 
between November 2013 and March 2018, using the search algorithm listed in Table 
2. 
 
Two types of studies were included in this updated review: meta-analyses of 
observational associations between circulating vitamin D concentrations and any 
clinical outcome; meta-analyses of randomized controlled trials (RCTs) assessing the 
effect of vitamin D supplements. Only studies on humanity were eligible for inclusion. 
Letter, correspondence, conference abstracts, and articles not written in English were 
excluded. In addition, the following type of studies were also excluded from the review: 
studies on vitamin D related genetic variants; meta-analyses assessing dietary vitamin 
D intake or UVB exposure; studies which treat vitamin D level as outcome rather than 
exposure; meta-analysis of RCTs in which the treatment arm combined vitamin D with 
calcium or other vitamins or compounds versus placebo. However, if the treatment 
arum and control arm included the same additional compound (e.g. vitamin D plus 
calcium vs calcium), the study was included in my review. 
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Vitamin d/ or 25-OHD.mp. or 25 hydroxyvitamin D.mp. or 
cholecalciferol/ or colecalciferol.mp. or hydroxycholecalciferols/ or 
hydroxycolecalciferols.mp. or calcifediol/ or 
dihydroxycholecalciferols/ or dihydroxycolecalciferols.mp. or 
calcitriol/ or 24,25-dihydroxyvitamin d 3/ or 24,25-OH2 D3.mp. or 
ergocalciferols/ or dihydrotachysterol/ or 25-hydroxyvitamin d 2/ or 
25- OHD2.mp. or 1,25-dihydroxyvitamin d.mp. or 1,25-OH2 D.mp. or 
1,25- dihydroxyvitamin d2.mp. or 1,25-dihydroxyergocalciferol.mp. or 
1,25-OH2 D2.mp. or 1,25-dihydroxyvitamin d3.mp. or 1,25-OH2 
D3.mp. or ergocalciferols/ or vitamin D2.mp. or vitamin D 2.mp. or 
vitamin D3.mp. or vitamin D 3.mp 
 AND 






Vitamin d/ or 25-OHD.mp. or 25 hydroxyvitamin D/ or colecalciferol/ 
or cholecalciferol.mp. or hydroxycolecalciferols/ or 
hydroxycholecalciferols.mp. or calcifediol/ or 
dihydroxycolecalciferols/ or dihydroxycholecalciferols.mp. or 
calcitriol/ or 24,25 dihydroxycolecalciferol/ or 24,25-OH2 D3.mp. or 
ergocalciferol/ or dihydrotachysterol/ or 25-hydroxyvitamin d 2.mp. or 
25- OHD2.mp. or 1,25-dihydroxyvitamin d.mp. or 1,25-OH2 D.mp. or 
1,25 dihydroxyergocalciferol/ or 1,25-dihydroxyvitamin d2.mp. or 
1,25-OH2 D2.mp. or 1,25-dihydroxyvitamin d3.mp. or 1,25-OH2 
D3.mp. or ergocalciferol/ or vitamin D2.mp. or vitamin D 2.mp. or 
vitamin D3.mp. or vitamin D 3.mp 
 AND 
Review terms systematic review / or systematic review.mp or meta-analysis/ or 
metaanalysis.mp 
Note: /, mapped afore term to subject heading; mp, including title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier and synonyms matching.  




1.2.2.2 Literature search and review results 
Medline and Embase were accessed on 21st March, 2018. Terms and algorithms from 
Table 2 were used in the literature search. 416 references were identified from Medline, 
and 1645 references were identified from Embase. After deletion of duplications, 1702 
references were retained, which went to a subsequent review process. During title 
review, 1107 references were deleted. 208 were deleted in the abstract review, and thus 
we downloaded full text for 315 articles and did full text review for them. In the full 
text review, 141 studies were excluded because they were on outcomes which had been 
covered by the previous umbrella review, 4 studies were umbrella reviews of other 
systematic reviews and meta-analyses, 3 studies used vitamin D as outcomes, 6 studies 
explored vitamin D intake, 29 studies were just systematic reviews without any 
quantitative meta-analysis, 16 studies were meta-analyses of trials, however, the 
intervention strategy did not meet our inclusion criteria, and 21 studies were excluded 
due to other reasons. As a result, a total of 95 studies were included in the final dataset 









Figure 5. Flowchart of updated umbrella review for vitamin D. 
SLR, systematic literature review; MA, meta-analysis. 
 
1.2.2.3 Summary results of the updated systematic review 
Among the included studies there were 66 meta-analyses of observational studies, and 
29 meta-analyses of RCTs. For a summary of the results, please see Table 3 and Table 
4. 
Cancer outcomes 
The risk for basal cell melanoma, cutaneous melanoma, non-melanoma skin cancer 
and squamous cell cancer was explored and the associations for basal cell melanoma 
(RR = 1.82, 95% CI: 1.38-2.40) and non-melanoma skin cancer (RR = 1.64, 95% CI: 
1.02-1.65) reached statistical significance level (26). 














total N Relative 
Risk (95% 
CI) 
P value I2 
(95% 
CI) 
P value for 
heterogeneity 
Cancer outcomes           




5 NS NS 1.82 (1.38, 
2.40) 
NS 0 NS 
bladder cancer (27) 25(OH)D RR high vs low 5 2238 89610 0.75 (0.65, 
0.87) 
<0.001 0 0.42 
bladder carcinoma (28) 25(OH)D RR low vs high 7 NS NS 1.34 (1.17, 
1.53) 
<0.001 0 0.53 
breast cancer, disease free 
survival (29) 
25(OH)D HR high vs low 4 NS NS 0.42 (0.29, 
0.62) 
<0.001 29 0.24 
breast cancer, overall 
mortality (30) 
25(OH)D RR high vs low 6 NS NS 0.61 (0.48, 
0.79) 
NS 35.9 0.17 
breast cancer, overall 
mortality (31) 
25(OH)D HR high vs low 5 471 4443 0.56 (0.4, 
0.7) 
<0.001 NS 0.35 
breast cancer, overall 
mortality (32) 
25(OH)D HR high vs low 5 622 4413 0.62 (0.49, 
0.78) 
NS 4.6 0.2 
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breast cancer, overall survival 
(29) 
25(OH)D HR high vs low 6 NS NS 0.63 (0.51, 
0.77) 
<0.001 14 0.32 
breast cancer, specific 
mortality (30) 
25(OH)D RR high vs low 4 NS NS 0.58 (0.40, 
0.85) 
NS 26.7 0.251 
breast cancer, specific 
mortality (29) 
25(OH)D HR high vs low 4 NS NS 0.65 (0.44, 
0.98) 
0.04 45 0.14 
breast cancer, specific 
mortality (32) 
25(OH)D HR high vs low 3 194 2636 0.57 (0.38, 
0.84) 
NS 17 0.12 
colorectal cancer, overall 
mortality (32) 
25(OH)D HR high vs low 5 1214 2330 0.71 (0.55, 
0.91) 
NS 29 0.12 
colorectal cancer, overall 
survival (29) 
25(OH)D HR high vs low 5 NS NS 0.55 (0.33, 
0.91) 
0.02 89 <0.001 
colorectal cancer, specific 
mortality (29) 
25(OH)D HR high vs low 3 NS NS 0.65 (0.47, 
0.88) 
0.005 6 0.35 
colorectal cancer, specific 
mortality (32) 
25(OH)D HR high vs low 3 566 1558 0.65 (0.49, 
0.86) 
NS 0 0.34 
colorectal cancer, specific 
mortality (33) 
25(OH)D HR high vs low 4 809 2559 0.63 (0.5, 
0.8) 
<0.001 NS 0.5 




4 NS NS 1.46 (0.60, 
3.53) 
NS 54 NS 




gastric cancer (34) 25(OH)D OR high vs low 3 NS NS 0.92 (0.74, 
1.14) 
0.42 22.5 0.27 
haematological malignancies, 
disease free survival (35) 
25(OH)D HR low vs high 5 NS NS 1.45 (1.25, 
1.70) 
<0.001 0 0.558 
haematological malignancies, 
overall survival (35)  
25(OH)D HR low vs high 7 NS NS 1.85 (1.54, 
2.23) 
<0.001 0 0.747 
lung cancer, overall mortality 
(36) 
25(OH)D OR high vs low 3 NS NS 0.39 (0.28, 
0.54) 
<0.01 92.5 <0.001 
lung cancer, overall mortality 
(37) 
25(OH)D RR high vs low 4 NS NS 0.76 (0.61, 
0.94) 
0.014 96.1 <0.001 
lung cancer, overall survival 
(29) 
25(OH)D HR high vs low 4 NS NS 0.75 (0.30, 
1.86) 
0.54 93 <0.001 
lung cancer, overall survival 
(36) 
25(OH)D OR high vs low 4 NS NS 1.01 (0.87, 
1.18) 
0.87 19.4 0.293 
lung cancer, overall survival 
(37)  
25(OH)D RR high vs low 5 NS NS 1.01 (0.88, 
1.16) 
0.872 0 0.437 
lymphoma, disease free 
survival (29) 
25(OH)D HR high vs low 6 NS NS 0.80 (0.65, 
0.98) 
0.04 0 0.61 
lymphoma, overall survival 
(29) 
25(OH)D HR high vs low 7 NS NS 0.48 (0.36, 
0.64) 
<0.001 0 0.86 
lymphoma, specific mortality 
(29) 
25(OH)D HR high vs low 6 NS NS 0.50 (0.36, 
0.68) 
<0.001 0 0.83 
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non-melanoma skin cancer 
(26) 




2 NS NS 1.64 (1.02, 
2.65) 
NS 81 NS 




4 NS NS 1.68 (0.44, 
6.39) 
NS 81 NS 
thyroid cancer (38) 25(OH)D OR low vs high 9 NS NS 1.42 (1.17, 
1.73) 
NS 35.6 0.134 




7 NS NS -0.20 (-
0.36, -
0.03) 
NS 55.4 0.037 
           
Cardiovascular outcomes           
atrial fibrillation (39) 25(OH)D OR low vs high 5 NS NS 1.31 (1.06, 
1.62) 
0.01 60 0.04 
           
Autoimmune diseases           




26 1748 3596 -0.77 (-
1.12, -
0.42) 
NS 95.5 <0.001 
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Grave's disease (40) 25(OH)D OR low vs high 12 NS NS 2.24 (1.31, 
3.81) 
NS 84.1 <0.001 
inflammatory bowel disease 
(41) 
25(OH)D OR cases vs 
controls 
14 938 1891 1.64 (1.30, 
2.08) 
<0.001 7 0.37 




6 554 875 -8.72 (-
10.11, -
7.32) 
<0.001 48 0.09 
ulcerative colitis (41)  25(OH)D OR cases vs 
controls 
7 177 539 2.28 (1.18, 
4.41) 
0.01 41 0.12 




5 235 517 -6.72 (-
16.49, 
3.05) 
0.1777 NS NS 




8 296 810 -0.50 (-
0.85, -
0.15) 
NS 77.5 <0.001 
ulcerative colitis (44) 25(OH)D OR cases vs 
controls 
3 NS NS 2.02 (1.13, 
3.60) 
NS 0 0.773 
           
Mental health disorders and 
Cognitive traits 
          




11 NS 1652 -8.63 (-
13.17, -
4.09) 
0.0002 98 <0.0001 
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cognitive impairment (46) 25(OH)D OR low vs high NS NS NS 1.56 (1.05, 
2.33) 
0.028 NS NS 
cognitive impairment (46) 25(OH)D MD  cases vs 
controls 
7 1179 6068 -6.83 (-
11.36, -
2.30) 
<0.001 99 NS 
dementia (47) 25(OH)D OR low vs high 5 NS NS 1.49 (1.09, 
1.88) 
NS 0 0.46 
dementia (48) 25(OH)D OR low vs high 5 NS 18933 1.54 (1.19, 
1.99) 
NS 20 NS 




14 NS NS -5.91 (-
10.68, -
1.14) 
NS 97.6 <0.001 
schizophrenia (49) 25(OH)D OR low vs high 8 NS NS 2.16 (1.32, 
3.56) 
NS 46.8 0.068 
           
Infectious diseases           






3 NS NS -3.54 (-
6.89, -
0.39) 
NS 48 0.15 
clostridium difficile infection 
recurrence (50) 
25(OH)D OR low vs high 4 NS NS 1.26 (0.56, 
2.83) 
NS 63 0.04 
clostridium difficile infection 
severity (50) 
25(OH)D OR low vs high 3 NS NS 1.61 (1.02, 
2.53) 
NS 1 0.37 
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mortality among pneumonia 
patients (51) 
25(OH)D RR low vs high 6 NS NS 2.59 (1.32, 
5.08) 
0.005 71.4 <0.001 
Metabolic disorders           
antiphospholipid syndrome 
(52) 




3 NS NS -3.605 (-
5.449, -
1.761) 





25(OH)D OR cases vs 
controls 
4 NS NS 3.063 
(2.120, 
4.426) 




diabetic peripheral neuropathy 
(Asian diabetes patients) (53)  
25(OH)D OR low vs high 4 NS NS 1.22 (1.17, 
1.27) 
NS 0 0.77 
diabetic nephropathy (diabetes 
patients) (54) 
25(OH)D OR low vs high 6 NS NS 1.80 (1.25, 
2.59) 
0.002 59.4 0.031 
diabetic peripheral neuropathy 
(diabetes patients) (53) 




10  1368 -1.12 (-
1.58, -
0.65) 
NS 94.1 <0.001 
diabetic peripheral neuropathy 





5 NS 606 -6.36 (-
8.57, -
4.14) 
<0.001 56 0.06 
diabetic peripheral neuropathy 
(T2D patients) (55) 
25(OH)D OR low vs high 4 NS NS 2.88 (1.84, 
4.50) 
<0.001 0 0.47 
diabetic retinopathy (T2D 
patients) (56) 
25(OH)D OR low vs high 8 2348 13435 2.03 (1.07, 
3.86) 
0.03 96 <0.001 
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obesity (57)  25(OH)D RR obesity vs 
entrophic 
21 NS NS 1.35 (1.21, 
1.50) 
NS 87.3 <0.001 
obesity (58) 25(OH)D RR cases vs 
controls 
12 NS NS 1.52 (1.33, 
1.74) 
NS 89.3 <0.001 
obesity (59) 25(OH)D OR cases vs 
controls 
15 3867 13209 3.43 (2.33, 
5.06) 
NS 81.2 <0.001 
overweight (57) 25(OH)D RR obesity vs 
overweight 
19 NS NS 1.21 (1.14, 
1.29) 
NS 66.4 <0.001 
type 2 diabetes (old adults) 
(60) 
25(OH)D RR low vs high 6 1320 13563 1.31 (1.11, 
1.54) 
0.001 37 NS 
Urolithiasis (61) 1,25(OH)D MD cases vs 
controls 
23 2189 4237 10.19 
(4.31, 
16.07) 
0.0007 97 <0.001 
Urolithiasis (61) 25(OH)D MD cases vs 
controls 
12 1934 20850 0.88 (-
1.04, 2.80) 
0.37 84 <0.001 
           
Neonatal/infant/child related 
outcomes 
          
allergic sensitization in 
children (maternal VD) (62) 
25(OH)D OR high vs low 9 NS NS 1.00 (0.95, 
1.06) 
0.962 0 0.739 
FEVA in children (maternal 
VD) (62) 
25(OH)D OR high vs low 4 NS NS 0.07 (-
0.01, 0.15) 
0.104 0 0.876 
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FVC in children (maternal 
VD) (62) 
25(OH)D OR high vs low 4 NS NS 0.05 (-
0.03, 0.13) 
0.192 NS NS 
lower respiratory tract 
infection (children) (63) 
25(OH)D OR cases vs 
controls 
5 197 550 3.29 (1.27, 
8.56) 
0.01 51 0.09 
lower respiratory tract 
infection (children) (63) 




6 NS 578 -8.75 (-
15.70, -
1.80) 
0.01 66 0.01 
respiratory tract infection in 
children (maternal VD) (62) 
25(OH)D OR high vs low 13 NS NS 0.64 (0.47, 
0.87) 
0.005 82.9 <0.001 
           
Pregnancy related outcomes           
biochemical pregnancy (64) 25(OH)D OR high vs low 5 975 1700 1.34 (1.04, 
1.73) 
0.03 21 0.28 
clinical pregnancy (64) 25(OH)D OR high vs low 11 1305 2700 1.46 (1.05, 
2.02) 
0.02 61 0.004 
clinical pregnancy (in vitro 
fertilization) (65) 
25(OH)D RR low vs high 4 631 1139 0.92 (0.73, 
1.16) 
NS 61 0.053 
live birth (64) 25(OH)D OR high vs low 7 895 2026 1.33 (1.08, 
1.65) 
0.009 5 0.39 
live birth rate (in vitro 
fertilization) (65) 
25(OH)D RR low vs high 3 243 655 0.75 (0.61, 
0.93) 
NS 0 0.357 
miscarriage (64) 25(OH)D OR high vs low 6 240 1635 1.12 (0.81, 
1.54) 
0.49 0 0.76 
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polycystic ovary syndrome 
(66) 




14 1150 2262 -0.64 (-
1.12, -
0.15) 
0.01 96 <0.001 
polycystic ovary syndrome 
(67) 




10 1130 1879 -0.45 (-
1.68, 0.79) 
0.48 99 <0.001 
polycystic ovary syndrome 
(68)  




10 NS NS -0.86 (-
1.46, -
0.26) 
0.005 97.2 <0.001 
spontaneous abortion (69) 25(OH)D RR low vs high 3 NS NS 1.04 (0.95, 
1.13) 
NS 0 0.71 
spontaneous preterm birth 
(<35-37 weeks) (69) 
25(OH)D RR low vs high 4 NS NS 1.11 (0.75, 
1.65) 
NS 38 0.184 
still birth (69) 25(OH)D RR low vs high 2 NS NS 1.02 (0.96, 
1.09) 
NS 0 0.65 
Musculoskeletal and related 
outcomes 
          
chronic widespread pain (70) 25(OH)D OR cases vs 
controls 
9 NS NS 1.63 (1.20, 
2.23) 
NS 37.8 0.117 




12 851 1713 -0.56 (-
1.05, -
0.08) 
NS 95.5 <0.001 
low back pain (72) 25(OH)D OR low vs high 19 NS NS 1.60 (1.20, 
2.12) 
0.001 84.9 NS 
Chapter I: Introduction – Vitamin D 

 
stress fracture (military 
population) (73) 
25(OH)D MD  cases vs 
controls 
8 761 2634 -2.44 (-
4.05, -
0.84) 
0.003 53 0.04 
walking speed in elderly (74) 25(OH)D MD  VDD vs NVD 7 3313 7623 -0.08 (-
0.09, -
0.07) 
<0.001 85 NS 
           
Other outcomes           
30-day mortality (patients in 
ICU) (75) 
25(OH)D RR low vs high 7 2857 2857 1.42 (1.00, 
2.02) 
0.05 29 0.21 
advanced liver fibrosis (76) 25(OH)D OR low vs high 
(10 ng/mL) 
2 NS NS 2.37 (1.20, 
4.72) 
NS NS NS 
advanced liver fibrosis (76) 25(OH)D OR low vs high 
(20 ng/mL) 
3 NS NS 1.44 (0.99, 
2.12) 
NS NS NS 
advanced liver fibrosis (76) 25(OH)D OR low vs high 
(30 ng/mL 
3 NS NS 2.22 (1.24, 
3.97) 
NS NS NS 
aeroallergen specific Ig-E 
sensitization (77) 
25(OH)D OR high vs low 4 NS NS 0.889 
(0.754, 
1.048) 
0.16 66.2 <0.001 
aeroallergen specific Ig-E 
sensitization (adults) (77) 
25(OH)D OR high vs low 3 NS NS 1.263 
(1.121, 
1.423) 
<0.001 0 0.89 
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aeroallergen specific Ig-E 
sensitization (children) (77) 
25(OH)D OR high vs low 2 NS NS 0.542 
(0.433, 
0.678) 
<0.001 49.7 0.002 
age-related macular 
degeneration (78) 




3 1126 9332 -0.15 (-
0.41, 0.11) 
0.272 NS NS 
age-related macular 
degeneration (78) 




4 2784 26572 0.83 (0.71, 
0.97) 
0.019 78.4 NS 
age-related macular 
degeneration (79) 
25(OH)D OR low vs high 8 NS NS 0.91 (0.69, 
1.22) 
0.12 79.7 <0.01 
chronic obstructive pulmonary 
disease (80) 




9 NS NS 0.60 (0.31, 
0.89) 
<0.001 88.5 <0.001 
chronic obstructive pulmonary 
disease (81) 




13 1981 3264 -0.69 (-
1.00, -
0.38) 
<0.001 94 <0.001 
chronic obstructive pulmonary 
disease (81) 
25(OH)D OR cases vs 
controls 
12 3224 9923 1.77 (1.18, 
2.64) 
0.006 83 <0.001 
fibrosis score (NAFLD) (82) 25(OH)D MD of 
VD 
high vs low 
score 
6 NS NS 0.88 (-
2.65, 4.42) 
0.65 64 0.62 
frailty (83) 25(OH)D OR low vs high 7 NS 17815 1.27 (1.17, 
1.38) 
<0.001 59 0.02 




infection (patients in ICU) 
(75) 
25(OH)D RR low vs high 5 334 1965 1.49 (1.12, 
1.99) 
0.007 52 0.08 
in-hospital mortality (patients 
in ICU) (75) 
25(OH)D RR low vs high 4 2572 2572 1.76 (1.37, 
2.26) 
<0.001 0 0.83 
mortality (critically ill 
patients) (84) 
25(OH)D OR low vs high 6 NS NS 1.76 (1.38, 
2.23) 
NS 2.3 0.402 
NAFLD activity score (82) 25(OH)D MD of 
VD 
high vs low 
score 
5 NS NS -0.93 (-
2.45, 0.58) 
0.23 0 0.64 
non-alcoholic fatty liver 
disease (85) 




21 NS NS -0.76 (-
0.97, -
0.54) 
NS 95.6 <0.001 
non-alcoholic fatty liver 
disease (85) 
25(OH)D OR low vs high 6 NS NS 1.26 (1.15, 
1.38) 
NS 39.7 0.141 
non-alcoholic steatohepatitis 
(85) 




4 NS 374 -1.30 (-
2.37, -
0.23) 
0.02 94 <0.001 
non-cardiovascular, non-
cancer death (86) 
25(OH)D RR bottom vs top 
thirds 
10 2565 51561 1.34 (1.13, 
1.60) 
NS 49.3 0.038 




5 NS 2381 -0.08 (-
0.29, 0.13) 
0.46 44 0.13 





6 NS 1922 -0.29 (-
0.55, -
0.04) 
0.02 61 0.02 
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7 NS 1942 -0.56 (-
0.85, -
0.27) 
0.0002 77 0.0002 




7 NS 5544 -16.88 (-
33.54, -
0.23) 
0.05 99 <0.001 
Parkinson's disease (88) 25(OH)D OR low vs high 2 385 870 1.50 (1.14, 
1.97) 
0.003 49 0.16 




6 NS 1893 -11.55 (-
12.23, -
10.86) 
<0.001 99 <0.001 
Parkinson's disease (90) 25(OH)D OR low vs high 3 NS NS 1.50 (1.31, 
1.71) 
NS 55.9 0.045 
sepsis (hospitalized patients) 
(91) 
25(OH)D OR low vs high 7 1452 7194 1.78 (1.55, 
2.03) 
<0.001 0 0.97 
sepsis (patients in ICU) (75) 25(OH)D RR low vs high 7 854 3844 1.46 (1.27, 
1.68) 
<0.001 0 0.47 
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Table 4. General characteristics of meta-analyses of randomized controlled trials of vitamin D supplementation on health outcomes.  










effect (95% CI) 
P value 
Skeletal outcomes        
chromic nonspecific musculoskeletal pain (92) general SMD NA random 3 0.05 (-0.37, 0.46) 0.83 
hand grip strength (93) older adults MD kg fixed 3 0.40 (-1.11, 1.92) 0.6 
joint space width (94) knee OA patients SMD NA fixed 2 0.07 (-0.08, 0.23) 0.36 
knee osteoarthritis, WMAC function (95) knee OA patients WMD NA NA 4 -1.87 (-2.58, -1.17) NA 
knee osteoarthritis, WMAC pain (94) knee OA patients SMD NA random 4 -0.32 (-0.63, -0.02) 0.04 
knee osteoarthritis, WMAC pain (95) knee OA patients WMD NA NA 4 -1.65 (-2.16, -1.14) NA 
knee osteoarthritis, WMAC stiffness (95) knee OA patients WMD NA NA 3 0.03 (-0.17, 0.24) NA 
leg strength (93) older adults SMD NA fixed 7 0.09 (-0.05, 0.24) 0.22 
pain score (96) general MD NA random 8 -0.57 (-1.00, -0.15) 0.007 
physical performance (93) older adults SMD NA fixed 4 0.12 (-0.07, 0.30) 0.22 
tibial cartilage volume (94) knee OA patients SMD NA fixed 2 0.12 (-0.05, 0.29) 0.15 
time up and go (93), a older adults MD seconds fixed 7 -0.75 (-1.44, -0.07) 0.03 
visual analog scale of pain intensity (97) chronic widespread 
pain patients 
MD NA random 4 0.46 (0.09, 0.89) 0.02 
walking capacity (93) older adults SMD NA fixed 3 0.04 (-0.17, 0.24) 0.73 
        
cardiovascular outcomes       
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6-minute walk distance (98) chronic heart failure 
patients 
MD meters fixed 2 8.90 (-48.47, 66.26) 0.761 
augmentation index (99) general SMD NA fixed 8 -0.15 (-0.32, 0.02) 0.08 
augmentation index (100) general MD NA random 4 0.25 (-4.43, 4.92) 0.92 
cardiovascular mortality (101) CKD patients RR NA random 6 0.79 (0.26, 2.38) NA 
cardiovascular serious adverse events (101) CKD patients RR NA random 8 1.20 (0.48, 2.99) NA 
diastolic blood pressure (102) obese individuals SMD mmHg random 5 0.124 (-0.003, 0.251) 0.055 
endothelial function (103)  general SMD NA random 14 0.08 (-0.06, 0.22) 0.28 
fasting flow-mediated vasodilation (104) general WMD % change fixed 9 0.15 (-0.21, 0.51) 0.41 
flow mediated dilation (105) general SMD % change random 11 1.27 (0.20, 2.34) NA 
flow mediated dilation (106) general MD % change random 8 0.96 (-0.14, 2.06) 0.09 
incident CVD (107) predialysis CKD 
patients 
RR NA random 5 0.27 (0.13, 0.59) 0.001 
interleukin-10 concentration (98) chronic heart failure 
patients 
MD pg/mL random 2 0.94 (-0.72, 2.59) 0.269 
left ventricular ejection fraction (98) chronic heart failure 
patients 
MD % change random 4 4.11 (-0.91, 9.12) 0.109 
N-terminal pro-B-type natriuretic peptide (98) chronic heart failure 
patients 
MD pg/mL random 3 -80.8 (-305.3, 143,7) 0.48 
pulse wave velocity (99) general SMD NA fixed 10 -0.10 (-0.24, 0.04) 0.17 
pulse wave velocity (100) general MD NA random 6 0.18 (-0.17, 0.52) 0.31 
systolic blood pressure (102) obese individuals SMD mmHg random 5 0.239 (0.086, 0.391) 0.002 
Chapter I: Introduction – Vitamin D 

 
TNF-a concentration (98) chronic heart failure 
patients 
MD pg/mL random 3 -2.42 (-4.26, -0.57) 0.01 
        
metabolic disorders        
adiponectin concentration (108) general MD % change random 7 4.45 (-3.04, 11.93) 0.244 
body mass index (102) obese individuals SMD kg/m2 random 4 0.097 (-0.113, 0.307) 0.365 
fasting plasma glucose (109) T2D patients SMD mg/dL random 16 -6.7 (-11.0, -2.2) 0.003 
fat mass (110) general WMD kg random 10 -0.03 (-0.63, 0.57) 0.92 
fat mass (111) general SMD kg random 10 -0.014 (-0.355, 
0.308) 
0.934 
fat mass (%) (111) general SMD % change random 12 0.051 (-0.098, 0.200) 0.503 
HbA1c (109) T2D patients SMD % change random 18 -0.25 (-0.41, -0.09) 0.003 
HDL-C (102) obese individuals SMD mmol/L random 4 0.110 (-0.056, 0.277) 0.194 
HOMA-IR (102) obese individuals SMD mL/min/kg random 4 -0.078 (-0.221, 
0.066) 
0.288 
HOMA-IR (109) T2D patients SMD NA random 8 -0.62 (-1.2, -0.05) 0.03 
LDL-C (102) obese individuals SMD mmol/L random 4 0.338 (0.071, 0.605) 0.013 
leptin concentration (108) general MD % change random 6 -4.51 (-25.13, 16.11) 0.668 
triglycerides (102) obese individuals SMD mmol/L random 4 -0.236 (-0.497, 
0.025) 
0.076 
weight (110) general WMD kg random 16 0.01 (-0.21, 0.23) 0.9 
weight (102) obese individuals SMD  kg random 5 0.097 (-0.113, 0.307) 0.365 
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Neonatal/infant/child related outcomes      
asthma exacerbation in children (112) children RR NA random 3 0.41 (0.27, 0.63) <0.001 
asthma exacerbations requiring treatment with 
systemic corticosteroids in children (113) 
individuals with 
athma 
RR NA random 7 0.74 (0.56, 0.97) 0.03 
asthma exacerbation in children (114) children RR NA random 3 0.41 (0.27, 0.63) <0.001 
        
Other outcomes        
all-cause mortality (101) CKD patients RR NA random 13 0.84 (0.46, 1.52) NA 
C-reactive protein concentration (115) overweight and 
obese individuals 
SMD mg/L random 12 -0.11 (-0.27, 0.04) 0.15 
C-reactive protein, Systemic inflammatory (116) general WMD NA random 8 -0.32 (-1.01, 0.36) 0.352 
high-density CRP (117) general WMD mg/L random 10 -1.08 (-2.13, -0.03) NA 
hospital length of stay (118) ICU patients WMD days random 6 -3.11 (-10.04, 3.82) 0.38 
ICU length of stay (118) ICU patients WMD days random 6 -1.42 (-3.78, 0.94) 0.24 
interleukin 6 concentration (115) overweight and 
obese individuals 
SMD pg/mL random 5 0.10 (-0.43, 0.63) 0.71 
interleukin 6, Systemic inflammatory (116) general WMD NA random 3 0.10 (-0.17, 0.37) 0.462 
length of hospital stay (119) ICU patients SMD NA fixed 5 -0.06 (-0.22, 0.10) 0.47 
length of ICU stay (119) ICU patients SMD NA fixed 5 -0.13 (-0.29, 0.03) 0.11 
length of mechanical ventilation (119) ICU patients SMD NA fixed 3 -0.04 (-0.21, 0.13) 0.65 
mechanical ventilator days (118) ICU patients WMD days random 4 -1.20 (-3.72, 1.33) 0.35 
mortality (118) ICU patients RR NA random 6 0.84 (0.66, 1.06) 0.14 
mortality (119) ICU patients OR NA fixed 5 0.70 (0.50, 0.98) 0.04 
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number of dominant follicles (120) PCOS patients OR NA fixed 4 2.34 (1.39, 3.92) 0.001 
number of regular menstrual cycles (120) PCOS patients OR NA fixed 3 1.51 (0.80, 2.83) 0.2 
PTH level (120) PCOS patients MD NA random 5 -13.23 (-23.30, -3.17) 0.01 
TNF-a concentration (115) overweight and 
obese individuals 
SMD pg/mL random 8 -0.13 (-0.38, 0.12) 0.31 
urine albumin to creatinine ratio (54) T2D patients WMD NA random 4 17.99 (-35.36, 71.33) 0.51 
a. time up and go, a measurement for physical performance, which is the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the 
chair. 
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The risk for bladder cancer was newly reported for 2 systematic reviews for 
observational studies. The risk for bladder cancer was reported to be 0.75 (95% CI: 
0.65-0.87, P<0.001, high vs low level of vitamin D) (27), while another review on 
bladder carcinoma reported the risk to be 1.34 (95%CI: 1.17-1.53, P<0.001, low vs 
high level of vitamin D) (28).  
 
Four studies included breast cancer mortality as their outcome, and the results were all 
statistically significant and consistent in direction: 0.58 (95% CI: 0.40-0.85), 0.56 (95% 
CI: 0.40-0.70), 0.57 (95% CI: 0.38-0.84), 0.65 (95% CI: 0.44-0.98), respectively (29-
32). One study further analysed breast cancer overall survival (HR = 0.63, 95% CI: 
0.51-0.77), and breast cancer disease-free survival (HR = 0.42, 95% CI: 0.29-0.62), all 
of which were statistically significant. 
 
Colorectal cancer risk was studied in two articles, both of which were statistically 
significant (HR = 0.65, 95% CI: 0.47-0.88; HR = 0.65, 95% CI: 0.49-0.86) (29, 32). 
In addition, colorectal cancer overall survival was also found to be statistically 
significantly associated with vitamin D (HR = 0.55, 95% CI: 0.33-0.91) (29). 
 
Only one study used gastric cancer as their outcome of interested, and the result of MA 
was not statistically significant (RR = 1.46, 95% CI: 0.60-3.53). 
 
Lung cancer mortality was studies in two studies and the results were statistically 
significant and consistent (OR = 0.39, 95% CI: 0.28-0.54; RR = 0.76, 95% CI: 0.61-
0.94) (36, 37). However, the results for lung cancer survival were not statistically 
significant in all three studies (29, 36, 37). 
 
Overall survival and disease free survival of haematological malignancies were also 
found to be statistically significantly associated with vitamin D (HR = 1.85, 95% CI: 
1.54-2.23 for overall survival; HR = 1.45, 95% CI: 1.25-1.70 for relapse-free survival) 
(35).  
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The evidence for risk of thyroid cancer was synthesized in one study. And it was found 




There was only one study of observational studies summarizing the evidence for 
cardiovascular outcomes. It studied the risk of atrial fibrillation and found it to be 
statistically significant (OR = 1.31, 95% CI: 1.06-1.62) (39).  
 
Jiang et al. studied the effect of vitamin D supplementation in a MA of RCTs. They 
found that vitamin D intervention did not change 6-minute walk distance, left 
ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide or interleukin-
10 concentration profile. But it showed a statistically significant association with 
tumour necrosis factor-a level (MD = -2.42 pg/mL, 95% CI: -4.26~ -0.57) (98). 
 
Arterial stiffness was studied by two MA of RCTs, presenting by augmentation index 
and pulse wave velocity. But neither were statistically significant (99, 100). 
 
The association of vitamin D supplementation with blood pressure of obese individuals 
was studied, and systolic blood pressure was statistically significantly affected by the 
intervention (SMD = 0.239 mmHg, 95% CI: 0.086, 0.391) (102).  
 
The association of vitamin D supplements with flow mediated dilation, a marker to 
access risk of CVD events, was explored in 3 MA studies of RCTs (104-106). The 
results were inconsistent between studies, and only one study found a statistically 
significant association (SMD = 1.27, 95% CI: 0.20-2.34) (105). 
 
Among predialysis chronic kidney disease (CKD) patients, vitamin D supplements 
statistically significantly decreased incident cardiovascular disease (CVD) (RR = 0.27, 
95% CI: 0.13-0.59) as reported by a MA of RCTs (107). Another MA of RCTs studied 
cardiovascular serious adverse events and CVD mortality in CKD patients, however 
the results were not statistically significant (101). 





The associations between vitamin D concentration and ulcerative colitis were reported 
by three studies (41, 43, 44). Two of them reported statistically significant results (OR 
= 2.28, 95% CI: 1.18-4.41; OR= 2.02, 95% CI: 1.13-3.60) (41, 44). 
 
By a MA of observational studies, risk Grave’s disease was statistically significantly 
associated with serum vitamin D level (OR = 2.24, 95% CI: 1.31-3.81; SMD of 
vitamin D (cases vs controls): -0.77, 95% CI: -1.12 ~ -0.42) (40). 
 
The risk of inflammatory bowel disease (OR = 1.64, 95% CI: 1.30-2.08) and systemic 
sclerosis (MD of VD: -8.72, 95% CI: -10.11 ~ -7.32) were also found to be statistically 
significant by MA of observational studies (41, 42).  
 
Cognitive disorders 
The association between autism spectrum disorder and vitamin D level was studied in 
one MA of observational studies. Patients with autism spectrum disorder had a 
decreased level of 25(OH)D concentration compared to control group (MD: -8.63, 95% 
CI: -13.17 ~ -4.09, P<0.0001) (45). Cognitive impairment was studied in one MA of 
observational studies. The association was statistically significant in their summary 
results (OR = 1.56, 95% CI: 1.05-2.33, P=0.028; MD of VD: -6.83, 95% CI: -11.36 ~ 
-2.30, P<0.001) (46).Two MA studies of observational studies summarized the 
evidence for association between vitamin D level and dementia from previous studies, 
and both reported statistically significant associations (OR = 1.49, 95% CI: 1.09-1.88; 
OR = 1.54, 95% CI: 1.19-1.99) (47, 48). Association between vitamin D level and 
schizophrenia was studied by one MA of observational studies, and the association 
was statistically significant from their study (MD of VD: -5.91, 95% CI: -10.68 ~ -
1.14, cases vs controls; OR = 2.16, 95% CI: 1.32-3.56) (49). 
 
Infectious diseases 
Infection of clostridium difficile was studied by one MA of observational studies. They 
found that clostridium difficile infection (WMD of VD: -3.54, 95% CI: -6.89 ~ -0.39, 




cases vs controls) and clostridium difficile infection severity (OR = 1.61, 95% CI: 
1.02-2.53) were statistically significantly associated with vitamin D level (50). In 
addition, mortality among pneumonia patients was also found to be statistically 
significantly associated with vitamin D level by MA of observational studies (RR = 
2.59, 95% CI: 1.32-5.08) (51). 
 
Metabolic disorders 
The association between vitamin D concentration and antiphospholipid syndrome was 
studied in one MA of observational studies, which reported a statistically significant 
association (SMD of VD: -3.605, 95% CI: -5.449, -1.761, P<0.001, cases vs controls; 
OR of vitamin D deficiency: 3.063, 95% CI: 2.120-4.426, P<0.001, cases vs controls) 
(52). 
 
The associations between vitamin D concentration and diabetic nephropathy was 
assessed by one study, and it suggested a statistically significant association (OR=1.80, 
95% CI: 1.25-2.59, P=0.002) (54). Diabetic peripheral neuropathy was assessed as the 
outcome in two MA studies of observational studies, and both consistently suggested 
statistically significant associations (OR = 1.22, 95% CI: 1.17-1.27; OR = 2.88, 95% 
CI: 1.84-4.50) (53, 55). The association between vitamin D and diabetic retinopathy 
was explored by one MA of observational studies, also suggesting a statistically 
significant association (OR = 2.03, 95% CI: 1.07-3.86, P=0.03) (56). 
 
Three MA of observational studies were on association between obesity or overweight 
and vitamin D, and all of them consistently reported statistically significant 
associations (57-59). From MA of RCTs, one study summarizing evidence from 
studies on obese individuals did not find any statistically significant between vitamin 
D supplements and BMI or weight (102). Two other MA of RCTs were on fat mass, 
fat mass percentage and weight in general population, but did not find any statistically 
significant association (110, 111).  
 
A MA of observational studies was conducted on risk of type 2 diabetes in old adults, 
and they found a statistically significantly elevated risk of 1.31 (95% CI: 1.11-1.54, 
Chapter I: Introduction – Vitamin D 

 
P=0.001) (60). One MA of observational studies was on association between risk of 
urolithiasis and 1,25(OH)D or 25(OH)D, and 1,25(OH)D level was found to be 
statistically significantly higher in stone formers compared with controls (MD=10.19, 
95% CI: 4.31-16.07, P=0.0007) (61).  
 
One MA of RCTs explored the associations between vitamin D supplementations and 
adiponectin concentration or leptin concentration but did not find any statistically 
significant change following vitamin D treatment (108). Another MA of RCTs 
summarized evidence regarding association of vitamin D supplements with fasting 
plasma glucose, HbA1c and HOMA-IR in T2D patients, all three biomarkers were 
statistically significantly reduced in intervention group (109). In addition, one MA of 
RCTs explored the association of vitamin D supplements with HDL-C, LDL-C, 
HOMA-IR, and triglycerides control in obese individuals, only LDL-C was found to 
be statistically significantly changed (SMD = 0.338, 95% CI: 0.071-0.605) (102). 
 
Neonatal/infant/child related respiratory outcomes 
Two MA of observational studies were on child-related outcomes. One study explored 
the association between child circulatory vitamin D concentration and lower 
respiratory tract infection and reported a statistically significant association (OR=3.29, 
95% CI: 1.27-8.56, P=0.01; MD of VD: -8.75, 95% CI: -15.70 ~ -1.80, P=0.01) (63). 
The other MA was on associations between maternal vitamin D level and 
respiratory/allergic outcomes in children. They found that maternal vitamin D was 
statistically significantly associated with risk of respiratory tract infection in children 
(OR = 0.64, 95% CI: 0.47-0.87, P=0.005) (62). 
 
Two MA of RCTs explored the association of vitamin D supplementations with risk of 
asthma exacerbation in children and reported statistically significant protective effects 
(RR = 0.41, 95% CI: 0.27-0.63, P<0.001; RR = 0.41, 95% CI: 0.27-0.63, P<0.001) 
(112, 114). Another MA of RCTs studied the risk of asthma exacerbation requiring 
treatment with systemic corticosteroids and found a statistically significant association 
with vitamin D (RR = 0.74, 95% CI: 0.56-0.97) (113). 
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Pregnancy related outcomes 
Two MA of observational studies were on assisted reproductive outcomes (64, 65). 
Biochemical pregnancy was studied by one of them and it was statistically significant 
(OR = 1.34, 95% CI: 1.04-1.73, P=0.03). The risk for clinical pregnancy was studied 
by both, but neither was statistically significant. Live birth was explored by both 
studies, and both showed a statistically significant protective effect of high vitamin D 
concentration (OR = 1.33, 95% CI: 1.08-1.65, high VD vs low; RR = 0.75, 95% CI: 
0.61-0.93, low vs high). Risk of miscarriage was studied by only one study, but not 
statistically significant. 
 
The risk of polycystic ovary syndrome was studied by three MA of RCTs, and results 
from the three study were not consistent. One of them did not find a statistically 
significant difference in vitamin D concentration between polycystic ovary syndrome 
patients and controls (SMF of VD: -0.45, 95% CI: -1.68 ~ 0.79) (67). The other two 
MA of observational studies consistently reported a statistically significant difference 
(SMD of VD: -0.64, 95% CI: -1.12 ~ -0.15; SMD of VD: -0.86, 95% CI: -1.46 ~ -0.26) 
(66, 68).  
 
Spontaneous abortion, spontaneous preterm birth and still birth were all assessed for 
their association with maternal vitamin D status as well, but the study did not find 
statistically significant association (69). 
 
Skeletal outcomes 
Chronic widespread pain was studied in one MA of observational studies, and 
individuals with chronic widespread pain were at higher risk of vitamin D deficiency 
compared to controls (OR = 1.63, 95% CI: 1.20-2.23) (70). Similarly, another MA of 
observational studies explored the association between low back pain and vitamin D 
concentration, and reported a statistically significant result (OR = 1.60, 95% CI: 1.20-
2.12) (72). Another MA of observational studies explored fibromyalgia and found that 
the 25(OH)D levels of individuals with fibromyalgia were statistically significantly 
lower than controls (SMD of VD: -0.56, 95% CI: -1.05 ~ -0.08) (71). For MA of RCTs, 
chronic nonspecific musculoskeletal pain was studied and the effect of vitamin D 
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supplementation was not statistically significant (SMD: 0.05, 95% CI: -0.37~0.46) 
(92). In another MA, vitamin D supplementation was found to statistically 
significantly reduce pain score (MD: -0.57, 95% CI: -1.00 ~ -0.15) (96). In addition, 
vitamin D supplementation was also found to have statistically significant effect on 
visual analog scale of pain intensity among chronic widespread pain patients 
(MD=0.46, 95 CI: 0.09-0.89, P=0.02) (97).  
 
The association between vitamin D level and walking speed in elderly was studied in 
a MA of observational studies and they found a statistically significant association 
(MD = -0.08, 95 CI%: -0.09 ~ -0.07, P<0.001, vitamin D deficiency vs normal vitamin 
D profile) (74). There was a MA of RCTs summarizing the association of vitamin D 
supplementation with physical performance outcomes, including hand grip strength, 
leg strength, physical performance, time up and go (a measurement for physical 
performance, which is the time that a person takes to rise from a chair, walk three 
meters, turn around, walk back to the chair) and walking capacity in old adults. 
Vitamin D supplement was found to nominally shorten time up and go (MD = -0.75, 
95% CI: -1.44 ~ -0.07, P=0.03), and none of the other outcomes studied were 
statistically significant. 
 
There was a MA of observational studies on association between vitamin D level and 
stress fracture in a military population which found that compared with controls, cases 
had a statistically significantly lower 25(OH)D level (MD: -2.44, 95% CI: -4.05 ~ -
0.84, P=0.003) (73). 
 
Two MA of RCTs focused on the benefits of vitamin D supplementation on knee 
osteoarthritis. Western Ontario and McMaster Universities Arthritis Index (WMAC) 
function and WOMAC pain was found to be improved by vitamin D supplements. 
However, these two study did not support any effect of vitamin D supplements on joint 








The association between vitamin D level and non-cardiovascular, non-cancer death 
(death due to any reasons other than cardiovascular events or cancer) was studies by a 
MA of observational studies. Compared to the top third of the vitamin D level 
distribution, individuals in the bottom third were 34% increased risk of non-
cardiovascular, non-cancer death (RR = 1.34, 95% CI: 1.13-1.60) (86). A MA study of 
RCTs explored the effect of vitamin D supplementation on all-cause mortality in CKD 
patients, and did not find any statistically significant effect (RR = 0.84, 95% CI: 0.46-
1.52) (101).  
 
Two MA studies of observational studies were on association between vitamin D and 
outcomes in critically ill patients (patients in intensive care unit). One study explored 
30-day mortality of patients in ICU, and found a nominal statistically significant risk 
for patients with low vitamin D level (RR = 1.42, 95% CI: 1.00-2.02, P = 0.05) (75). 
Another study explored mortality and suggested a statistically significant elevated risk 
(OR = 1.76, 95% CI: 1.38-2.23) (84). Infection, in-hospital mortality and sepsis among 
patients in ICU were also included as outcomes in the first study, and the results were 
statistically significant for all of the three outcomes (75). Finally, another MA of 
observational studies explored the association between vitamin D level and sepsis in 
hospitalized patients, and found a statistically significant elevated risk for patients with 
low vitamin D level as well (OR = 1.78, 95% CI: 1.55-2.03, P<0.001) (91). Two MA 
of RCTs involved length of hospital stay, length of ICU stay, length of mechanical 
ventilation and mortality among ICU patients as their outcomes. Results from the two 
studies were consistent, and only mortality risk was found to be statistically 
significantly reduced by vitamin D supplements (RR = 0.84, 95% CI: 0.66-1.06; OR 
= 0.70, 95% CI: 0.50-0.98) (118, 119). 
 
Two MA of observational studies were on non-alcoholic fatty liver disease (NAFLD). 
The NAFLD fibrosis score and activity score were not statistically significantly 
associated with vitamin D level (MD: 0.88, 95% CI: -2.65 ~ 4.42 for fibrosis score; 
MD: -0.93, 95% CI: -2.45 ~ 0.58 for activity score) (82). However, the risk of NAFLD 
was found to be statistically significantly associated with vitamin D level in another 
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MA (OR=1.26, 95% CI: 1.15-1.38), and the difference of vitamin D level between 
non-alcoholic steatohepatitis patients vs controls was also explored and reported to be 
statistically significant by this study (SMD of VD: -1.30, 95% CI: -2.37 ~ -0.23) (85). 
Two MA of observational studies were on age-related macular degeneration. The 
results from the two studies were inconsistent. One of them reported a nominally 
statistically significant association when the highest quintile of vitamin D level was 
compared with the lowest quintile (SMD of VD: -0.15, 95% CI: -0.41 ~0.11, P=0.272, 
cases vs controls; OR = 0.83, 95% CI: 0.71-0.97, P=0.019, highest quintile vs lowest 
quintile of vitamin level) (78). However, the other MA did not find any statistically 
significant association (OR = 0.91, 95% CI: 0.69-1.22, P=0.12, for an increase of 
25(OH)D concentration by 10 ng/mL), partly due to the different comparison used 
from the previous study (121).   
 
Two MA of observational studies were on chronic obstructive pulmonary disease 
(COPD) and both found a statistically significantly higher vitamin D concentration in 
controls compared to cases with COPD (SMD of VD: 0.60, 95% CI: 0.31 ~ 0.89; SMD 
of VD: 0.69, 95% CI: 0.38 ~ 1.00) (80, 81).  
 
Three MA of observational studies were on risk of Parkinson’s disease, and all of them 
suggested a statistically significant association between vitamin D and risk of 
Parkinson’s disease. Compared with controls, cases with Parkinson’s disease had a 
lower 25(OH)D concentration (SMD of VD: -16.88, 95% CI: -33.54 ~ -0.23; MD of 
VD: -11.55, 95% CI: -12.23 ~ -10.86) (88, 89). In individuals with low vitamin D level, 
the risk of Parkinson’s disease was statistically significantly elevated compared to 
individuals with high vitamin D level (OR = 1.50, 95% CI: 1.14-1.97; OR = 1.50, 95% 










1.2.3 Association between vitamin D and health outcomes – published review 
From the published umbrella review in 2014, a total of 137 outcomes were explored 
in their relationship with vitamin D. These included skeletal outcomes, autoimmune 
diseases, cancer outcomes, cardiovascular outcomes, cognitive disorders, infectious 
diseases, metabolic disorders, neonatal/infant/child related outcomes, pregnancy 
related outcomes, and some other outcomes. In this section, I will give more details 
for outcomes of high prevalence/high burden based on the articles which were 
included in the published umbrella review of vitamin D. For more information, please 
refer to the published version of the vitamin D umbrella review (25) . 
 
1.2.3.1 Skeletal outcomes 
As has already been described above, vitamin D regulates calcium and phosphorus 
homeostasis. In a systematic review including 167 studies some evidence of an 
association between low 25(OH)D and established rickets was found (122). In addition, 
while evidence on impact of 25(OH)D on bone mineral contents in infants was found 
to be inconsistent, associations with bone mineral density in adolescents and the 
elderly were identified (122). However, in contrast to these findings, a systematic 
review and meta-analysis by Winzenberg and colleagues, including 6 studies in 
children and adolescents (343 participants receiving placebo vs 541 receiving vitamin 
D), reported a weak trend showing a small increase in lumbar spine bone mineral 
density with increased vitamin D concentration (SMD: 0.15, 95% CI: -0.01 ~ 0.31, P 
= 0.07) (123). Another systematic review and meta-analyses of RCTs published in 
2014 included 23 studies on bone mineral density, and only a small benefit at the 
femoral neck was found, with no effects on any other sites (124).  
 
A systematic review and meta-analysis of 17 case-control studies found 33% lower 
serum 25(OH)D levels in cases of hip fracture compared to controls (1903 fracture 
cases vs 1953 controls), however, the pooled result of RCTs did not support any effect 
(8 RCTs; pooled RR = 1.13, 95% CI: 0.98-1.29) (125). Furthermore, a statistically 
significant protective effect of vitamin D supplementation against non-vertebral was 
identified in meta-analysis of 12 RCT studies (for non-vertebral fracture: 12 RCTs, 
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pooled RR = 0.86, 95% CI: 0.77-0.96; for hip fracture: 8 RCTs, pooled RR = 0.91, 95% 
CI: 0.78-1.05), which did not suggest any association between vitamin D supplements 
and risk of hip fracture (126). However, robust evidence was still lacking regarding 
whether vitamin D supplementation alone is effective in osteoporosis and fracture 
prevention. In 2010, a meta-analysis of 7 major RCTs including 68517 participants, 
DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group, 
concluded that vitamin D alone was not effective, while given together with calcium, 
it could reduce risk of hip fractures and total fractures and probably vertebral fractures 
(127). In contrast, a more recent meta-analysis including 31022 participants found that 
vitamin D supplementation of more than 800 IU per day reduced the risk of hip fracture 
and any non-vertebral fracture independent of additional calcium intake (For hip 
fracture: HR = 0.70, 95% CI: 0.58-0.86; For non-vertebral fracture: HR = 0.86, 95% 
CI: 0.76-0.96) (128). Notably, agreement that combining vitamin D and calcium 
supplementation together could reduce fracture risk was reached by many reviews 
(129-133). 
 
For risk of falls, a meta-analysis of RCTs found that fall risk was statistically  
significantly reduced by high dose supplemental vitamin D (700-1000 IU/day) (RR = 
0.81, 95% CI: 0.71-0.92 from 7 RCTs involving 1921 participants), and meanwhile 
achieving serum 25(OH)D concentrations of 60 nmol/L or more reduced fall risk by 
23% (RR = 0.77, 95% CI: 0.65-0.90) (134). Another meta-analysis including 5 RCTs 
found that the OR of falling was reduced by 22% by vitamin D (OR = 0.78, 95% CI: 
0.64-0.92, 5 RCTs involving 1237 participants) (135).  
 
1.2.3.2 Cancer 
In a meta-analysis including 8 prospective studies, the top quantile of 25(OH)D had a 
OR of 0.66 (95% CI: 0.54-0.81) compared with bottom quantile on colorectal cancer 
risk, and for rectal cancer (OR=0.50, 95% CI: 0.28-0.88) the protective effect was 
stronger than that of colon cancer (OR=0.77, 95% CI: 0.56-1.07) (136). In addition, 
the association between 25(OH)D and colorectal adenoma incidence was also 
identified (OR=0.82, 95% CI: 0.69-0.97) by a meta-analysis of 10 observational 
studies (137).  




Evidence on associations between vitamin D levels and prostate cancer was 
inconclusive from meta-analyses studies of observational studies (138-140). In 
particular, in a systematic review and meta-analyses study including 25 papers 
published in 2011, the OR (95% CI) for per 1000 IU increase in dietary intake, per 10 
ng/mL increase in serum 25(OH)D concentration, per 10 pg/mL increase in 
1,25(OH)D concentration on total prostate cancer was 1.14 (0.99-1.31), 1.04 (0.99-
1.10) and 1.00 (0.87-1.14), while on aggressive prostate cancer it was 0.93 (0.63-1.39), 
0.98 (0.84-1.15) and 0.86 (0.72-1.02) respectively (139). 
 
In respect of breast cancer, a meta-analysis of 21 observational studies reported that 
women in the highest quantile of 25(OH)D were found to have a reduced risk of breast 
cancer risk of 0.86 (95% CI: 0.75-1.00) compared with those in the lowest quantile in 
nested case-control and retrospective studies, and the risk was 0.35 (95% CI: 0.24-
0.52) from meta-analysis of case-control studies (141). In a meta-analysis of 9 
prospective studies, an inverse association was found between serum 25(OH)D (27-
35 ng/mL) and breast cancer risk in postmenopausal women, with every 5 ng/mL 
increase associated with a 12% reduced risk (RR=0.88 per 5ng/mL, 95% CI: 0.79-0.97) 
(142). However, other meta-analyses failed to replicate these findings (132, 138). In a 
meta-analysis including 4 nested case-control studies (2363 cases vs 2363 controls), it 
was shown that each 10 nmol/L increase in 25(OH)D level was not associated with 
risk for breast cancer (OR = 0.99, 95% CI: 0.97-1.01, P=0.42) (132). In another meta-
analysis of 10 observational studies, although an overall association between vitamin 
D and breast cancer was shown (RR = 0.89, 95% CI: 0.81-0.98), it only existed in 
case-controls studies (5 studies of 3030 cases, pooled RR = 0.83, 95% CI: 0.79-0.87). 
In 5 prospective studies with 3145 cases, the pooled RR was 0.97 (95% CI: 0.92-1.03) 
(138). 
 
1.2.3.3 Cardiovascular diseases 
In a meta-analysis including 18 observational studies, the pooled OR of hypertension 
was 0.73 (95% CI: 0.63-0.84) for the highest category of serum 25(OH)D level 
compared to the lowest (143). In meta-analyses of RCTs, small effects of vitamin D 
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supplementation on both systolic (-2.44 mm Hg, 95% CI: -4.86 to -0.02) and diastolic 
(-3.1 mm Hg, 95% CI: -5.5 to -0.6) blood pressure were found (143-145).  
 
Various cardiovascular outcomes have been found to be associated with vitamin D 
status. In a meta-analysis of ten observational studies (58384 participants, and 2644 
cases), the highest quartile of 25(OH)D level had a statistically significant elevated 
risk for ischemic stroke compared to individuals in the lowest quartile (OR = 1.54, 95% 
CI: 1.43-1.65) (146). Similarly, in another meta-analyses including 7 prospective 
studies (1214 cases with stroke), the pooled risk of incident stroke was reported to be 
1.52 (95% CI: 1.20-1.85) (147). Another meta-analysis of prospective studies (24 
studies included, involving 6123 CVD cases and 65994 total participants) reported a 
pooled RR of 1.64 (95% CI: 1.27-2.10) for stroke, and they also reported statistically 
significantly elevated risk for total CVD, CVD mortality and coronary heart disease 
(total CVD: RR = 1.52, 95% CI: 1.30-1.77; CVD mortality: RR = 1.42, 95% CI: 1.19-
1.71; coronary heart disease: RR = 1.38, 95% CI: 1.21-1.57) (148). A meta-analysis of 
observational studies reported that risk for ischemic heart disease was increased by 39% 
(HR = 1.39, 95% CI: 1.25-1.54, 18 studies included), and risk for early death was 
increased by 46% (HR = 1.46, 95% CI: 1.31-1.64, 17 studies included) (149).However 
other meta-analyses failed to replicate these findings. In a meta-analysis including 50 
RCTs with 294,478 participants, no effects of supplementation with vitamins and 
antioxidants was found for any major cardiovascular events. Specifically, for vitamin 
D, including 7 studies, the summary RR was 1.02 (95% CI: 0.98-1.07) for prevention 
of major cardiovascular events (150). 
 
1.2.3.4 Metabolic disorders and diabetes 
Forouhi and colleagues incorporated their own data in a meta-analysis of prospective 
studies (11 studies included, 3612 cases and 55713 controls), and found that the 
combined RR of type 2 diabetes risk comparing the highest with lowest quartile of 
25(OH)D was 0.59 (95% CI: 0.52-0.67) (151). Similarly, in a study of 9841 
participants and a subsequent meta-analysis (14 studies included, 4877 cases and 
72204 total participants), Afzal and colleagues reported an association between low 
serum 25(OH)D with increased risk of type 2 diabetes (OR=1.50, 95% CI: 1.33-1.70) 




(152). However other meta-analyses and/ or systematic reviews failed to replicate 
these findings. A meta-analysis of RCTs showed a small effect on fasting glucose and 
small improvement in insulin resistance among patients with diabetes or impaired 
glucose tolerance, and the authors concluded that evidence was insufficient regarding 
the beneficial effect of vitamin D supplementation (153). 
 
1.2.3.5 Cognitive Disorders 
Relationships between vitamin D and cognitive performance and disorders have also 
been recently examined. In a systematic review and meta-analysis, Balion and 
colleagues showed that the group with higher vitamin D levels (>= 50 nmol/L) had a 
higher Mini-Mental State Examination score (WND = 1.2, 95% CI: 0.5-1.9, 8 studies 
included), and in addition, Alzheimer disease cases had a lower vitamin D 
concentration compared with controls (WMD = -6.2 nmol/L, 95% CI: -10.6 ~ -1.8, 4 
studies included) (154). Another meta-analysis in the same year reported similar 
results, with individuals of low vitamin D levels having an increased risk of cognitive 
impairment compared with individuals of normal vitamin D level (OR = 2.39, 95% CI: 
1.91-3.00, 7 studies included compromising 7688 participants) (155). In addition, 
vitamin D has also been found to be association with depression. In a meta-analysis of 
14 observational studies compromising 31424 participants, individuals with 
depression were found to have statistically significantly lower vitamin D concentration 
compared with controls (SMD = -0.60, 95% CI: -0.97 ~ -0.23) (156).  
  




1.3 Vitamin D GWAS 
By searching the GWAS Catalogue (https://www.ebi.ac.uk/gwas/), there were three 
previous GWAS studies on circulating 25-hydroxyvitamin D levels (157-159).  
 
In a European population of 4501 persons, Ahn J and colleagues conducted a GWAS 
for 25(OH)D concentration and found three loci in statistically significant association 
with vitamin D (GC, NADSYN1/DHCR7 and CYP2R1) (157). The Study of 
Underlying Genetic Determinants of Vitamin D and Highly Related Traits 
(SUNLIGHT) consortium conducted a GWAS in 33,996 white individuals in year 
2010 and found four loci in statistically significant association with vitamin D levels 
(GC, DHCR7, CYP2R1 and CYP24A1) (159). In year 2018, as an update of their old 
GWAS in 2010, SUNLIGHT published a new GWAS in 79,366 individuals, yielding 
two new loci in association with vitamin D (AMDHD1 and SEC23A) (158). For the 
details of genes and top variants identified by previous GWAS, please see Table 5. 
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Table 5. Genes associated with 25-hydroxyvitamin D level by previous GWAS. 
Study Variant Gene 
Chromosome: 
Position P value 
Ahn J. rs2282679 GC 4: 71742666 1.80*10-49 
Wang T.J. rs2282679 GC 4: 71742666 1.90*10-109 
Jiang X. rs3755967 GC 4: 71743681 4.74*10-343 
Jiang X. rs10741657 CYP2R1 11: 14893332 2.05*10-46 
Wang T.J. rs10741657 CYP2R1 11: 14893332 3.30*10-20 
Ahn J. rs2060793 CYP2R1 11: 14893764 2.90*10-17 
Jiang X. rs12785878 NADSYN1/DHCR7 11: 71456403 3.80*10-62 
Wang T.J. rs12785878 NADSYN1/DHCR7 11: 71456403 2.10*10-27 
Ahn J. rs3829251 NADSYN1/DHCR7 11: 71483513 3.40*10-9 
Jiang X. rs10745742 AMDHD1 12:95964751 2.10*10-20 
Jiang X. rs8018720 SEC23A 14:39086981 1.11*10-11 
Wang T.J. rs6013897 CYP24A1 20: 54125940 6.00*10-10 
Jiang X. rs17216707 CYP24A1 20:54115823 8.14*10-23 
Note: “chromosome: position” used version GRCh38.p7. 
 
The gene GC encodes vitamin D binding protein (DBP), which is a protein 
compromising 474 amino acids (160). DBP are found in multiple sites, including 
plasma, ascetic fluid, cerebrospinal fluid and on the surface of multiple cell types. In 
relation to vitamin D, it binds with vitamin D in skin and transports vitamin D to liver 
for 25 hydroxylation (161).  
 
The gene CYP2R1 (cytochrome P450 family 2, Subfamily R, Member 1) encodes an 
enzyme belonging to the cytochrome P450 superfamily. This enzyme catalyses many 
reactions involved in the synthesis of cholesterol, steroids and other lipids (162) and it 
could be the enzyme underlying 25-hydroxylation of vitamin D in the liver (162). 
 
The gene DHCR7 (7-Dehydrocholesterol Reductase) encodes an enzyme that removes 
the double bond in the B ring of sterols and catalyses the conversion of 7-DHC to 
cholesterol which is a vital step in the synthesis of vitamin D (163). 
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The gene AMDHD1 (Amidohydrolase Domain Containing 1) is a protein coding gene, 
which encodes a protein related to histidine degradation and viral mRNA translation 
(164). 
 
The protein encoded by gene SEC23A (Sec 23 Homolog A, Coat Complex II (COPII) 
Component) is a member of the SEC23 subfamily. In eukaryotic cells, secreted 
proteins are synthesized in the endoplasmic reticulum, wrapped by COPII-coated 
vesicles, and subsequently transported to the Golgi apparatus. SEC23 protein plays a 
role in promoting endoplasmic reticulum – Golgi protein transportation as part of 
COPII complex (158).  
 
The gene CYP24A1 (Cytochrome P450 Family 24 Subfamily A Member 1) encodes a 
protein belonging to the cytochrome P450 superfamily. It catalyses the inactivation of 
1,25(OH)2D by hydroxylation of the side chain on C24, which converts 1,25(OH)2D 
to calcitriol acid (165).  
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1.4 Systematic literature review of vitamin D Mendelian Randomization Studies 

Mendelian Randomization (MR) analysis employs exposure (serum 25(OH)D level in 
my project) related SNPs as instruments and explores the causal relationship between 
exposure and outcomes by analysing the association between instruments and 
outcomes. In a MR study, G denotes the instrumental variable (e.g. genetic variant(s)), 
E denotes the exposure of interest, and O denotes the outcomes/phenotypes (e.g. 
disease). The direct association between E and O may be biased by 
measured/unmeasured confounders (denotes by U). If G is associated with E and free 
from U, the causal effect of E on O can be estimated by the relationship between G 







Figure 6. Rationale of a Mendelian Randomisation Study. 
 
MR can, therefore, overcome the limitation of confounding factors and reverse 
causality. The idea of IV was first introduced in the econometrics literature by Wright 
and later adopted by the statistical measurement error and causal inference literature 
(166, 167). There are three assumptions underlying MR: 1) IV is associated with 
exposure (e.g., serum 25(OHD)); 2) IV is independent of outcome conditional on 
exposure and confounders (no pleiotropy); 3) IV is not associated with confounders 
(168). Genetic markers are therefore excellent IVs since they are randomly allocated 
at inception and thus randomly distributed (Mendel’s second law). This means that, 
even at population level, when relating genetic variants to diseases, alleles are 
generally unrelated to confounders and the association between genotypes and 
diseases are protected from reverse causality (169).  
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of Edinburgh, I conducted a systematic review for all published Mendelian 
Randomisation studies on vitamin D. Yazhou He ran the literature search. We both did 
the screening of the studies and I did the data extraction. 
 
1.4.1 Search strategy and review process 
For the systematic literature search, Medline and Embase were accessed in February 
2017. The search strategy is presented in Table 6. I included articles which were MR 
studies on association between vitamin D and health outcomes. Any review article, 
non-English article, letter or conference abstract was excluded. Studies on the impact 
of other markers/exposures on vitamin D levels were also excluded. After deletion of 
duplications, 95 references went into subsequent screening. Since the number of 
references is relative small, I downloaded full texts for all of them and implemented 
full text screening. After full text review, 27 studies were eligible for inclusion. At last, 
2 more eligible studies were identified by tracking the reference lists of the 27 included 
studies. As a result, a total of 29 studies met our inclusion criteria (Figure 7). 
  




Table 6. Search strategy and algorithm used in the systematic review for vitamin D Mendelian 
Randomization studies 
MEDLINE (OvidSP) 
1. Vitamin d/ or 25-OHD.mp. or 25 hydroxyvitamin D.mp. or cholecalciferol/ 
2. colecalciferol.mp. or hydroxycholecalciferols/ or hydroxycolecalciferols.mp. 
3. calcifediol/ or dihydroxycholecalciferols/ or dihydroxycolecalciferols.mp. 
4. calcitriol/ or 24,25-dihydroxyvitamin d 3/ or 24,25-OH2 D3.mp.  
5. ergocalciferols/ or dihydrotachysterol/ or 25-hydroxyvitamin d 2/ or 25-OHD2.mp.  
6. 1,25-dihydroxyvitamin d.mp. or 1,25-OH2 D.mp. or 1,25-dihydroxyvitamin d2.mp. 
7. 1,25-dihydroxyergocalciferol.mp. or 1,25-OH2D2.mp. or 1,25-dihydroxyvitamin d3.mp. or 
1,25-OH2 D3.mp. or ergocalciferols/ 
8. vitamin D2.mp. or vitamin D 2.mp. or vitamin D3.mp. or vitamin D 3.mp 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10. Mendelian Randomization Analysis/ or Mendelian randomisation.mp or Mendelian 
randomization.mp  
11. instrumental variable.mp or instrumental variables.mp or genetic instrument.mp or genetic 
instruments.mp 
12. random Mendelian.mp or genetic risk score.mp or genetic risk scores.mp or genetic score.mp 
or genetic scores.mp 
13. 10 or 11 or 12 
14. 9 and 13 
EMBASE (OvidSP) 
1. Vitamin d/ or 25-OHD.mp. or 25 hydroxyvitamin D/ or colecalciferol/ or cholecalciferol.mp.  
2. hydroxycolecalciferols/ or hydroxycholecalciferols.mp.  
3. calcifediol/ or dihydroxycolecalciferols/ or dihydroxycholecalciferols.mp.  
4. calcitriol/ or secalciferol/ or 24,25-OH2 D3.mp. or ergocalciferol/ or dihydrotachysterol/  
5. 25-hydroxyvitamin d 2.mp. or 25-OHD2.mp. or 1,25-dihydroxyvitamin d.mp. or 1,25-OH2 
D.mp.  
6. 1,25dihydroxyergocalciferol/ or 1,25-dihydroxyvitamin d2.mp. or 1,25-OH2 D2.mp.  
7. 1,25-dihydroxyvitamin d3.mp. or 1,25-OH2 D3.mp. or ergocalciferol derivative/  
8. vitamin D2.mp. or vitamin D 2.mp. or vitamin D3.mp. or vitamin D 3.mp 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10. Mendelian Randomization Analysis/ or Mendelian randomisation.mp or Mendelian 
randomization.mp  
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11. instrumental variable.mp or instrumental variables.mp or genetic instrument.mp or genetic 
instruments.mp 
12. random Mendelian.mp or genetic risk score.mp or genetic risk scores.mp or genetic score.mp 
or genetic scores.mp 
13. 10 or 11 or 12 
14. 9 and 13 
mp: any match for title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword. 
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Publications identified from MEDLINE and EMBASE (n=95) 
All publications went to full text review 
2 more articles were added tracing google scholar,  
PubMed and reference lists 
Excluded (n=68) 
  Not vitamin D MR (n=21) 
  Review articles (n=12) 
  Conference abstracts (n=16) 
  Comments/editorial (n=7) 
  Thesis for degree (n=1) 
  Risk score studies, but not MR (n=11) 
Publications included (n=29) 

Chapter I: Introduction – Vitamin D 

 	
1.4.2 Result summary 
 
For a summary of the most highly powered or most recent study for each outcome 
among the 29 eligible studies, please see Table 7. 
 
Among the 29 included studies, 5 were on glycaemic traits and diabetes, two of which 
found suggestive causal associations (170-174). Afzal et al. conducted MR for the 
effect of 25OHD on T2D in 96,423 white Danish individuals (5037 T2D cases). The 
genes DHCR7 and CYP2R1 were employed as IVs separately. For a sum score of 2 
SNPs (rs11234027, rs7944926) in DHCR7, the OR was estimated to be 1.51 (95% CI: 
0.98-2.33, P=0.04) per 20 nmol/L lower 25OHD as determined by genetic factors, 
which provided nominal evidence suggesting a causal relationship between vitamin D 
and T2D. However, in their own study, the OR for the CYP2R1 score (sum score of 
variants rs10741657 and rs12794714) was 1.02 (95%CI: 0.75-1.37, P=0.84). The 
inconsistent results might be due to DHCR7 and CYP2R1 being involved in distinctive 
steps of vitamin D synthesis, and only the step DHCR7 involved in (involved in skin 
synthesis of vitamin D3 from sun exposure) being associated with increased risk of 
T2D (171). In addition, Husemoen et al. studied the association between vitamin D 
and adiponectin, which is a protein involved in several metabolic processes, including 
glucose regulation and had been reported to be statistically associated with T2D (172). 
In a population of 6405 Danish individuals, they found that a doubling of 25(OH)D 
level was causally associated with a 61.46% (95% CI: 17.51-120.28, P=0.003) higher 
adiponectin. None of the other 3 studies found any evidence supporting a causal role 
of vitamin D in the glycaemic pathway or on risk of diabetes. Notably, Ye et al. 
conducted a summary statistics MR in populations of European descent with data from 
several consortiums (EPIC-InterAct, DIAGRAM, ADDITION-Ely, Norfolk Diabetes 
and Cambridgeshire) with SNPs in four genes reported to be associated with serum 
25OHD level by SUNLIGHT Consortium (159) as IVs, and for T2D they reached 
28,144 cases and 76,344 controls. Their estimated OR for risk of T2D was 1.01 (95% 
CI: 0.75-1.36, P=0.94) per SD decrease in 25OHD level as determined by genetic 
factors. In addition, they also analysed glycaemic traits including fasting glucose, 2-
hour glucose, fasting insulin, HbA1c, but none of them were statistically significantly 




associated with vitamin D (174).  
 
Concerned by its impact on circulatory outcomes, a total of 5 previous studies were on 
blood pressure and circulatory diseases (175-179). Skaaby and colleagues used three 
common filaggrin gene mutations of R501X, 2282del4 and R2447X as IVs and studied 
their associations with blood pressure, cholesterol, BMI, waist circumference and 
metabolic syndrome. Their analysis suggested a 23.8% (95% CI: 3.0-48.6, P=0.02) 
increase in HDL-cholesterol level and 30.5% (95% CI: 0.8-51.3, P=0.04) lower 
triglycerides level per doubling of vitamin D level (178). Another study employed a 
synthesis score of genes DHCR7 and CYP2R1, and with multiple consortia data of up 
to 140k individuals, each 10% increase in vitamin D levels was found to be associated 
with 0.37 mmHg (95% CI: -0.003-0.73, P=0.052) lower systolic blood pressure, 0.29 
mmHg (95% CI: 0.07-0.52, P=0.01) lower diastolic blood pressure and 8.1% 
decreased risk of hypertension (OR=0.92, 95% CI: 0.87-0.97, P=0.002) (179). The 
other 3 studies did not find any statistically significant associations.  
 
There were 4 studies that focused on autoimmune diseases (180-183). In a consortium 
of 14,498 multiple sclerosis (MS) cases and 24,091 controls, Morkry et al. found that 
the risk for MS was elevated by 1.02 (OR=2.02, 95% CI: 1.65-2.46, P=7.72*10-12) per 
standard deviation decrease in log-transformed 25OHD level as determined by IVs (4 
vitamin D related loci as previously identified by SUNLIGHT Consortium in 2010 
(159)) (180). Similarly, using 3 SNPs as IVs (rs2282679 in GC, rs2060793 in CYP2R1 
and rs3829251 in DHCR7), Rhead et al. observed an OR of 0.85 (95% CI: 0.76-0.94, 
P=0.003) in a white population of 7,391 MS cases and 14,777 controls (181). The 
other 2 studies were on rheumatoid arthritis severity and response to anti-tumour 
necrosis therapy for RA patients, but the outcomes they tested were not statistically 
significantly associated with the vitamin D IVs. 
 
Three studies explored cognitive functions and related outcomes (184-186). Jorde et 
al. tested the association between SNPs related to 25(OH)D level and cognitive 
functions, including word call test, digit-symbol coding test and finger tapping test. 
Only rs7975232 in gene VDR showed an association with word call test and digit-
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symbol coding test (homozygote of minor allele had significantly higher average mark 
than major allele homozygote). They tested 5 SNPs in VDR, one SNP in each of 
NADSYN1, CYP2R1, CYP24A1, DBP and a risk score, however, none of the others 
showed any statistically significant association (184). In addition, in a prospective 
cohort of 1207 white individuals, Kueider et al. investigated the causal effect of 
vitamin D on cognitive functions during aging with two SNPs (rs2282679 and rs7041) 
in GC gene as IVs. The score of the two SNPs was found to be causally associated 
with clock drawing task and psychomotor speed (185). Finally, Morkry studied the 
effect of vitamin D on risk of Alzheimer disease (AD) within the International 
Genomics of Alzheimer’s Project (17,008 cases and 37,154 controls). Meta-analysis 
of the associations between 4 SNPs (reported by SUNLIGHT Consortium in 2010 
(159)) and AD showed a 25% elevated risk (OR=1.25, 95% CI: 1.03-1.51, P=0.021) 
per standard deviation decrease of log-transformed 25OHD level (186). 
 
There were 3 studies on mortality or survival outcomes (187-189). Afzal et al. used 
four SNPs (rs11234027 and rs79449256 in DHCR7; rs10741657 and rs12794714 in 
CYP2R1) as IVs and studied their association with all-cause mortality, cardiovascular 
mortality, cancer morality, and mortality from other causes in three Danish cohorts of 
95,766 individuals and 10,349 deaths. From their IV analysis, every 20nmol/L 
decreased 25(OH)D level determined by genetic variants conferred a 30% increased 
risk to all-cause mortality (10,349 deaths; OR=1.3, 95% CI: 1.05-1.61), a 43% 
increased risk on cancer mortality (2839 deaths; OR=1.43, 95% CI: 1.02-1.99) and a 
44% increased risk on other mortality (2585 deaths; OR=1.44, 95% CI: 1.01-2.04). 
The association between IVs and cardiovascular mortality was not statistically 
significant (3231 deaths; OR=0.77, 95% CI: 0.55-1.08) (187). Trummer et al. studied 
the association between 3 25(OH)D related SNPs (rs2282679 in GC, rs10741657 in 
CYP2R1 and rs12785878 in DHCR7) and mortality (including all-cause mortality of 
995 deaths, cardiovascular mortality of 619 deaths and non-cardiovascular mortality 
of 355 deaths) in a prospective study of 3,316 participants. None of the genotypes was 
found to be associated with mortality outcomes (189). In addition, there was a study 
on melanoma survival by Davies et al. They studied the association between 
rs2282679 in GC, which has been reported to be associated with vitamin D level, and 
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overall survival and melanoma-specific survival in a meta-analysis of 3,137 melanoma 
patients. The SNP was not associated with overall survival but was associated with 
melanoma specific survival in cohorts where data were available (HR=1.22, 95% CI: 
1.04-1.43, P=0.01) (188).  
 
There were two studies on cancer (190). Ong et al. explored the effect of vitamin D on 
ovarian cancer in a sample of 10,065 cases and 21654 controls exploiting 3 SNPs as 
IVs (rs7944926 in DHCR7, rs12794714 in CYP2R1 and rs2282679 in GC). The odds 
were 1.27 (95% CI: 1.06-1.51) for all ovarian cancer (10,065 cases) and 1.54 (95% CI: 
1.19-2.01) for high grade serous type (4121 cases) (191). In addition, Theodoratou et 
al. studied the impact of vitamin D on colorectal cancer with 4 SNPs (reported by 
SUNLIGHT Consortium in 2010 (159)) as IVs, but did not find any statistically 
significant association (190). 
 
One study was on childhood caries. In this study, three SNPs (rs10741657 in CYP2R1, 
rs7944926 in DHCR7 and rs2282679 in GC) were employed as IVs. In a population 
of 5,545 children of European descent, they did not observe any statistically significant 
association with caries experience, dental general anesthetic or early caries onset (192). 
Another study was on bone mineral density and bone metabolism biomarkers 
(parathyroid hormone and procollagen type 1 N-terminal) in 1824 Chinese 
postmenopausal women. And they did not find any statistically significant association 
(193). 
 
There were two studies on body size related outcome. One of them was on birth weight 
(194) and the other one was on BMI (195). None of them found any significant causal 
association. Finally, there was one study on paediatric asthma (196), one study on C-
reactive protein (197), and one study on atherogenic lipoproteins (198), but none of 
them found any statistically significant association in their MR analyses. 
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Table 7. Findings from most highly powered or recent Mendelian Studies on each type of outcome. 
Study Outcomes Population No/No of Events Estimate of effect 
(95% CI) 
P value Metric 
Ye Z. 2015 (174) T2D white 104488/28144 1.01 (0.75, 1.36) 0.94 1 SD decrease in 25OHD level 
Ye Z. 2015 (174) Fasting glucoes white 46368 -0.02 (-0.04, 0.01) 0.28 mmol/L per SD decrease in  25OHD level 
Ye Z. 2015 (174) 2-h glucose white 46368 0.08 (-0.06, 0.22) 0.25 mmol/L per SD decrease in 25OHD level 
Ye Z. 2015 (174) Fasting insulin white 46368 -1.04 (-3.91, 1.83) 0.48 % difference per SD decrease in 25OHD level 
Ye Z. 2015 (174) HbA1c white 46368 0.01 (-0.04, 0.05) 0.8 % difference per SD decrease in 25OHD level 
Vim KS. 2014 (179) SBP white 146581 -0.37 (-0.73, 
0.003) 
0.052 mm Hg per 10% increase in 25OHD level 
Vim KS. 2014 (179) DBP white 142255 -0.29 (-0.52, -0.07) 0.01 mm Hg per 10% increase in 25OHD level 
Vim KS. 2014 (179) Risk of hypertension white 142255 0.92 (0.87, 0.97) 0.002 per 10% increase in 25OHD level 




white 86995/22233 0.99 (0.84, 1.17) 0.93 1 SD decrease in log-transfromed 25OHD level 
Morkry LE. 2015 
(180) 
multiple sclerosis white 38589/14498 2.02 (1.65, 2.46) 7.72E-
12 
1 SD decrease in log-transfromed 25OHD level 
Morkry LE. 2016 
(186) 
Alzheimer disease white 54162/17008 1.25 (1.03, 1.51) 0.021 1 SD decrease in log-transfromed 25OHD level 
Afzal S. 2014 (187) All-cause mortality white Danish 95766/10349 1.3 (1.05, 1.61) NA 20 nmol/L lower 25OHD 
Afzal S. 2014 (187) cardiovascular 
mortality 
white Danish 95766/3231 0.77 (0.55, 1.08) NA 20 nmol/L lower 25OHD 
Afzal S. 2014 (187) cancer mortality white Danish 95766/2839 1.43 (1.02, 1.99) NA 20 nmol/L lower 25OHD 
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Afzal S. 2014 (187) other mortality white Danish 95766/2585 1.44 (1.01, 2.04) NA 20 nmol/L lower 25OHD 
Ong JS. 2016 (191) all ovarian cancer white 31719/10065 1.27 (1.06, 1.51) NA 20 nmol/L lower 25OHD 
Ong JS. 2016 (191) high grade serous 
subtype 
white 31719/4121 1.54 (1.19, 2.01) NA 20 nmol/L lower 25OHD 
Theodoratou E. 2012 
(190) 
colotectal cancer white 4238/2001 1.16 (0.60, 2.23) NA per unit increase in log 25OHD level 
Dudding T. 2015 
(192) 
caries experience white 5545 0.93 (0.83, 1.05) 0.26 per 10 nmol/L increase 25OHD level 
Dudding T. 2015 
(192) 
detanl GA white 4072 0.96 (0.75, 1.22) 0.72 per 10 nmol/L increase 25OHD level 
Dudding T. 2015 
(192) 
early caries onset white 1933 1.09 (0.89, 1.34) 0.37 per 10 nmol/L increase 25OHD level 
Li SS. 2016 (193) Lumar 1-4 BMD Chinese 1824 -0.048 (0.056) 0.384 g/cm2_per unit increase in log-transformed 25OHD 
Li SS. 2016 (193) Femoral neck BMD Chinese 1824 -0.044(0.039) 0.261 g/cm2_per unit increase in log-transformed 25OHD 
Li SS. 2016 (193) Total hip BMD Chinese 1824 -0.041 (0.042) 0.326 g/cm2_per unit increase in log-transformed 25OHD 
Li SS. 2016 (193) PTH Chinese 1824 0.088 (0.062) 0.152 pg/mL_per unit increase in log-transformed 
25OHD 
Li SS. 2016 (193) P1NP Chinese 1824 -0.099 (0.098) 0.312 g/L_per unit increase in log-transformed 25OHD 
Tyrrell J. 2016 (194) birth weight white 30340 -26 (-54, 2) 0.13 g per 10% lower 25OHD level 
Vimaleswaran KS. 
2013 (195) 
BMI white 123864 -0.002 (-0.009, 
0.005) 
0.57 per risk allele 
Vimaleswaran KS. 
2013 (195) 
BMI white 123864 0.002 (-0.006, 
0.009) 
0.67 per risk allele 
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Hysinger EB. 2016 
(196) 
pediatric asthma white 5080/1203 -0.0000351 0.85 NA 




white NA -0.00833 0.86 NA 
Liefaard MC. 2015 
(197) 
LnCRP white 10788 -0.018 0.082 1 SD change in 25OHD level 
Ooi EM. 2014 (198) remnant cholesterol white 79743 4.0 (-2.4, 11) 0.22 % per 50% decrease in 25OHD level 
Ooi EM. 2014 (198) LDL cholesterol white 79812 2.2 (-1.7, 6.2) 0.28 % per 50% decrease in 25OHD level 
Ooi EM. 2014 (198) HDL cholesterol white 85363 -6.0 (-10, -2.3) 0.001 % per 50% decrease in 25OHD level 
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Chapter II: Introduction – PheWAS 
A systematic literature review of PheWAS studies 
There have been many PheWAS studies prior to my study. Thus, it is necessary to 
summarize the study design, methods applied and main results of the pervious 
PheWAS studies in order to understand the rational and process of conducting a 
PheWAS study and to setup the PheWAS methodology that I will apply before original 
data analyses. In this chapter, I conducted a systematic literature review of all 
published PheWAS studies, aiming to explore common PheWAS designs, statistical 
methods, the workflow for conducting and reporting PheWAS, and the advantages, 




2.1.1 Literature search strategy and inclusion and exclusion criteria 
I searched Medline and Embase bibliographic databases using the terms “phenome”, 
and “wide”, and “association” and “stud*”, or “PheWAS” up to end of 2017, which 
resulted in 305 papers. I did not include any reviews, correspondence, conference 
abstracts, literature introducing methodology or algorithm/software, literature which 
were not actual PheWAS, literature without full text, or research experiments 
conducted in animals or animal/ human cell lines. I also only retained papers written 
in English. With Xue Li, my PhD peer, we independently reviewed the literature and 
any discrepancies were solved by discussion. 
 
2.1.2 Data extraction 
From every study, I abstracted the following information: cohort name, sample size, 
ethnicity, age, type of data (i.e. EMR, clinical trial or large biobank), way of 
phenotyping (i.e. ICD curated/holistic, number of PheWAS groups, whether the rule 
of 2 was used, and the least number of cases), multiple comparison testing, regression 
covariates, method of association test (i.e. logistic regression, linear regression, chi-
square test, Fisher’s exact test, or others), the statistical software and packages they 
used, key findings, the statistically significant novel findings or the findings they gave 
emphasis to in their texts. 
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2.2 Review results 
2.2.1 Included studies and characteristics 
Forty-five papers were eligible for inclusion in my review through my literature search 
(Figure 8). The main characteristics and methodology applied of the included studies 




















Figure 8. Flow chart of study selection process of the systematic literature review of PheWAS studies.





No full text (n=1) 
Not a PheWAS (n=4) 
Review (n=10) 
Publications eligible for full text review (n=106) 
Number of studies 
included in the review 
(n=45) 
Excluded (n=199): 
Duplicate publications (n=98) 
Publications removed by title, 
abstract review (n=101) 
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Table 8. Characteristics and method of included PheWAS studies. 
Reference 
Sample 




testing method  
Covariates 
included 
PheWAS based on EMRs cohort 
Denny JC 
2010 (199)  





Proof of concept of a high 
throughput phenotyping algorithm, 
5 SNPs with known disease 
associations were genotyped 
ICD curated a 
25 as least 






13,617 European American rs965513 
(FOXE1) 
A GWAS for primary 
hypothyroidism, followed by a 
PheWAS for significant locus, 9q22 
near FOXE1 
ICD curated 
rule of 2 c  
20 as least 















To show the use of Resource 
Description Framework for 
representing EMR diagnoses and 
procedure data, and enable 
federated querying via standardized 
Web protocols to identify subjects 
ICD curated 
25 as least 












The first large scale PheWAS, 
exploring associations between 
3144 SNPs and 1358 EMR-derived 
phenotype groups in a sample of 
13835 participants 
ICD curated 
rule of 2 
25 as least 














To study the pleiotropic nature of 
HLA-DRB1, associations between 
rs3135388 and 4841 phenotype 
groups were tested. 
ICD holistic d 
rule of 2 






year of EMR 
Liao KP 
2013 (204) 
2,526 European ancestry autoantibodies 
(ACPA, ANA, 
anti-TPO) 
To study the association between 
autoantibodies and clinical 
diagnoses from EMR among 








Neuraz A  
2013 (205) 




To test the association between 
clusters of TPMT activity and 
diagnoses from ICD10 codes 
ICD curated 
















A GWAS for markers associated 
with QRS duration, and a 
subsequent PheWAS to search for 
associated diagnoses. 
ICD curated 
rule of 2 (actual 
chose 4) 
50 as least 





first 3 PCs 
Carroll RJ 
2014 (207) 
6,005 European American rs3135388 
(HLA-DRB) 
white blood cell 
count 
A proof of concept for a PheWAS 
R package 
ICD curated 
20 as least 












To study the pleiotropy of variants 
in FTO gene 
ICD curated 
rule of 2 
20 as least 







first 3 PCs 
study site 




11,519 African American mtSNPs To study the relationship between 
mtDNA variants and phenotypes 




first 2 PCs 
Namjou B 
2014 (210) 




A PheWAS in pediatric cohort for 
previously identified SNPs 
ICD curated 
rule of 2 
20 as least 












PLT, MPV or 
both 
A GWAS on MPV and PLT, 
followed by a PheWAS 
ICD curated 
rule of 2 
25 as least 









Multiple Birth month Systematically exploring the 
relationships between birth month 







29,377 European ancestry rs34536443 
rs35018800 
rs12720356 
Fine map the 19p13 locus (RA risk 
locus) to find causal variants, and 
explore the pleiotropic effect by 
PheWAS 
ICD curated 

















European TA repeat in 
UGT1A1 
GWAS of serum bilirubin levels, 
followed by PheWAS 
ICD curated 
377 outcomes 




Ye Z 2015 
(215) 




PheWAS on functional variants ICD holistic 
rule of 2 





year of EMR 
Hebbring SJ 
2015 (216) 
42,35 98% white or non-
Hispanic 




PheWAS using clinical text data in 
phenotyping 
clinical text based 
50 as least 
number of cases 
NA NA 




Multiple Birth month Replicating the publication by 





Liu J 2016 
(218) 
7,481 Multiple 2692 human 
major 
PheWAS for 2692 MHC variants ICD holistic Independent 
replication 
Sex 
Year of EMR 





rule of 2 






91,428 Chinese rs76863441 PheWAS for rs76863441, 
associated with lipoprotein-











29,349 European SNPs in the 
human 
leukocyte region 
PheWAS using linear mixed model ICD curated 
rule of 2 
50 as least 
number of cases 




6,892 European and African 
Americans 
184 functional 
variants in 34 
pharmacogenes 
Identify the pleiotropy of 
pharmacogenes.  
ICD curated 
rule of 2 
35 as least 





5,923 European 76,861 SNPs PheWAS for variants in immune 
related loci 
ICD holistic 
rule of 3 
10 as least 
number of cases 
Bonferroni Age 
sex 
first 5 PCs 




12,039 European 286 SNPs GWAS for 21 lab measurement 
extracted from EMR, followed by 
PheWAS for significant SNPs 
ICD holistic 
rule of 3 
200 as least 







first 4 PCs 
Verma A 
2016 (224) 
41,057 Multiple 25 stop-gain 
variants 
PheWAS for stop-gain variants ICD holistic 
rule of 3 
10 as least 






first 3 PCs 
Verma A 
2016 (225) 
45,899 European 687 SNPs GWAS for 25 laboratory traits, 
followed by PheWAS stratified by 
variance of laboratory traits (high 
variance and low variance 
individuals were analysed 
separately) 
ICD holistic 
rule of 3 
200 as least 





First 4 PCs 
Cortes A 
2017 (226) 
152,732 Multiple HLA-B*27:05 
allele 
PheWAS for HLA variants using a 
Bayesian analysis framework 
ICD holistic NA NA 
Doss J 2017 
(227) 
2,199 Multiple Seropositive RA 
vs seronegative 
RA; 
PheWAS for rheumatoid arthritis 
subgroups 
ICD curated 
rule of 2 
20 as least 
number of cases 
FDR Sex 
age 


















37,270 European 1,164 HLA 
variants 
PheWAS for HLA variants ICD curated 
rule of 2 
40 as least 




first 2 PCs 
Liao KP 
2017 (230) 
1,006 Multiple 36 
autoantibodies 
PheWAS for associations between 
autoantibodies implicated in RA 









Liu J 2017 
(231) 
14,275 Multiple SULT1A1 copy 
number 
variation 
ICD-9 code and text-based 
PheWAS for SULT1A1 copy 
number variation 
ICD holistic 




length of EMR 




23,382 text terms 
Robinson R 
2017 (232) 
2,907 Multiple loxoscelism PheWAS for phenotypic 
associations with loxoscelism. 
ICD curated 
rule of 2 
20 as least 








70,061 Multiple 83 GWAS-
derived variants 





14,042 Multiple 80 SNPs Comprehensive test of associations 
between 80 SNPs and 1008 






8,121 European children BMI allele score 
including 32 
loci  
MR-PheWAS: exploring causal 
associations between BMI and 











5,954,294 SNPs To identify pharmacogenomic 
associations, a PheWAS in a HIV 









first 5 PCs 









19 and 21 
PheWAS between clusters of 




























PheWAS for 13 genome-wide 
polygenic scores 








Identify novel traits associated with 
alcohol or nicotine use related 
variants. 
360 traits Bonferroni age 
age squared 
first 10 PCs 






521,000 NA 7 variants in 
Th17 and IL-17 
pathway 
A PheWAS with self-reported data 





first 5 PCs 
Polimanti R 
2017 (242) 
11,271 Multiple rs113288603 
(CYP2A6) 
PheWAS for CYP2A6 locus 358 traits FDR Sex 
age 
age-squared 
first 10 PCs 
Verma A 
2017 (243) 
1181 AIDS patients 
Multiple ethnicities 
2,544 SNPs Testing associations for laboratory 
phenotypes among antiretroviral 
treatment naïve patients 
774 phenotypes Permutation Sex 
age 
first 10 PCs 
a. ICD curated, ICD diagnosis codes were binned into phenotype categories due to predefined criteria. 
b. the required least number of cases for a phenotype to be included in statistical analysis. 
c. to be defined as case for a specific phenotype group, a participant must have at least two occurrence of related ICD codes on separate episodes. 
d. ICD holistic, the phenotype group in statistical analysis is simply defined by ICD codes, without any binning. 
Abbreviations: EMR, electronic medical record; ICD, International Statistical Classification of Diseases and Related Health Problem; least number of cases, phenotype 
groups with case numbers under which will not be analyzed; PC, ancestral principle components based on genotypic information, used to adjust for population 
stratification; FDR, false discovery rate; SNP, single nucleotide polymorphism; mtSNP, mitochondrial single nucleotide polymorphism.
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Table 9. Main findings of included PheWAS studies 
Reference Predictors Key findings 
PheWAS based on EMRs cohort 





l Four of seven known associations were replicated. 
l 19 novel associations identified. 
Denny JC 2011 (200) rs965513 (FOXE1) l The strongest association was with hypothyroidism. 
l Additional associations included: thyroiditis, nodular, multinodular goiters, and 
thyrotoxicosis. 
l Associations with Graves’ disease and thyroid cancer were not significant. 




l All of four SNPs were associated with diabetes and related traits. 
l Did not replicate associations between rs12255372 and breast cancer or prostate 
cancer. 
l All of four were associated with skin and tissue related diseases. 
Denny JC 2013 (202) 3144 SNPs in NHGRI's 
GWAS catalogue 
l Successfully replicated 66% of previous identified associations.  
l 63 novel associations were identified surviving multiple testing correction, the 
strongest of which was actinic keratosis and rs12203592 (IRF4). 
Chapter II: Introduction - PheWAS 
 	

Hebbring SJ 2013 (203) rs3135388 (HLA-
DRB1*1501) 
l None of the results met a conservative Bonferroni correction threshold. 
l The established association with MS was replicated. 
l The strongest association was with alcohol cirrhosis of the liver. 
l Also identified associations with erythematous conditions, benign neoplasms of the 
respiratory and intrathoracic organs, and benign neoplasm of other parts of the digestive 
system (replicating previous findings). 
Liao KP 2013 (204) autoantibodies (ACPA, 
ANA, anti-TPO) 
l anti-TPO was associated with hypothyroidism in both cases and controls; and 
associated with thyroiditis in controls. 
l The presence of ANAs was significantly associated with a diagnosis of Sjogren's/Sicca 
syndrome in RA cases; and other chronic non-alcoholic liver disease in controls. 





l very high TPMT activity was found to be associated with iron-deficiency anemia and 
diabetes mellitus. 
Ritchie MD 2013 (206) 23 SNPs in five loci 
associated with QRS 
duration 
l None of the results survived multiple testing. 
l The most significant associations were between rs6795970 (SCN10A) and cardiac 
arrhythmias or atrial fibrillation and flutter, which were independent of QRS duration. 
Carroll RJ 2014 (207) rs3135388 (HLA-DRB) 
white blood cell count 
l rs3135388 was associated with multiple sclerosis. 
l white blood cell count was associated with infections, leukemias, myeloproliferative 
diseases and anemia. 
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Cronin RM 2014 (208) 54 FTO SNPs previously 
associated with BMI and/or 
T2D 
l rs8050136 was found to be associated with obesity, morbid obesity, T2D, OSA, 
NAFLD and fibrocystic breast disease. After adjustment for BMI, associations with 
obesity, T2D and OSA were highly attenuated.  
l Associations between rs16952520 and non-inflammatory disorders of cervix, 
rs7199182 and chronic periodontitis, were not affected by adjustment, and they were 
also not associated with obesity or T2D. 
Mitchell SL 2014 (209) mtSNPs l 7 mtSNPs were found to be associated with total cholesterol. 
l 13 mtSNPs were found to be associated with T2D. 
l More SNPs were significantly associated than would be expected by chance alone for 
total cholesterol and T2D. 
l mt16189 was found to be associated with T2D, which was previously reported only in 
Asian and European descents. 
Namjou B 2014 (210) 2476 SNPs from previously 
published GWAS studies 
l Many previous associations were replicated, including JRA, thyroiditis and T1D. 
l Several novel findings were identified, the strongest of which were between PLCL1 
(best SNP 1595825) and developmental delays and speech disorder, IL5-IL13 region 
(best SNP rs12653750) with Eosinophilic Esophagitis. 
Shameer K 2014 (211) 81 SNPs associated with 
PLT, MPV or both 
l The strongest associates were between rs3819299 and inflammatory spondylopathies, 
ankylosing spondylitis and non-infectious uveitis. 
Boland MR 2015 (212) Birth month l 55 diseases statistically significantly associated with birth month. 
l 19 diseases were previously reported by literatures, 20 diseases were closely related 
to the previously reported ones, 16 birth month-disease associations were novel. 
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Diogo D 2015 (213) rs34536443 
rs35018800 
rs12720356 
l Three SNPs were found to be protective against RA, SLE and suggestive IBD. 
l No convincing evidence for association with complex phenotypes other than 
autoimmune diseases were found. 
Namjou B 2015 (214) TA repeat in UGT1A1 l None of the associations were statistically significant controlling for multiple 
corrections. 
l There were toward trend effects on cerebrovascular disease and ischemic stroke in 
adults. 
Ye Z 2015 (215) 105 presumed functional 
(stop-gain and stop-loss) 
variants 
l The most significant association reported was between rs3731608 and current long-
term drug use, but it was not replicated in another independent set. 
l A nonsense variant rs2736911 was found to be associated with age-related macular 
degeneration. 
Hebbring SJ 2015 (216) 5 SNPs with previously 
known associations 
l The association between rs1061170 and age-related macular degeneration 
(specifically, with words strings "macular degeneration", "non-exudative" and 
"exudative"), as well as word string "visudyne", a drug commonly used to treat age-
related macular degeneration, survived multiple testing. 
Li L 2016 (217) Birth month l Four circulatory outcomes were significant at FDR adjusted level, including coronary 
arteriosclerosis, essential hypertension, angina and pre-infarction syndrome. 
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Liu J 2016 (218) 2692 human major 
histocompatibility complex 
(MHC) variants 
l Eight novel outcomes were found to be associated with MHC region. These include 
unspecific histoplasmosis retinitis, haemangioma of intra-abdominal structures, 
pneumonia due to staphylococcus, lichen planus, dyshidrosis, other and unspecified 
nonspecific immunological findings, infraspinatus (muscle) (tendon) sprain, contusion 
of wrist. 
Millwood IY 2016 (219) rs76863441 l None of the outcomes were statistically significantly associated with rs76863441. 
Mosley JD 2016 (220) SNPs in the human leukocyte 
region 
l 44 phenotypes were associated with HLA variants. 
Oetjens MT 2016 (221) 184 functional variants in 34 
pharmacogenes 
l Previously known association between rs2231142 and gout, and association between 
rs4149056 and jaundice were replicated. 
l Novel associations between rs1143672 and renal osteodystrophy were identified. 
Verma A 2016 (222) 76,861 SNPs l rs6910071 (C6orf10) were significantly associated with rheumatoid arthritis. 
l rs2239167 (ATN1) were significantly associated with type 2 diabetes. 
Verma A 2016 (223) 286 SNPs l 39 associated survived the Bonferroni correction. The most significant one was 
between rs9273363 (in HLA region) and type 1 diabetes. 
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l The majority of the PheWAS phenotype groups highly related to the clinical lab 
measures associated with same SNPs. 
Verma A 2016 (224) 25 stop-gain variants l Previously known associations were replicated. 
l rs328 (LPL) was found to be associated with disorder of lipoid metabolism. 
l rs1137617 (KCNH2) was found to be associated with acquired hypothyroidism. 
l rs12060879 (DPT) was found to be associated with complications of peculiar to certain 
specified procedures. 
Verma A 2016 (225) 687 SNPs l 717 PheWAS associations were found at P level of 0.001. 
l 39 SNPs associated with type 1 diabetes in patients with high variance of plasma 
glucose levels, but not in patients with low variance. 
l 4 SNPs in UMOD were associated with chronic kidney disease in patients with high 
variance for aspartate aminotransferase. 
Corte A 2017 (226) HLA-B*27:05 allele l Their Bayesian analysis framework increased statistical power by more than 20%. 
l Bayesian analysis identified associations not found by traditional PheWAS methods, 
including association between HLA-B*27:05 and 145 ICD-10 terms. 
Doss J 2017 (227) Seropositive RA vs 
seronegative RA; 
RF-positive vs RF-negative; 
ACPA-positive vs RA-negative 
l Seronegative RA was associated with myalgia and myositis, fibromyalgia, and back 
pain. 
l Seropositive RA was associated with chronic airway obstruction and tobacco use. 
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Jannot AS 2017 (228) Hospital acquired acute kidney 
injury (HA-AKI) 
l Surgical procedures and hemodynamic impairment were found to be the main risk 
factors for HA-AKI. 
Karnes JH 2017 (229) 1,164 HLA variants l 1,955 significant allele-phenotype associations were found for HLA variants. 
l HLA-DQB:1*03:02 was associated with type 1 diabetes. 
l HLA-B*27 was associated with ankylosing spondylitis. 
Liao KP 2017 (230) 36 autoantibodies l 24 significant associations were identified. 
l Autoantibodies against fibronectin was associated with obesity. 
l Autoantibodies against fibrinogen was associated with pneumonopathy. 
Liu J 2017 (231) SULT1A1 copy number 
variation 
l No phenotype passed the Bonferroni correction from the ICD-9 based PheWAS. 
l In the text-based PheWAS, association with term ‘Nasacort’ passed Bonferroni 
threshold. 
Robinson 2017 (232) loxoscelism l 29 associations were significant, including rash, toxic effect of venom, and haemolytic 
anemia. 
PheWAS based on other cohorts 
Chapter II: Introduction - PheWAS 
 

Pendergrass SA 2013 (233) 83 GWAS-derived variants l 111 associations were significant for the same ethnicity, SNP and phenotype-class 
across two or more study sites. 
l 52 replicated associations, 26 represented phenotypes closely related to previous 
associations, 33 potentially novel associations. 
l Most significant novel finding: association between rs1333049 (CDKN2A/B) and 
haemoglobin levels in African Americans, which was found to be associated with type 
2 diabetes in European Americans previously. 
Hall MA 2014 (234) 80 SNPs l 39 replicated associations. 
l 9 related to reported associations. 
l 21 novel associations. 
l 13 SNPs showed evidences of pleiotropy. 
Millard LA 2015 (235) BMI allele score including 32 
loci 
l A total of 21 outcomes were associated with BMI at P < 0.05 level, after Bonferroni 
correction, only association between BMI and HDL at age 9 kept significant. 
l A novel effect of BMI on global self-worth score were suggested. 
Moore CB 2015 (236) 5,954,294 SNPs l 20 SNP-phenotype pairs matched identical or very close related GWAS catalog 
associations. 
l 23 SNPs with 29 associations which differed considerably from GWAS catalog, 
including rs10494326 with neutrophil count and rs2201841 with plasma chloride 
concentrations. 
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Roesch SL 2015 (237) Fibroblast Growth Factors 19 
and 21 
l 21 variables associated with either FGF19 or FGF21, never both. Always, higher 
FGF21 or lower FGF19 were associated with some variables. After Bonferroni, only 
high glucose and high FGF21 kept significant. 
Karaca S 2016 (238) 21 SNPs in 9 immune related 
loci 
l rs2280090 (ADAM33) was associated with MEF240%, allergic bronchitis. 
l rs3918396 (ADAM33) was associated with risk of wheezing and eczema comorbidity. 
l rs2243250 (IL4) was associated with FEV240. 
l rs2569190 (CD14) was associated with diagnosis of asthma. 
Krapohl E 2016 (239) 13 scores for cognition and 
psychiatric disorders 
NA 
Polimanti R 2016 (240) CHRNA3-CHRNA5 locus, 
ADH1B, ALDH2 
l Prior association between ADH1B and drinking behaviour was replicated. 
l Novel associations between ADH1B and psychological traits, socioeconomic status, 
vascular/metabolic conditions, and reproductive health were suggested. 
l Prior associations between CHRNA3-CHRNA5 and smoking status, lung cancer and 
asthma were replicated. 
l Novel associations between CHRNA3-CHRNA5 and high-cholesterol-median use, 
distrustful attitude were suggestive. 
Ehm MG 2017 (241) 7 variants in Th17 and IL-17 
pathway 
l TYK2 was associated with tonsillectomy, strep throat occurrences and teen acne. 
l IL23R was associated with dandruff frequency. 
l TRAF3IP2 was associated with risk of male-pattern balding. 
l RORC (variant rs4845604) was associated with protection from allergries. 
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Polimanti R 2017 (242) rs113288603 (CYP2A6) l rs113288603 was associated with hearing loss symptoms in nicotine-exposed elderly 
subjects significantly. 
l In non-nicotine-exposed elderly subjects, this association was not significant. 
Verma 2017 (243) 2,544 SNPs l rs12683493 was associated with atazanavir pharmacokinetics. 
l rs2368393 was associated with CD4 T-cell count. 
l rs7865618 was associated with HIV-1 RNA phenotypes. 
l Both previously reported and possibly novel associated were identified. 
Abbreviations: IRF4, interferon regulator factor 4; MS, multiple sclerosis; anti-APO, anti-thyroidperoxidase antibody; ANAs, antinuclear antibodies; RA, rheumatoid 
arthritis; TPMT, thiopurine S-methyltransferase; SCN10A, sodium voltage-gated channel alpha subunit 10; OSA, obstructive sleep apnoea; NAFLD, non-alcoholic fatty 
liver disease; JRA, juvenile idiopathic arthritis; PLCL1, phospholipase C like 1; IL5, interleukin 5; IL13, interleukin 13; PLT, number of circulating platelets; MPV, mean 
platelet volume; SLE, systemic lupus erythematosus; IBD, inflammatory bowel disease; CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; FGF19, fibroblast growth 
factor 19; FGF21, fibroblast growth factor 21; T1D, type 1 diabetes. 
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In 2010, Denny et al. conducted a state-of-the-art PheWAS in a sample of 6,005 
European Americans. In this study, they first proposed the phecode system. This is an 
automatic code translation table working with ICD9 billing codes. Related ICD9 codes 
representing the same disease were classified into the same identical phecode group 
by the algorithm. All participants were linked to their EMR data, and a total of 776 
different disease groups were defined by the phecode system. In their study, five 
genetic polymorphisms were genotyped in order to validate the ability of PheWAS to 
replicate established associations and find novel associations. The genetic predictors 
included rs1333049 (associated with coronary artery disease and carotid artery 
stenosis), rs2200733 (associated with atrial fibrillation), rs3135388 (associated with 
multiple sclerosis and systemic lupus erythematosus), rs6457620 (associated with 
rheumatoid arthritis) and rs17234657 (associated with Crohn’s disease). For every 
distinct phenotype group, they calculated case and control genotype distributions and 
the c2 distribution, associated P values and allelic OR values. Rarer phenotypes, whose 
case numbers were less than 25, were not included into the analyses. Out of the seven 
previously established associations, four were replicated by their PheWAS (rs3135388 
with multiple sclerosis, rs17234657 with Crohn’s disease, rs1333049 with coronary 
artery disease and rs6457610 with rheumatic arthritis). In addition, 19 novel 
associations were identified for these five variants at a threshold of P <0.001. However, 
none of them survived the Bonferroni correction (199). The results of this study 
supported the capacity of PheWAS for replicating known associations and further 
providing statistical evidences on possibly novel associations. 
 
Following their first PheWAS study, Denny et al. published another one in 2011. In 
this study, they first conducted a GWAS for hypothyroidism in 1317 cases and 5053 
controls. Four SNPs (rs7850258, rs965513, rs925489, and rs10759944) near gene 
FOXE1 were found to be statistically significantly associated with hypothyroidism. In 
a subsequent PheWAS, rs965513 was selected and its association with 957 phenotypes 
defined by the phecode system were tested comprehensively in 13,617 individuals. In 
this PheWAS analysis, they required each case to have at least two ICD codes in a 
PheWAS case group, which could act to increase positive predictive value. Phenotypes 
with less than 20 cases were excluded. Logistic regressions were ran adjusting for age, 




sex, the first three ancestral principle components and hypothyroidism status. 
Hypothyroidism (OR = 0.76, P = 2.7*10-13), thyroiditis (OR = 0.58, P = 1.4*10-5), 
nodular goitres (OR = 0.76, P = 3.1*10-5), multinodular goitres (OR = 0.69, P = 
3.9*10-5), thyrotoxicosis (OR = 0.76, P = 1.5*10-3) were associated with rs9655133. 
However, Graves’ disease (OR = 1.03, P = 0.82) and thyroid cancer (OR = 1.29, P = 
0.09) were not associated with the SNP (200).  
 
In another PheWAS, data were stored and represented within the Resource Description 
Framework (RDF). RDF provides a powerful framework for expressing and 
integrating any type of data by representing data as labelled graphs. Therefore, it 
allows fast querying and information retrieval across multiple sources of data, 
including genotype data, EMR data and lab data. This study selected four SNPs to be 
associated with T2D, including rs5219, rs7903146, rs12255372 and rs13266634, and 
studied their associations with all disease and procedure types in 6,307 T2D cases. In 
this study, researchers first extracted all ICD9 billing codes, and defined phenotype 
groups with Clinical Classification Software (CCS) (244) based on ICD9 codes. CCS 
classified over 14,000 diagnoses codes and 3,900 procedure codes into 285 and 231 
distinct diagnosis and procedure phenotype groups, respectively. Similarly, 
phenotypes with less than 25 cases were not analysed in their PheWAS. From their 
analyses, all 4 SNPs were associated with diabetes and related traits. In addition, all 4 
SNPs were associated with skin and tissue related diseases (e.g., corns, seborrheic 
dermatitis), which had not been reported by previous studies. At last, although the 
association between rs12255372 and breast cancer (245) and prostate cancer (246) had 
been found by previous studies, this study failed replicating these associations, which 
might be caused by the relative small sample size (201). 
 
In addition, Denny et al. conducted a very large scale PheWAS, which explored 
phenome wide associations for 3144 SNPs with known associations on the GWAS 
catalogue in 13,835 individuals, and published their findings in year 2013 on Nature 
Biotechnology. EMR data were retrieved and the coded into 1,358 unique phenotypes 
by the phecode system. Two instances of related ICD billing codes were required for 
an individual to be coded as a case for specific phenotype group; Groups with less than 
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25 cases were not analysed. Their PheWAS successfully replicated 66% of previously 
reported genotype-phenotype associations (51/77) at P level of 0.05. Sixty-three novel 
statistically significant associations (surviving false discovery rate correction) were 
identified. The strongest novel association observed was between rs12203592 (IRF4, 
which was previously reported to be associated with hair and eye colour) and actinic 
keratosis (OR = 1.69, P = 4.1*10-26) (202).  
 
Hebbring et al. studied the associations between the rs3135388 polymorphism and 
4,841 phenotypes in a sample of 4,235 individuals. In phenotyping, they did not 
classify ICD billing codes into phenotype groups in the same way as the above studies. 
Alternatively, they used ICD9 codes directly as phenotypes. Each code represents a 
unique phenotype group, and individuals without records of the specific code were 
treated as controls for the code group. To be defined as a case for a coding group, an 
individual must have at least two occurrences of that code. Rare diseases whose case 
number were less that 9 were not analysed. In their study, none of the phenotypes 
survived a conservative Bonferroni correction. However, the previously established 
association with multiple sclerosis was suggested (P = 0.023) at P level of 0.05. 
Moreover, rs3135388 was found to be nominally associated with alcohol cirrhosis of 
the liver (P = 0.00011), erythematous conditions (P = 0.0054), benign neoplasms of 
the respiratory and intrathoracic organs (P = 0.042), and benign neoplasms of other 
parts of the digestive system (P = 0.0023) (203). Considering their limited sample size 
and the large number of phenotypes tested, the multiple testing burden was 
considerably large and it was hard for them to find any statistically significant 
association which survived multiple testing.  
 
All of the above 5 PheWAS studies employing genetic variants as their predictors of 
interest. In addition to genetic factors, other exposures can also be used as predictors 
in PheWAS, such as plasma biomarkers. In another PheWAS, the phenome wide 
association for the presence of anti-citrullinated protein antibodies (ACPAs), 
antinuclear antibodies (ANAs), and anti-thyroid peroxidase (anti-TOP) antibodies 
were studied in a sample of 1,290 RA cases and 1,236 controls. The phecode system 
was used in defining phenotype groups, and only phenotypes with greater than 1% 
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prevalence were analysed. For RA cases, 512 phenotype groups were analysed and for 
controls, 698 groups were analysed. Logistic regression models were fitted adjusting 
for age and sex. From their results, the presence of anti-TPO antibodies was associated 
with hypothyroidism in both RA cases (P = 1.2*10-16) and controls (P = 9.2*10-10). 
Anti-TPO was also associated with thyroiditis in controls (P = 1.2*10-7). The presence 
of ANAs antibodies was significantly associated with diagnosis of Sjogren’s/Sicca 
syndrome in cases (P = 8.6*10-6) and associated with other chronic non-alcoholic lever 
disease in controls (P = 2.9*10-5) (204). 
 
Another PheWAS with biomarkers as predictors was conducted by Neuraz et al. In 
their study, thiopurine S-methyltransferase activity (TPMTa) was classified into low 
TPMTa, normal TPMPa and very high TPMTa and association between categories of 
TPMTa and phenotypes were tested comprehensively in 442 individuals. Phenotyping 
was conducted in two different ways. Since the EMR of their individuals were in 
ICD10 codes, they first defined phenotype groups just based on first three digits of 
ICD10 billing codes (i.e. ICD10 holistic), and this led to 156 groups. In addition, they 
translated ICD10 codes back to ICD9 codes with the United Medical Language System, 
and then applied the phecode system, which generated 289 phenotype groups. Only 
phenotypes with no less than 5 cases were analysed. In the very high TPMTa versus 
other TPMTa (normal plus low TPMTa) group analysis, very high TPMTa was found 
to be associated with iron deficiency anaemia (P = 0.0005) and diabetes mellitus (P = 
0.0009) from the ICD10 phenotype analysis. The results of ICD9 phenotype analysis 
were consistent with the ICD10 results (205). 
 
In 2013, Ritchie et al. conducted another PheWAS following a GWAS. They first 
conducted a GWAS for QRS duration, which represents activation time in the cardiac 
ventricle and has been associated with adverse cardiovascular outcomes, in a sample 
of 5,272 European Americans. Twenty-three SNPs in 5 loci, which had been reported 
by previous GWAS, were replicated successfully by their GWAS. Then, they 
conducted a PheWAS for these 23 SNPs in 13,859 European Americans. They used 
the phecode system for their phenotyping, which generated 778 genotype groups. To 
be defined as a case for a specific phenotype group, an individual need to have at least 
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4 occurrences of related ICD9 codes. Phenotype groups of less than 50 cases were 
excluded from statistical analysis. Age, sex, and first 3 ancestral principal components 
were adjusted as covariates. In their study, none of the genotype-phenotype 
associations survived Bonferroni correction. The most significant associations were 
between rs6795970 (SCN10A) and cardiac arrhythmias (P = 7.21*10-4) or arterial 
fibrillation and flutter (P = 8.45*10-4), which were independent of QRS duration (206). 
 
Denny et al. then produced a R package, which runs their phecode system, and 
published another PheWAS using the package. In this PheWAS, both genetic predictor 
(rs3135388 in HLA-DRB) and a non-genetic predictor (white blood count) were 
selected. In their study, 1,127 phenotype groups were generated by the phecode system. 
Phenotype groups with less than 20 cases were excluded from statistical analyses. For 
covariates, age and gender were adjusted. There had been another PheWAS study for 
rs3135388 on the same cohort (199) and the results from this study replicated known 
associations with multiple sclerosis found by the previous one (OR = 2.56, P = 1.4*10-
4 in this study; OR = 2.24, P = 2.8*10-6 from previous PheWAS study), which 
demonstrated the robustness of this R package. In the PheWAS for white blood cell 
count, it was found to be associated with infections, leukaemia and other expected 
conditions (207). 
 
In order to study the pleiotropy of genetic variants near gene FTO, which had been 
found to be associated with obesity and type 2 diabetes, Cronin et al. conducted a 
PheWAS in two populations of European ancestry. The first population comprised 
10,487 individuals of European ancestry, and the other one comprised 13,711 
individuals of European ancestry. PheWAS analyses were conducted in two 
populations separately, then a combined meta-analysis was conducted. PheWAS 
analyses were ran for 54 FTO SNPs. The previously described R package for phecode 
system was used in phenotyping. Cases for a given disease were defined as having at 
least two relevant ICD9 codes on different days. Analyses were conducted for only 
phenotypes occurring in at least 20 individuals. Analyses were first ran adjusting for 
age, sex, study site and first three ancestral principal components. Then, BMI was 
further adjusted to explore the association between variants and phenotypes 
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independent of BMI. The established associations between FTO (rs8050136) and 
obesity (OR = 1.25, 95% CI: 1.16-1.35, P = 2.10*10-9), and T2D (OR = 1.14, 95% CI: 
1.08-1.21, P = 2.34*10-6) were successfully replicated by their study. Polymorphism 
rs8050136 was also significantly associated with sleep apnoea, but this was greatly 
attenuated after adjusting for BMI. Phenotypes which were associated with rs8050136 
and this was not changed by adjustment of BMI included fibrocystic breast disease 
(OR = 0.84, 95% CI: 0.75-0.92, P = 4.8*10-4) and non-alcoholic liver disease (OR = 
1.19, 95% CI: 1.07-1.33, P = 1.9*10-3). In addition, associations between rs16952520 
and non-inflammatory disorders of cervix (OR=6.66, 95% CI: 3.03-14.64, P = 
2.36*10-6), associations between rs7199182 and chronic periodontitis (OR = 14.58, 95% 
CI: 3.97-53.57, P = 5.40*10-5) were independent of BMI as well. Polymorphisms 
rs16952520 and rs7199182 were not associated with obesity or type 2 diabetes (208). 
 
In another PheWAS, Mitchell et al. used variants on mitochondrial DNA (mtDNA) as 
their predictors. They studied the associations between 86 mtSNPs and 8 
cardiovascular related traits, including BMI, total cholesterol, high-density lipoprotein 
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, 
mean corpuscular haemoglobin (MCH), type 2 diabetes and hypertension in 11,519 
African Americans. Age, sex and the first two ancestral principal components were 
adjusted as covariates. Seven mtSNPs and 13 mtSNPs were found to be associated 
with total cholesterol and type 2 diabetes, respectively. More SNPs were statistically 
significantly associated than would be expected by chance alone for total cholesterol 
and type 2 diabetes. In addition, mt16189 was found to be associated with type 2 
diabetes, which was previously reported only in Asians and European descents (209). 
 
Namjou et al. conducted the first large-scale PheWAS in paediatrics. In their study, 
associations between 2,476 SNPs derived from published GWAS and 539 phenotypes 
were tested in 4,268 individuals of European ancestry. The phecode system was 
employed in phenotyping. An individual had to have two records of related ICD9 
codes in order to be defined as case for specific phenotype group. Phenotype groups 
of less than 20 cases were not analysed. Logistic regression models were fitted, 
adjusted for the first two ancestral principal components. Known associations were 
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replicated, including associations between rs2476601 and juvenile rheumatoid arthritis 
(JRA), thyroiditis and type 1 diabetes, association between rs3806932 and 
Eosinophilic Esophagitis (EoE). Novel findings included associations between PLCL1 
(rs1595825) and developmental delays and speech disorders (OR = 0.65, 95% CI: 
0.57-9.76, P = 1.13*10-8) and association between IL5-IL13 (rs12653750) and EoE 
(OR = 1.73, 95% CI: 1.44-2.07, P = 3.03*10-9) (210). 
 
In 2013, Shammer et al. conducted a GWAS which aimed to identify genetic variants 
affecting number of circulating platelets (PLT) and mean platelet volume (MPV) and 
explored the pleiotropic effect of significant SNPs by PheWAS. They had 13,582 
individuals with data o PLT and 6,291 individuals with data on MPV. In their GWAS, 
they identified five chromosomal regions associated with PLT and eight regions 
associated with MPV. Eighty-one SNPs (56 associated with PLT, 29 associated with 
MPV and 4 SNPs associated with both) were studied in their subsequent PheWAS. 
They generated 1,368 phenotypes with the phecode system. At least two instances of 
related ICD9 billing codes were required for definition of cases. Rare phenotypes with 
less than 25 cases were not analysed. Age and gender were adjusted as covariates. 
Multiple autoimmune and haematological conditions were associated with these SNPs. 
The strongest associations were between rs3819299 and ankylosing spondylitis (P = 
3.3*10-7), inflammatory spondylopathies (P = 5.7*10-8) and non-infectious uveitis (P 
= 4.6*10-7) (211). 
 
In 2015, Bolland et al. conducted a PheWAS for birth month, which was suggested to 
impact health outcomes of multiple categories, among 1,749,400 individuals. They 
derived ICD-9 diagnosis codes of participants from their EMRs, and mapped ICD9 
codes to Systemized Nomenclature for Medical-Clinical Terms (SNOMED-CT) codes. 
SNOMED-CT codes capture more clinical content compared with ICD-9 codes, thus 
is an alternative curating method for the ‘phecode’ system. In their PheWAS, a total of  
1688 diseases were tested against their association with birth month. Fifty-five diseases 
were statistically significantly associated with birth month, among which 16 were novel 
associations which had not been reported by previous studies (212). 
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In 2015, Diogo et al. first fine mapped the RA risk locus at 19p13 to define causal 
variants, and then studied the pleiotropy of theses variants with PheWAS. In their study, 
three protein coding variants (P1104A, A928V and I684S) in gene TYK2 were found 
to be associated with RA susceptibility. PheWAS was conducted in a sample of 29,377 
white individuals. The phecode system was employed in phenotyping. A person 
needed to have two occurrences of related ICD9 codes in order to be defined as a case 
of a specific phenotype group. Outcomes with prevalence of more than 1% were 
analysed (502 phenotype groups), and logistic regression models were fitted adjusting 
for age, sex and ancestral principal components. The only statistically significant 
association from their PheWAS was between P1104A and RA (OR = 0.65, P = 2.3*10-
5). Thus, their study did not support any association between RA related variants and 
phenotypes other than RA (213). 
 
In 2015, Namjou and colleagues conducted a GWAS for total serum bilirubin level and 
other liver function tests and found that a TA repeat in UGT1A gene was significantly 
associated with total serum bilirubin level. Then they conducted a PheWAS for this TA 
repeat in 1067 children and 2227 adults of European ancestry. A total of 377 
phenotypes generated by the ‘phecode’ systems were tested. No phenotype survived 
multiple testing correction. There were toward trend effects on cerebrovascular disease and 
ischemic stroke in adults (214). 
 
Most previous PheWASs studied SNPs identified by GWAS studies. However, top 
SNPs from GWAS were just tagging variants, and they did not necessarily have any 
biological functions. Causal variants, although they may have larger P values than 
tagging variants are of direct clinical relevance. Therefore, following GWAS studies, 
many studies focused on attempting to identify the true causal variant in the loci or 
nearby regions, which were reported to be associated with phenotypes. Ye et al. 
conducted a PheWAS for 105 presumed functional (stop-gain and stop-loss) variants. 
They implemented their PheWAS in 4,235 individuals and validated significant 
associations in another population of 10,640 individuals. ICD billing codes were used 
directly as phenotype groups. Two instances ICD codes were required for definition of 
cases. Codes with less than 8 cases were excluded from analyses. A total of 4,841 
Chapter II: Introduction - PheWAS 
 
coding groups were analysed. Logistic regression models were fitted adjusting for sex, 
and year of EMR. The association with the lowest P value was between rs3731608 
and current long-term drug use (P = 3.2*10-6). However, it was not replicated in the 
validation set. In addition, the nonsense variant rs2736911 was found to be nominally 
associated with age-related macular degeneration (P = 0.030). In the validation set, the 
observed association was directionally consistent, although not statistically significant 
(P = 0.081) (215). 
 
In 2015, Hebbring et al. conducted a text-based PheWAS in 4,235 individuals for 5 
SNPs reported by GWAS, including rs3135388, rs9501572, rs12678919, rs220073 and 
rs1061170. In their study, phenotype groups were defined by clinical texts rather than 
ICD codes. In brief, a total of 1,564,831 participant clinical notes were extracted, 
representing 423,537,905 unique words. For each participant, all clinical notes were 
concatenated together, and broken down into strings of words of four forms, single 
word, two adjacent words, three adjacent words and four adjacent words. As a result, 
there were a total of 270,885 single word, 7,507,412 double, 40,568,628 triple and 
92,755,314 four word strings. Then these word strings were cross referenced with 
terms from UMLS. A total of 23,384 word strings appeared in both clinical texts and 
UMLS, and the dataset was restricted to conditions with at least 50 cases. Then, for 
every SNP, its associations with all these 23,384 word strings were analysed. 
Associations were tested by chi square test. All five SNPs were nominally associated 
with the previously reported phenotypes at P<0.02 in the PheWAS. Associations 
between rs1061170 and word strings ‘macular degeneration’ (P = 1.8*10-8), ‘non-
exudative’ (subtype of macular degeneration, P = 2.3*10-7), ‘exudative’ (subtype of 
macular degeneration, P = 1.4*10-6), and ‘visudyne’ (commonly used drug in macular 
degeneration treatment, P = 3.9*10-7) survived conservative Bonferroni correction 
(216). 
 
From 2016, the number of PheWAS began to take off. During year 2016 and 2017, 
there were 16 PheWAS studies published, which used data from EMR. Among these 
16 studies, there were 6 using the ‘phecode’ system proposed by Denny et al, and 8 
studies choosing the ICD holistic way of defining phenotype. In addition, one study 
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mapped ICD-9 codes to SNOMED-CT codes as Bolland and colleagues did. The last 
study used the ICD holistic way, but they introduced a novel Bayesian analysis 
framework and compared results between their Bayesian analysis and general linear 
models. Details for the methods they employed and their main findings were listed in 
Table 8 and Table 9.  
 
All above PheWAS were conducted in populations with EMR data. In addition, there 
are other PheWAS studies whose phenotyping were not based on EMR. Pendergrass 
et al. conducted a PheWAS for 83 GWAS-derived variants in five population-based 
samples collected from different sites of multiple ethnicities (70,061 total participants). 
Their PheWAS were based on epidemiological studies, five studies collected data 
which included a wide range of common diseases, risk factors, intermediate 
biomarkers and quantitative traits. Since the phenotype collection was quite 
independent across individual studies, a total of 105 phenotype-classes were manually 
created to bin phenotypes from different studies together, and to compare results 
between individual studies. From their PheWAS, 111 associations were significant 
from the same ethnicity, SNP and phenotype-class across two or more study sites. 
Among them, 52 were reported by previous studies, 26 associations represented 
phenotypes closely related to previously reported associations, and 33 associations 
were potentially novel. The most significant novel associations were between 
rs1333049 (CDKN2A/B) and haemoglobin levels in African Americans, which had 
been previously reported to be associated with type 2 diabetes in Europeans (233).  
 
Similarly, Hall et al. conducted another PheWAS on epidemiological samples. Their 
study covered three surveys of three ethnicities (non-Hispanic whites, n=6,634; non-
Hispanic blacks, n=3,458; Mexican Americans, n=3950). A total of 1,008 phenotypes 
were collected and they were binned into 184 phenotype classes. Associations between 
80 GWAS-derived SNPs and phenotypes were tested, stratified by ethnicity. From their 
PheWAS, 69 associations were significant, of which 39 replicated previously reported 
association, 9 associations were closely related to previously reported phenotypes and 
21 represented novel associations. A total of 13 SNPs showed evidence of pleiotropy 
(234). 
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Integrating the idea of PheWAS and MR, Millard and colleagues implemented a MR-
PheWAS study of BMI. They created a genetic score comprising 32 BMI-related SNPs, 
and analysed associations with the score and 172 phenotypic outcomes. As explained 
before, this equals a two-stage MR. After Bonferroni correction, only the putative 
association between BMI and HDL-cholesterol at age 9 kept significant. In addition, 
their study suggested an possible causal association between BMI and a global self-
worth score (235).  
 
In order to identify pharmacogenomic associations, Moore et al. conducted a 
PheWAS for association between 5,954,294 SNPs and 27 laboratory assays in 
2,547 pre-treatment individuals from 4 AIDS clinical trial studies. Age, sex, the 
first 5 ancestral principal components and the square root of CD-4 cell counts 
were treated as covariates and adjusted in their analyses. From their results, 20 
SNP-phenotype pairs matched identical or very close to GWAS catalog reported 
associations. In addition, 23 SNPs in 29 associations differed considerably from 
those in the GWAS catalog, including an association between rs10494326 and 
neutrophil count, and an association between rs2201841 and plasma chloride 
concentrations (236). 
 
Roesch et al. studied the association between fibroblast growth factor (FGF) 19 
and FGF21 and 205 clinical outcomes, including anthropometric, diagnostic, 
biomarker and medication variables, in 62 patients with type 2 diabetes and 66 
controls without type 2 diabetes. From their analyses, 21 variables were 
associated with either FGF21 or FGF19, but never both. Only the association 
between high glucose and high FGF21 survived Bonferroni correction (P = 
3.0*10-5) (237). As a drawback of their study, the sample size is quite limited, 
which was only 128 in total. It was possible that the associations they observed 
was caused by chance, but they did not make further effort exploring that. 
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Furthermore, they applied Wilcoxon Rank sum tests and least-square linear 
regression in the PheWAS and reported only the P value. However, P values do 
not provide enough information, it could be better if they reported the effect 
estimates (e.g., coefficient value) of the associations. 
 
In year 2016 and 2017, there were 6 PheWAS studies published, which did not 
base their phenotype analysis on EMRs. Three of them used trial data as their 
study population, and the other three study used epidemiological data. Details 
of their methods and main findings were listed in Table 8 and Table 9. 
 
2.2.2 Critical steps in conducting a PheWAS 
Several steps are essential for a PheWAS, and I will describe them in detail in this 
section. A flow chart on the critical steps of conducting a PheWAS and on how to 
report results of PheWAS are presented in Figure 9 and Figure 10. 
 
Step 1: Determining the study sample 
Any type of study population with comprehensive collection of phenotypes can be 
used in PheWAS. To explore associations between variants and phenotypes 
comprehensively, a large population with blood samples and outcome measurements 
is crucial. As a rich resource for disease prevalence and medical history, an Electronic 
Medical Record (EMR) based population is the choice for the majority of previous 
PheWAS studies (199, 200, 202). Most of these PheWAS studies defined their case 
and control groups by ICD codes within the hospitalization episode data within the 
EMR system. The advantage of using an EMR cohort is that ICD coding makes 
phenotyping straight forward. With the hierarchy structure of ICD codes, samples can 
be categorized into case/control groups in a high throughput and effective manner. In 
addition to billing code, other information, such as clinical texts in the EMR data can 
also be integrated to the phenotyping procedure to make phenotyping more accurate 
and sensitive (216). However, in a general population with EMR data, it is hard to 
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study some outcomes of low prevalence due to limited power caused by relatively 
small case numbers. 
 
In addition to the comprehensive PheWAS described above, there is also the targeted 
PheWAS study design which focuses on only a certain category of outcomes, or 
biomarkers and other disease related risk factors (247). In that case, the sample does 
not need to be an EMR population, but samples with the variables of interest are 
suitable. 
 
Furthermore, some studies may focus on individuals with a specific disease or side 
effects of a new drug, and then a clinical trial can be a good choice (236, 243). In a 
trial design, the number of participants is guaranteed and thus the study power can be 
estimated. In addition, since confounders are well controlled, pharmacogenomics 
associations can be better explored (236). 
 
In recent years, large biobanks are emerging, such as the UK Biobank, China Kadoorie 
Biobank (248), the Kaiser Permanente Research Program on Genes, Environment, and 
Health (RPGEH) (249), and the Veteran Administration’s Million Veteran Program 
(MVP) (250). They provide a very wide spectrum of variables, such as EMR data, 
serum biomarkers, urine biomarkers, as well as lifestyle and environment exposures. 
With nearly all the potentially interesting variables, these biobanks could be used to 
explore associations in multiple levels and resolutions, which could eventually form 
networks or pathways to uncover biological mechanisms behind statistical associations.  
 
However, as a common challenge, especially for those using prospective cohort linked 
EMR cohorts, it is hard to study some outcomes of low prevalence due to limited 
power caused by relatively small case numbers. In addition, as with all epidemiological 
studies, biases in the sampling process should also be carefully considered and 
discussed. As with UK Biobank, since it is of higher than average socio-economic 
status compared to the whole UK population, genotype-phenotype associations which 
differ between social economic strata might not be well identified. 
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Step 2: Selecting predictors 
The selection of predictors depends on the aim of study. Genetic variants could be 
involved as predictors. Candidate genetic variants could be determined in different 
ways. Firstly, variants which were identified by previous studies (e.g., GWAS) to be 
related with certain outcomes could be used (199, 202, 203, 210). By using GWAS 
derived variants, the already established associations could be validated and 
meanwhile, those selected variants could probably be found to be associated with other 
outcomes not yet found to be relevant by previous studies. Secondly, and more 
comprehensively, an independent GWAS could be conducted ahead of the subsequent 
PheWAS, and then significant SNPs in GWAS used as predictors in the following 
PheWAS (206, 211). This kind of study could help identify new GWAS and PheWAS 
related variants. Lastly, since most variants of GWAS are just tagging variants without 
any biological function, fine mapping or functional stop-gain or loss variants could be 
used (215). For instance, for a certain outcome, the well-established associated locus 
can be fine mapped first in an attempt to identify causal variants and then these variants 
can be used in subsequent PheWAS analysis. In addition to nuclear DNA, mtDNA can 
be considered too (209).  
 
In addition to genetic predictors, non-genetic predictors are also an option. PheWAS 
can be used to the study the broad associations between biomarkers (or any 
intermediate phenotypes) and disease outcomes, and possibly identify common 
biological pathways. For example, autoantibodies (204), enzyme activity (205) have 
been used by previous PheWAS as predictors. 
 
Step 3: Phenotype coding 
In a PheWAS study hundreds of phenotypes are simultaneously analyzed and thus 
phenotyping is the most important and demanding step in a PheWAS. Several types of 
phenotyping are possible. 
 
In a study of population linked with EMR, ICD codes are a valuable resource for 
phenotyping. There are two ways to transform ICD codes into PheWAS phenotype 
groups, i.e. ICD curated and ICD holistic. A well-known way of curating ICD codes is 
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the PheWAS code (phecode) system developed by Denny and colleagues (207). In the 
phecode system, codes that represent common aetiology are combined together in the 
same phenotype group, while clinically distinct phenotypes which are represented by 
a single code are divided into separate phenotype groups, such as Type 1 Diabetes and 
Type 2 Diabetes (199). Controls for a specific phenotype group are all participants that 
do not have prevalent ICD codes which define cases or highly related codes. An 
alternative way of curating ICD codes is the Systematized Nomenclature of 
Medicine—Clinical Terms (SNOMED-CT) codes, which is a standardized and 
comprehensive clinical terms. As what has been done by previous studies, ICD codes 
were first mapped to SNOMED-CT codes, as they are more clinical relevant, and then 
associations between predictors and SNOMED-CT code groups were analyzed (212, 
217). In a holistic manner, phenotype groups are defined at multiple levels of 
resolution (for example in an ICD-9 holistic phenotyping, individuals with code 695.11 
are defined as a case group, but they belong to the super case groups of 695.1 and 695 
as well). Those without recodes of each billing codes are classified as controls in each 
phenotype group (203). 
 
In addition to the phenotyping rationale, there are some other factors to be considered 
for data analysis. To increase positive predictive values, individuals are always 
required to have presentation of a specific code more than twice within the EMRs to 
be considered as cases. This is especially true for populations from the USA because 
some codes are recorded as a hypothetical reason for a test, and thus they are not 
suitable as cases. To increase statistical power and help control the multiple testing 
burden, case groups with sizes smaller than a certain number (e.g., 20, 25 or 40) are 
not analyzed. Alternatively, some studies determined a threshold for prevalence of ICD 
code which will go into data analysis, for example more than 1% (204). 
 
ICD code-based phenotyping is straightforward and thus rapid and effective. However, 
ICD codes omit some useful information, such as biomarker level or clinical text, 
which may negatively impact the accuracy of phenotyping. In addition, both curated 
and holistic phenotyping have their specific advantages and disadvantages. Since 
multiple ICD codes are clustered into the same phenotype groups, compared with the 
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holistic approach, the curated phenotyping has smaller number of phenotype groups 
and thus greater case numbers in each group, which will increase the statistic power 
and decrease the sample size needed. In holistic phenotyping, the size of some case 
groups will be too small to be analyzed and the multiple testing burden and the number 
false positive findings are greater. But holistic coding has the advantage of making no 
assumptions regarding the genetic or environmental contributions to any one disease 
(251), which is similar to the design of GWAS studies, which is a hypothesis 
generating design. In addition, in a statistically significant association found by curated 
coding, the signal might be led by one of the ICD codes which are binned into the same 
phenotype group. In such a case, analyzing individual ICD codes separately in the 
holistic manner could help in clarifying potential biologically causal pathways. 
 
The majority of previous PheWAS were conducted with the ICD 9th version. The 
implementation of ICD 10th version, has resulted in more and more hospitalization 
data having to be adapted to this new system, including data from the UK Biobank. 
Whereas the ICD 9 system allows for nearly 17 000 possible codes, the ICD 10 system 
allows for more than 155 000 different codes (251). In such an updated ICD system 
with fine granularity, the granularity of phenotyping algorithm should be considered 
carefully based on sample size and disease prevalence.  
 
Apart from ICD code based phenotyping, there are some other efficient options. Since 
clinical texts present more information than ICD codes, they could be considered in 
phenotyping. Hebbring et al. conducted such a study exploiting text-based 
phenotyping (216). In their study, clinical notes of participants were broken down into 
unigrams (one word), bigrams (two adjacent words), trigrams (three adjacent words) 
and 4-grams (four adjacent words), which were subsequently cross referenced with the 
National Library of Medicine’s Unified Medical Language System (UMLS) medical 
dictionary. Word strings which were observed in both the UMLS medical dictionary 
and clinical text data and meanwhile had at least 50 cases were used to define 
phenotype groups. By comparison with ICD based coding, Hebbring demonstrated 
efficacy of text-based phenotyping. But as their phenotyping on word strings was 
imperfect, they were still faced with the problem of misclassification. Introducing 
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natural language processing would be helpful in refining this method. In the future, an 
advanced phenotyping methodology, which combines ICD codes, laboratory values, 
medication records, clinical texts, imaging data or other data, would be expected. 
Denny et al. conducted a combination study of GWAS and PheWAS on 
hypothyroidism, and in the preliminary GWAS study, an algorithm incorporating ICD9 
codes, laboratory values, text queries, and medication records was exploited for 
identifying cases/controls of hypothyroidism. In the subsequent PheWAS, 
phenotyping was still relied on ICD codes (200). Up to date, there is still no PheWAS 
approach which incorporates all above information in phenome-wide phenotyping. 
 
There are some epidemiological survey samples which do not have participants’ 
hospitalization data available (233, 234). However, with the great number of 
phenotypes collected, a PheWAS could still be feasible on this kind of data. The 
problem is that phenotype definition in epidemiological studies is not standardized. 
Different surveys will have their own phenotype variables and number of phenotypes. 
Therefore, for collaboration between study sites to gain a greater sample size and 
power, or to validate and compare results between study sites, phenotypes must be 
manually binned into phenotype classes. Then, a certain threshold (e.g. P<0.01) 
observed in two or more studies for the same predictor, phenotype class and 
race/ethnicity and consistent direction of effect could be considered as significant. As 
a tool for phenotype harmonization, the DataSchema and Harmonization Platfrom for 
Epidemiological Research (DataSHaPER) has been developed and its utility has been 
demonstrated (252). 
 
As discussed above, the prevalence of disease is not the only outcome that PheWAS 
are interested in. Some other phenotypes, such as body mass index, total cholesterol, 
high-density lipoprotein cholesterol or other laboratory phenotypes could also be 
involved in a PheWAS study (236). 
 
Step 4: Statistical analysis 
To establish the associations between predictors and multiple outcomes, logistic or 
linear regression can be used under an additive model, in which genetic predisposition 
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of wild type, heterozygotes and effect allele homozygotes are defined as 0, 1 and 2 
respectively. Meanwhile, chi-square and student T-test can also be considered for use. 
For small size groups (n=5), Fisher’s exact test needs to be conducted. Possible 
confounding factors include age, sex, ethnicity, year of EMR records, study site, and 
ancestral principle components (calculated on genotype information to adjust for 
population stratification), which is commonly the first three or first five. 
 
Common software used in this type of analysis include R, PLINK and SAS that can 
all complete the high throughput analysis effectively. In addition, EIGENSTRAT and 
EIGENSOFT are helpful in generating ancestral principle components and QUANTO 
can be used for sample size and power calculation. 
 
Similar to genome wide association studies, PheWAS is also challenged by multiple 
comparison testing. Four main ways could be used to correct the observed P-values 
for multiple testing. These include Bonferroni correction, false discovery rate (FDR), 
permutation, and inter-database replication. Since phenotype groups in PheWAS are 
correlated, especially in a holistic ICD coding based PheWAS, Bonferroni is widely 
considered to be over-conservative. The FDR is the expected proportion of erroneous 
rejections among all rejections. The more hypotheses are rejected, the more errors are 
treated as acceptable (253). Thus, FDR is more tolerable than Bonferroni and has been 
proven effective in dependency situations. Permutation, which could be implemented 
with PLINK, takes the correlations between phenotypes into consideration and thus 
could be treated as another option. Inter-database replication needs two or more 
comparable and independent cohorts. If an association is statistically significant in 
more than one database with consistent effect direction, it is considered as positive 
(233, 234, 236).  
 
Recently, a new Bayesian analysis framework has been developed by Cortes and 
colleagues, in order to deal with the interrelations between phenotypes. In this analysis, 
the relationships between phenotypes were accounted by the Markov process. It 
calculated a posterior probability, and do not need to implement the multiple testing 
correction. This method was proved to increase power, meanwhile identify novel 
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associations which could not be found by conventional analysis methods (226). 
 
Step 5: Interpreting significant results 
In a PheWAS, if the SNPs or other predictors were determined by GWAS or other 
previous studies, results replicating known associations are expected. For the 
replicated association, interpretation combining previous studies and known functional 
and biological information is suggested. It is relatively straightforward to identify true 
associations when knowledge of expected associations is incorporated into the 
interpretation of PheWAS results (215). In contrast, some known associations may not 
be replicated as expected. This inconsistency could result for several reasons, such as 
small case number due to low disease prevalence and small sample size, different 
environmental exposures and genetic/phenotypic heterogeneity. In addition, in an ICD 
coding based PheWAS, the phenotyping algorithm might also drive this. In the 
PheWAS conducted by Denny and colleagues in 2010, a chart view for systemic lupus 
erythematosus (SLE) cases defined by ICD9 based algorithm was presented. Among 
the 141 cases defined automatically by the algorithm, only 95 (67%) had documented 
or probable SLE as indicated by their treating physicians. The other false positive 
records contained SLE ICD9 codes due to tests or hypothetical diagnoses which were 
later dismissed (199). In addition, exclusionary events predating electronic records or 
events occurring outside medical facilities could also cause further bias in 
classification (200). Therefore, for the results which are not replicated but of major 
importance and with strong functional evidence, a manual inspection of the 
automatically defined cases is recommended.  
 
In a PheWAS, a single predictor can be found to be associated with multiple outcomes. 
In such a scenario of probable evidence of pleiotropy (i.e. a single predictor is 
associated with more than one distinct phenotypes), the correlations between these 
outcomes should be carefully considered and discussed. The relationship might be due 
to a common biological process with known genetic contribution (true pleiotropy). 
Alternatively, there may be a network or intermediary relationship (false pleiotropy), 
in which genetic variation may impact the variation of a single phenotype, but variation 
in that phenotype could then results in changes in other downstream phenotypes 
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indirectly (234). Namjou found PTPN22 to be associated with JRA, T1DM and 
thyroiditis; pleotropic effects which were expected due to known underlying biological 
correlations (210). FTO variants were found to be associated with T2D and obesity by 
Cronin et al., and they further discussed the relationship between FTO, T2D and BMI 
(208). A mediation analysis will be helpful in clarifying this kind of relationship.  
 
In addition, combining separate PheWAS results into a network could be a way to 
understand the underlying etiology and find true causation. For example, Hall and 
colleagues found rs328 (associated with HDL Cholesterol) near LPL and rs174547 
(associated with ferritin) near FADS1 both to be involved in TGF-beta receptor 
regulated NetPath pathway (234).  
 
Step 6: Reporting results 
On reporting PheWAS results, there are several helpful suggestions to be followed 
(Figure 10). The study sample, sample size, ethnical structure, other demographical 
data, outcomes collected, and whether it is a general population sample or clinical 
sample should be reported first.  
 
Then the way of selecting targeted predictors should be explained. If they were 
selected based on known associations, the previous findings should be included to be 
compared and discussed further in later sections. 
 
A crucial part is the rationale of phenotyping and being explicit about how this was 
conducted. The number of phenotype groups and definition of cases and controls 
should be reported. The sensitivity, specificity and positive predictive value of the 
phenotyping method, if applicable, could be reported. If outcome aggregation is 
involved, the method of binning should be explained (examples of some of the 
phenotype groups would be helpful). The problem of misclassification should be 
explored and reported. In addition, for curated ICD code phenotyping, the application 
of the rule of two (an individual is required to have at least two presentations of the 
same code to be considered as a case) and the minimal case number of phenotype 
groups which went to analysis (groups with few cases may be omitted) should also be 




In statistical analysis, the analytic method used should be reported. Details of the 
covariates included in the analysis should be reported. The way to deal with multiple 
testing challenge or the corrected significant threshold should be reported. 
 
The results of a PheWAS could be categorized into replicated results, related results 
(results of predictors associated with an outcome which is closely related to another 
previous reported outcome) and novel results. If there are some interesting predictors, 
which show some evidence of pleiotropy, they can be placed into a separate table or 
figures.  
 
For a PheWAS, the result table should include predictor information (e.g. SNP ID, SNP 
location, nearest gene), previous reported phenotype (to make comparison between 
previous studies), P value, effect size, and case numbers of each phenotype, which 
varies between different phenotype groups in PheWAS.  
 
A Manhattan plot can also be useful for the result presentation. In contrast to that of 
GWAS, the X axis of Manhattan plot of PheWAS is the phenome spectrum. Lines of 
different significant levels could be plotted. And besides, the effect size could be 
presented with the size of dots. An alternative option is sun plot (234, 254). In a sun 
plot, the results across the whole phenome spectrum cannot be shown. However, the 
statistically significant results for a specific predictor could be more easily visualized. 
With the name of the predictor labelled within a circle in the center, every significant 
result is presented surrounding it, whose significant level is presented by the length of 
a line connected the circle and the phenotype names around. 
 
To explore relationships or common biological pathways between different predictors 
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Figure 9. Flow chart of conducting a Phenome wide association study. 
sample 
selection
• general population linked with electronic medical records (EMR)/large biobanks




• genetic variants: GWAS derived; conduct independent GWAS; fine mapping; functional variants; mtDNA
• non-genetic predictors (e.g. autoantibodies, enzyme activity)
phenotyping
• EMR based: ICD curated; ICD holistic; clinical text; combination of all available data in  meidical records
• epidemiologiccal data: binning into phenotype classes
• others: biochemical measurements (e.g. cholesterol), physical measurements (e.g. height, weight)
statistical 
analysis
• Chi-square/Student T-test/Fisher's exact test
• general linear model (common coviarates: age, sex, ethnicity, ancestral principle components); Bayesian analysis
• correction for multiple testing (Bonferroni, false discovery rate, permutation, inter-database replication)
interpreting 
results
• success/failure in replicating known associations
• evidence of pleiotropy/causality/linkage
• exploring common pathways between results
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• reason for selecting certain predictors
• previous identified associations
phenotyping
• number of phenotype groups; definition of cases/controls
• details of the rationale of phenotyping agrregation or binning




• confounding factors adjusted as covariates
• multiple testing and corrected P values
result 
presentation
• replicated/related/novel results to be reported and discussed seperately
• tables: predictor information; previous reported phenotypes; effect size; P value; case numbers of each group
• figures: Manhattan plot; sun plot
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2.2.3 Follow up studies for significant associations from PheWAS 
Since PheWAS is a hypothesis-generating methodology similarly to a GWAS, 
statistically significant results from a PheWAS need to be replicated. Generally, an 
independent case-control study would be an option for replication, which could avoid 
the multiple testing and misclassification biases of the high throughput PheWAS. To 
determine the sample size of disease specific replications, assumption on prevalence, 
allele frequency and effect size must be considered. In addition, in the separate 
replicating study, defining cases and controls must be careful and precise, with 
preference to a combination of all available information such as serum biomarker, trait 
measurements, gold standard diagnosis, and even a case by case manual adjudication. 
In addition, possible effects of covariates such as age, sex, and environmental 
exposures on the association between predictor and phenotypic outcome should also 
be investigated (233). 
 
After a result has been replicated by independent studies of different type (i.e., general 
population, case-control, prospective cohort or trial), further follow up analysis could 
be conducted. Since most predictors of PheWAS are SNPs derived from published 
GWAS, PheWAS results have the same problem as those of GWAS. Many SNPs are 
just tagging SNPs in intergenic region without any function. Thus, fine mapping 
searching for causal variants in nearby or located genes is a critical step. Subsequently, 
functional or pathway studies could be conducted to reveal the true biological 
mechanisms underlying the significant results, which will pave the way for future 
genetic prediction or drug development. 
 
2.2.4 Strengths and limitations of PheWAS 
Strengths 
Focusing on SNPs identified by previous GWAS, PheWAS provides an approach for 
replicating GWAS results. In addition to replication and validation, PheWAS could 
also help in discovering novel genotype-phenotype relationships which are not found 
by disease specific GWAS or candidate gene studies. In many cases, the initial 
association found by GWAS may not be due to causality. By exploring associations 
between specific SNPs and a wide spectrum of outcomes, therefore a PheWAS could 
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help in identifying potentially causative associations underlying discoveries in 
disease-specific GWAS. If conducted in combination with GWAS, a network between 
genotypes and phenotypes can be constructed, providing a comprehensive catalogue 
of human diseases associated with published variants and a broad insight into the 
pathophysiology of multiple disease processes. 
 
The majority of PheWAS studies are conducted in populations with EMR data. This 
brings several certain advantages. Firstly, since individuals commonly experience 
multiple health conditions which will be all recorded in EMR, there is potential to 
support investigation of a wide variety of diseases. Meanwhile, the logical architecture 
of ICD codes makes phenotyping relatively straightforward and cost effective. In 
addition, since records of individuals are recorded longitudinally in EMR, it holds the 
promise of examining longitudinal healthcare outcomes such as disease complications 
or response to drug therapies, which has been demonstrated in a previous PheWAS by 
Ritchie and colleagues (206).  
 
Moreover, in pharmacogenomics, by exploring associations between genotype and 
drug targets as well as other outcomes or traits, PheWAS could provide an estimate of 
drug efficacy and toxicity, which will also help in identifying drug side effects. 
 
Limitations and future developments 
As a high-throughput analysis approach, PheWAS is faced with the problem of sample 
size. In previous PheWAS studies, some prior associations were successfully validated, 
however, others were not. Failure in replicating an identified association may be a 
result of limited power. The power to detect an association is determined by the minor 
allele frequency, effect size and prevalence. For some case groups, due to limited 
sample size and low prevalence, case numbers may be too low to draw any significant 
conclusions. This can also happen for rare variants. In addition, as a result of high-
throughput analysis, only standard covariates (i.e., age, gender, and ethnicity) are 
usually adjusted for in the analysis. However, other important confounding factors, 
such as environmental exposures and family history, are not considered. To resolve the 
problems due to limited sample size, large samples with genetic data linked to EMR 
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records are needed, which will increase the power of both GWAS and PheWAS studies 
and pave the way for studies on rare variants and rare diseases. In the near future, some 
large population cohorts will come into being (e.g., Kaiser Permanente, the Million 
Veterans Programs, the UK Biobank) and that will benefit future studies. 
 
Since SNPs identified by past GWAS are mostly used in PheWAS, we still have the 
same problem of identifying causal variants. Most SNPs identified by GWAS are just 
intergenic ones which do not have any biological function and they are just markers 
for other casual variants in linkage disequilibrium. As proved by Ye et al. (215), future 
studies targeting functional variants (e.g., functional stop-gain and stop-loss variants) 
or deleterious variants will be more effective in finding causal variants and biological 
mechanisms and at the same time are likely to have a relatively higher effect size, 
which may also increase power and mitigate the challenge brought by low allele 
frequencies. 
 
A major challenge with PheWAS is the multiple testing burden. Common methods for 
correcting the significance level include Bonferroni, FDR, inter-data replication and 
permutation. The hypothesis of Bonferroni requires independence between the 
regressions. However, in a PheWAS study, there is large correlation between 
phenotypes, which makes Bonferroni overly strict and inappropriate in this situation. 
Future novel correction methods (e.g., the Bayesian analysis framework) should be 
expected, which can take the complex relation network between genotypes and 
phenotypes into consideration.  
 
Developed by Denny et al., an automatic phenotyping algorithm based on ICD9 codes 
is widely used in PheWAS. However, there are several problems with this ICD coding 
system. As has been elucidated by Denny et al. (199), there can be false positives in 
ICD coding, in which billing codes are recorded as a hypothetical reason for a test. 
Besides, the ICD codes can miss medical conditions that predate an EMR system. 
Therefore, the sensitivity and accuracy of ICD coding is imperfect and it may not 
provide a comprehensive assessment for individuals’ disease history. The replicability 
of phenotyping in previous PheWAS maybe limited partly due to this reason. However, 
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since multiple phenotyping methods are available (phecode, SNOMED-CT, ICD 
holistic, epidemiological measurements) and there are several options to choose in 
process of phenotyping (digits of ICD codes to consider, use of the rule of 2, least 
number of cases to involve), different case-control groups could be generated by 
different choice of phenotyping methods. Methodological choices are determined by 
study aim and available resources. Differences in results generated by different 
phenotyping methods may not necessarily mean low replicability. It could be due to 
differences in statistical power of different methods, or different phenotype groups 
defined by different methods. Hence, the replicability of phenotyping process is not 
straightforward to investigate. In the future, some advanced phenotyping algorithm 
incorporating of various available information such as laboratory data, medication text, 
imaging data as well as ICD coding and taking advantage of natural language 
processing and machine learning should be established to provide a reliable automatic 
phenotyping tool of high sensitivity and high positive predictive value. Besides, this 
improved phenotyping algorithm is also expected to improve the replicability of 
PheWAS phenotyping. 
 
Finally, samples within an EMR system are always clinical populations which are 
exposed to a healthcare system and could have different characteristics from the 
general population, such as age or prevalence of diseases. Thus, associations found 
from EMR populations might not apply to the general population well. To resolve this 
concern, medical care systems covering a much broader population and richer 
resources of information which should also include daily and home care data as well 
as data in clinical facilities, and combination of EMR populations across a variety of 
geographical locations can be a possible solution. This is especially true for my study, 
since only the inpatient ICD data has been released by the UK Biobank. For the health 
care system in UK, a large proportion of medical care episodes were in general practice 
and outpatient departments. With data linked with inpatient EMR only, cases treated 
only by general practice and outpatient departments will be misclassified as controls. 
The degree of misclassification differs by outcomes. For outcomes which normally go 
to inpatient department, this problem is minimal, such as cancer and cardiovascular 
outcomes. However, for outcomes which are mostly treated out of inpatient 
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departments, such as hypertension, depression and vitamin D deficiency, the problem 
of misclassification will be more prominent.  
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Chapter III: Aims and Objectives 
In Chapter I, I described that vitamin D deficiency is a highly prevalent condition and 
that it has been found to be broadly associated with many health outcomes. However, 
there is a lack of evidence to support a causal role of vitamin D. In this chapter, the 
aims and objectives of the thesis will be presented. In short, this thesis has two major 
aims, to investigate the association between vitamin D related SNPs and a wide range 
of health-related outcomes, and to explore the causal relationship between vitamin D 
and health-related outcomes. 
 
3.1 Aim 1: Association between vitamin D related SNPs and health-related 
outcomes in the UK Biobank cohort 
The first aim of my thesis is to present the results of a number of PheWAS analyses 
conducted with data from the UK Biobank cohort. Since 6 SNPs have been found to 
be associated with vitamin D in previous large GWAS studies in white populations, I 
aim to explore the phenome wide associations of these SNPs. Specific objectives 
include: 
 
1) To conduct a systematic literature review on existing PheWAS studies, their applied 
methodology and most important findings; discuss their advantages and challenges, 
and try to raise some suggestions for future PheWAS methodology. (presented in 
Chapter II) 
2) For the 6 vitamin D related SNPs reported by the largest GWAS, describe their 
genotype distribution in UK Biobank cohort, and test for their HWE. For each SNP, 
test the associations with confounding factors, including UK Biobank assessment 
centre, gender, age, outdoor activities in winter/summer, qualifications, household 
income and drinking and smoking status. 
3) Prepare and code the relevant phenotype data (especially the inpatient data, cancer 
register and death register data) for use in the PheWAS analysis. 
4) For each SNP and scores of all SNPs (score weighted by their effects estimated by 
previous GWAS), conduct PheWAS to comprehensively test their associations with all 
medical outcomes defined by ICD coding system. 
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3.2 Aim 2: Investigate the evidence for causality between vitamin D and health 
outcomes in the UK Biobank cohort using a MR methodology 
Following the first aim, a MR methodology will be used to explore the causal 
association between vitamin D and health outcomes with vitamin D related SNPs in 
aim 1 as IVs. Specific objectives include: 
 
1) Conduct a systematic literature review for all previous MR studies on vitamin D, to 
explore the findings of previous MR vitamin D studies (presented in Chapter I, section 
1.4). 
2) In UK Biobank, conduct MR analyses for PheWAS outcomes that survived multiple 
testing correction, for outcomes with sufficient power, and for outcomes which had 
been explore by previous MR studies. Multiple MR methods will be used in this stage, 
including two-stage method, Inverse Variance Weighted (IVW) MR and Egger’s MR, 
followed by sensitivity analyses. 
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Chapter IV: Methodology 
In this chapter, I will describe the methodology of my study, which comprise two parts. 
In the first part, I will give the details of UK Biobank cohort, which is the population 
I will use in my study. In the second part, I will give details of the statistical methods 
which were explicitly used in my study. 
 
4.1 The UK Biobank Cohort 
In this section, information on the UK Biobank cohort, which are relevant to my study 
will be given. This include the study design, ethical approval, participant recruitment, 
data collection and release of UK Biobank data. Since UK Biobank is publically 
available, all details of this cohort are online at: http://www.ukbiobank.ac.uk/. For my 
study, an application for data usage was submitted to the UK Biobank group 
(Application ID: 10775). All the analyses I have conducted are included within this 
data application. 
 
4.1.1 Study design 
UK Biobank is a very large, prospective cohort study founded by the Wellcome Trust 
medical charity, the Medical Research Council, the Department of Health, Scottish 
Government and the Northwest Regional Development Agency. It aims to allow 
detailed investigations of genetic and non-genetic determinants of diseases of middle 
and old ages, which are commonly caused by a combination of lifestyle, environmental, 
and genomic factors, with individually modest effects and complex interactions (255).  
The cohort is designed to include ~500k general population from the UK. It intends to 
collect comprehensive baseline measurements and phenotypes from every participant, 
including whole and saliva sample collection, and links participants to their medical 
records in the National Healthcare Services (NHS) system. The participant recruitment 
and baseline data collection had been completed during 2006-2010. The follow-up will 
last for 20 years to facilitate the investigation for a wide range of diseases and 
outcomes. 
  
4.1.1.1 Ethical approval 
In order to keep independent of the UK Biobank team, the UK Biobank Ethics and 




Governance Council (EGC) was established by the Medical Research Council and the 
Wellcome Trust. EGC is responsible for the setup the ethical standards for UK Biobank, 
monitoring and reporting publicly on the conformity of the UK Biobank project, and 
advising on the interests of participants and the general public in relation to UK 
Biobank. 
 
The UK Biobank project has been approved by the North West Multicentre Research 
Ethics Committee (MREC), which covers the whole UK. It also has got ethical 
approval from the National Information Governance Board for Health & Social Care 
(NIGB) in England and Wales and from the Community Health Index Advisory Group 
(CHIAG) in Scotland. In addition, a generic Research Tissue Banc (RTB) approval 
(meaning that , research applications from the great majority of researchers will not 
need separate ethical approval). At lasts, UK Biobank also possesses a Human Tissue 
Authority (HTA) license. Therefore, researcher receiving samples from UK Biobank 
do not need a separate HTA license. 
 
4.1.1.2 Participant recruitment and enrolment 
UK Biobank identified potential eligible individuals’ name, address, sex, date of birth, 
NHS/CHI number from the NHS records. Invitations were sent to their addresses on 
NHS system. From year 2006 to 2010, UK Biobank recruited 502,665 UK residents 
aged between 40-69 years across the whole UK. Consent was given by all participants. 
They have been informed that they may be re-contacted by UK Biobank (e.g., for a 
follow-up visit, to seek consent to proposed new uses, etc.). It was explained to 
participants that they can withdraw their participation in the following 3 forms at any 
point of time and without giving a reason: 1) no further contact (UK Biobank would 
no longer contact the participant, but keep the right of obtaining further information 
from the health-relevant records, using their data and biological samples); 2) no further 
access (UK Biobank would no longer contact the participant, would not access their 
health records, but would still use the information the biological sample that have been 
collected); 3) no further use (totally quit, any data of this participant would not be used 
in any UK Biobank research project). 
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4.1.2 UK Biobank baseline data collected at recruitment 
Participants who agreed to join were invited to an initial assessment visit, which 
happened in one of the 22 assessment centres across the whole UK (Table 10). The 
assessment visit comprised electronic signed consent; a self-completed touch-screen 
questionnaire; a brief computer-assisted interview; physical and functional 
measurements; and collection of blood, urine, and saliva samples (255). The 
questionnaire and interview cover participants’ family history and early life exposures; 
psychosocial factors; environmental factors; lifestyle information; health status; 
hearing threshold and cognitive functions. The physical measurements include blood 
pressure and heart rate, grip strength, anthropometric measures, spirometry, bone 
density, arterial stiffness, eye examination and fitness test. Further detailed 
descriptions of the collection of phenotypes/information from UK Biobank relevant to 
this study are given below. 
 
4.1.2.1 Phenotypes collected from touch-screen questionnaire 
A touchscreen questionnaire was completed by every participant at recruitment, with 
a variety of demographic, lifestyle and other phenotypes collected, including gender, 
date of birth, height, weight, time spend outdoors in summer/winter, average 
household income before tax, qualifications, alcohol intake frequency, participant’s 
home address and self-reported medical conditions (for details of the touch-screen 
questionnaire: http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=113241). 
 
4.1.2.2 Age and gender collection and presentation in UK Biobank data 
Participants’ date of birth, month of birth, year of birth are recorded by UK Biobank 
into 3 distinct variables. Date of birth is highly sensitive and is supplied by UK 
Biobank to researchers only when necessary. Month of birth and year of birth are 
readily available to researchers. In addition, age at recruitment and age when attending 
assessment centre are also derived by UK Biobank and ready to use for researchers. In 
my study, I used age when attending assessment centre as a covariate in analyses.  
 
Gender was reported by participants at assessment centre and was used as a covariate 
in my data analyses. There are 229,165 males (45.6%) and 273,455 females (54.4%) 
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in the cohort.  
 
4.1.2.3 Height, Weight and BMI collection and presentation in UK Biobank data 
Standing height was measured through assessment using a Seca 202 device, with a 
mean of 168.68 cm and SD of 9.27. Weight was measured by a variety of means during 
initial assessment, and then merged into a single item, with a mean of 77.97 kg and a 
SD of 15.92. Body mass index (BMI) was derived by weight in kilograms divided by 
square of height in metres, with a mean of 27.39 kg/m2 and a SD of 4.79.  
 
4.1.2.4 Other baseline variable collection and presentation in UK Biobank data 
Outdoor activity time was reported as the number of hours participants spend outdoors 
on a typical summer/winter day. The home address of participants was represented by 
the east co-ordinate and north co-ordinate of the postcodes to which invitations were 
sent, using the Ordnance Survey reference (256). Household income before tax, 
qualifications, alcohol intake and smoking status were reported as categorical variables 
(Table 10). 
 
Table 10. Characteristics of baseline phenotypes. 
Variable Name Feature  
Continuous Mean (S.D.) 
Number of 
missingness 
Age at assessment 56.85 (8.13) years 0 
Standing height 168.48 (9.27) cm 2,490 
Weight 77.97 (15.92) kg 2,716 
BMI 27.39(4.79) kg/m2 3,041 
Time spend outdoors 
in summer 
3.93 (2.33) hours/day 3,997 
Time spend outdoors 
in winter 
2.22 (1.84) hours/day 3,997 
   
Categorical Levels Number of 




Sex Male 229,165 
 Female 273,455 
 Missing 0 
Household income  
before tax 
Less than £18,000 102,711 
£18,000 to £30,999 118,413 
 £31,000 to £51,999 120,677 
 £52,000 to £100,000 93,032 
 Greater than £100,000 24,645 
 Do not know 22,409 
 Prefer not to answer 52,085 
 Missing 5,353 
Qualifications College or University degree 178,083 
 A levels/AS levels or equivalent 143,300 
 O levels/GCSEs or equivalent 244,107 
 CSEs or equivalent 69,024 
 NVQ or HND or HNC or equivalent 98,636 
 Other professional qualifications 
(eg: nursing, teaching) 
152,598 
 None of the above 88,180 
 Prefer not to answer 5,618 
 Missing 3,985 
Alcohol intake  
frequency 
Daily or almost daily 108,494 
3 or 4 times a week 125,562 
 1 or 2 times a week 139,209 
 1 to 3 times a month 60,204 
 Special occasions only 61,927 
 Never 43,135 
 Prefer not to answer 612 
 Missing 889 
Smoking status Current 54,639 
 Previous 186,131 
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 Never 296,226 
 Prefer not to answer 2,153 
 Missing 883 
Tobacco smoking Smokes on most or all days 2,873 
 Occasionally 1,924 
 Ex-smoker 44,012 
 Never smoked 71,867 
 Prefer not to answer 615 
 Missing 381,329 
Assessment centre Barts 12,583 
 Birmingham 25,503 
 Bristol 43,015 
 Bury 28,336 
 Cardiff 17,882 
 Croydon 27,385 
 Edinburgh 17,201 
 Glasgow 18,651 
 Hounslow 28,879 
 Leeds 44,209 
 Liverpool 32,818 
 Manchester 13,940 
 Middlesborough 21,289 
 Newcastle 37,008 
 Nottingham 33,877 
 Oxford 14,062 
 Reading 29,417 
 Sheffield 30,397 
 Stockport(pilot) 3,798 
 Stoke 19,440 
 Swansea 2,281 
 Wrexham 649 
 Missing 0 





4.1.2.5 Medical and drug history at baseline collection  
In addition, with the touch screen questionnaire, participants were asked about their 
personal medical history for specific diseases (including vascular/heart problems, 
blood clot/DVT/bronchitis/emphysema/asthma/rhinitis/eczema/allergy, diabetes, 
gestational diabetes, cancer, fracture/broken bones, other serious medical condition/ 
disability; url: http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=100044) and the age at 
diagnosis. Following the questionnaire, there was a verbal interview by a trained 
research nurse on all past and current medical conditions. If the participant had ticked 
any kind of major disease in the questionnaire, the research nurse confirmed that by 
interviewing the participant. If in the interview, it turned out that these have been 
incorrectly selected by participants, the nurse would cancel the wrong response(s). If 
the participant stated that he/she had other serious medical condition or disability, the 
nurse would fill in the relevant disease code(s) as coded by UK Biobank data coding 
6, which is a customized disease coding system developed by the UK Biobank 
(different from the ICD coding system, which was used in the health records from 
linkage to NHS system, for more details on this data coding 6, please see: 
http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=20002). If the participant stated in the 
questionnaire that they had no major illnesses or disability or were not sure, this 
question was asked again and confirmed by the research nurse.  
 
Similarly, participants were asked about any prescription, medication, or dietary 
vitamins/supplements they regularly took when completing the touchscreen 
questionnaire (http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=100045). Then during 
the subsequent verbal interview with the research nurse, any regularly drugs taken 
were confirmed (http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=100075).  
  




4.1.3 Hospital Episode Statistics, Cancer Registry and Death Registry data 
UK Biobank participants were linked to electronical medical records (EMR) data, 
including Hospital Episode Statistics (HES), cancer registry and death registry data. 
In 2018, UK Biobank participants will be further linked to their General Practice data 
and imaging data. 
 
4.1.3.1 Hospital Episode Statistics [HES] 
HES data consists of three parts: in-patient admissions data, outpatient data and 
accident and emergency data. Only the inpatient data (including maternity and 
psychiatric episodes of care) have been released by UK biobank, with the other two 
parts to be made available in the future. The hospital inpatient data are sent to UK 
Biobank on an annual basis and includes data on admissions and discharges, diagnostic 
and operation codes and maternity and psychiatric data. Records from both National 
Health Service (NHS)-funded and private health care within NHS hospitals were 
included. The World Health Organization’s ICD codes were used to record diagnosis 
information, and from 1997 onwards, episodes are coded in the ICD 10th version. Any 
earlier records were coded using the ICD 9th version.  
 
The inpatient data are constructed on an episode basis, and every episode of a 
participant is a single line of record in the data, which is different to the way UK 
Biobank baseline data are organised (which is on an individual basis with every row 
of data representing a unique participant and with phenotypes running across the 
columns). Episode is defined as a continuous period of admitted patient care 
administrated under one consultant within one healthcare provider. If the patient is 
transferred to another consultant or to a different healthcare provider during a spell of 
treatment, a new episode is generated. A hospital spell is the total time a patient is in 
hospital, from date of admission to date of discharge. A hospital spell can consist of 
multiple consultant episodes (e.g., if the patient is transferred between consultants or 
providers during their time in hospital). Therefore, there can be one or more episodes 
within a hospital spell; likewise, there can be one or more hospital spells per participant 
(http://biobank.ctsu.ox.ac.uk/showcase/docs/HospitalEpisodeStatistics.pdf) (257).  




The inpatient data are organised into 5 sub-categories, which include 
admissions/discharge, operations/procedures, diagnoses, maternity and psychiatric 
admissions. Admissions and discharge include data on admission and discharge, 
hospital stay and type of care given. The operations/procedures domain contains 
operation and procedure codes coded by the OPCS. The diagnosis domain contains 
diagnosis codes for main and secondary diagnoses coded by the ICD system. The 
maternity part contains data related to maternity inpatient care (e.g., method of delivery, 
place, sex and status of baby). Finally, the psychiatric part includes data related to 
psychiatric inpatient care (e.g., carer support, history of psychiatric care, legal status). 
 
4.1.3.2 Cancer and Death Registry data 
The cancer registry data are sent to UK Biobank by the Medical Research Information 
Service, which is based on the NHS Information Centre (for participants residing in 
England and Wales) and Information Services Division, part of NHS Scotland (for 
participants residing in Scotland). Cancer registries acquire information on cancer 
diagnoses from multiple sources including hospitals, cancer centres and treatment 
centres, hospices and nursing homes, private hospitals, cancer screening programmes, 
other cancer registries, general practices, death certificates, HES, and Cancer Waiting 
Time data. The cancer registry data include date of cancer diagnosis, age at cancer 
diagnosis, type of cancer (coded by ICD), reported occurrences of cancer, histology 
code and behaviour code 
(http://biobank.ctsu.ox.ac.uk/crystal/docs/CancerLinkage.pdf) (258). UK Biobank has 
cancer register data prior to study inception, during the study and after the study 
finished. The type of cancer is coded according to the version of ICD coding that was 
relevant for that time period. There is a small amount of records in ICD8, which have 
been grouped into the ICD-9 tree structure. From year 2000, the type of cancer is coded 
with the ICD10 structure. The histology and behaviour codes of cancer are represented 
as separate variables, which are presented as five-digit codes in ICD10-O-3, ranging 
from M-8000/0 to M-9989/3. The first four digits code the histology and the fifth digit 
codes the behaviour.  
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Finally, death registry data are also available in UK Biobank. NHS Information Centre 
and the NHS Central Register, Scotland updates death certificates for UK Biobank on 
a quarterly basis. The data includes date of death, age at death, underlying cause of 
death (only one), contributory causes of death (could be multiple) and description of 
cause of death (http://biobank.ctsu.ox.ac.uk/crystal/docs/DeathLinkage.pdf) (259).  
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4.1.4 Genotyping and imputation data 
4.1.4.1 Genotyping and imputation 
Two 10mL blood sample per participant were collected by UK Biobank per participant. 
DNA was extracted from 850 µL buffy coat recovered from one of the 10 mL EDTA 
whole blood sample by a customized and automatic DNA extraction system. 
Genotyping plates (96 wells with two controls on each plate), 90 µL DNA in each well 
were shipped from UK Biobank, Stockport, UK to Affymetrix Research Services 
Laboratory, Santa Clara, CA, USA for genotyping.  
 
DNA samples were genotyped using either the Affymetrix UK BiLEVE Axiom 
(50,000 individuals) or Affymetrix UK Biobank Axiom (450,000 participants). These 
platforms are similar with 95% shared contents. UK BiLEVE is a study on chronic 
obstructive pulmonary disease, which included 50,008 UK Biobank participants with 
middle or extreme values (relative to the population distribution) of forced expiratory 
volume in 1 second from the UK Biobank 500k participants (260). The UK BiLEVE 
Axiom array (807,411 markers) was designed to a) measure rare coding variants, b) 
optimize imputation performance for common (MAF>5%) and low frequency (MAF 
1-5%) non-genotyped variants, and c) cover genes and genomic regions with 
established or putative roles in lung related outcomes comprehensively. The UK 
BiLEVE study was completed before the genotyping of 450k UK Biobank participants, 
and the UK BiLEVE Axiom array was used to finalise the design of the Affymetrix 
UK Biobank Axiom array. The UK Biobank Axiom array includes 820,967 genetic 
makers, providing good coverage for GWAS markers of common and low frequency, 
biological function and human disease (including Alzheimer’s disease, 
autoimmune/inflammatory, cancer, cardio-metabolic variants, lung function 
phenotypes, neurological disorders) in the European and British populations. It also 
includes rare coding variants, pharmacogenomics markers, copy number regions, HLA, 
inflammation, and eQTL (Figure 11). Samples were analysed in batches of 
approximately 4700 items, and there were 11 batches for UK BiLEVE Axiom array 
and 95 batches for the UK Biobank Axiom array 
(http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=22000). 
 





Figure 11. Summary of Affymetrix UK Biobank array content.  
A representation of different categories of content on the UK Biobank Axiom array. Numbers indicate 
the approximate count of markers within each category, ignoring any overlap. 
Source: reproduced from Figure 1 of reference 261. This figure was slightly different from the original 
figure in article because it came from an online available old version of the paper on biorxiv 
(www.biorxiv.org). This work is licensed under the Creative Commons Attribution 4.0 International 
License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter 
to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA. 
 
The genotyping data of UK Biobank was released in two chunks: the intermediate data 
release, which contains ~150,000 samples (50,000 UK BiLEVE samples and 100,000 
UK Biobank Axiom array), and the full data release of 488, 377 participants. 
 
The UK Biobank imputation was implemented after the array genotyping was done at 
Affymetrix. Imputation for intermediate data release was done using the programme 
IMPUTE 2 and was based on a merged reference panel of the Phase 3 of 1000 Genome 
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Project and the UK10K. For the full data release, the imputation was conducted with 
both the HRC panel and the merged panel of UK10K and 1000 Genome panel. The 
intermediate data imputation consisted of 87,696,888 bi-allelic markers in 12,570 
haplotypes, and the final data imputation included 92,693,853 autosomal SNPs (261). 
 
4.1.4.2 Quality Control 
A number of quality checks were implemented for the processes of sample retrieval, 
DNA extraction, and genotype callings. Affymetrix also carried out measurements to 
check the quality for array markers, especially those newly designed markers which 
were not on Affymetrix array before. Any sample or marker that failed these checks 
was excluded from the final data release. 
 
Subsequently, genotype data were sent from Affymetrix to the Wellcome Trust Centre 
for Human Genetics (WTCHG) at the University of Oxford, where, before the full data 
release, quality control checking marker-based quality and sample quality were 
conducted (261). 
 
The marker-based quality control included tests on batch effects, plate effects, and 
departure from Hardy-Weinberg Equilibrium (HWE), sex effects, array effects, and 
discordance across control replicates (Table 11). If a marker failed at least one test in 
a given batch, the genotype calls in that specific batch were set to missing. If a marker 
was considered to be unreliable across all batches, the marker was excluded from all 
the data.  
 
Table 11. UK Biobank marker-based quality control. 
Test 
Average number of SNPs 
failed per batch (sd) 
Fraction of all genotype 
calls affected 
Affymetrix cluster QC 1109 (699) 0.00140 
1. Batch effect 197 (86) 0.000249 
2. Plate effect 284 (266) 0.000358 
3. Departure from Hardy- 572 (77) 0.000723 




4. Sex effect 45 (5) 0.0000569 
5. Array effect 5417 0.00683 
6. Discordance across 
controls 
622 and 632 0.000796 
Total 7704 (721) 0.00971 
For all numbered tests a marker was set to missing if the test yielded a p-value < 10-12, except in case 
of test 6, for which a marker was set to missing if the test yielded < 95% concordance. The array effect 
test was applied across all batches and only for markers present on both arrays. The discordance test 
was applied across all batches, but not all markers are present on both arrays. The first value is the 
number of unique marker on the UK BiLEVE Axiom array that failed this test, and the second is for 
markers on the UK Biobank Axiom array. 
Source: from Extended Data Table 4, reference 261. This work is licensed under the Creative Commons 
Attribution 4.0 International License. To view a copy of this license, visit 
http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, 
Mountain View, CA 94042, USA. 
 
For sample quality control, missingness rate and heterozygosity (derived using a set 
of ~600k high quality autosomal markers) were used to identify poor quality samples. 
In addition, with ~15k high quality markers on X and Y chromosome, the sex of each 
individual was inferred from genotyping data, and confirmed with self-report sex from 
that participant. UK Biobank did not remove any individuals from their data release 
for the above reasons but they created tagging variables for individuals who were 
outliers on the above tests or with probable low sample quality (Table 12). However, 
they excluded 835 samples which were identified as duplicates, ~10 samples which 
were liable to sample mishandling in the lab, and 33 participants who asked to be 
withdrawn from UK Biobank. 
 
Table 12. Sample quality control for UK Biobank. 
Test Number of participants 
Outliers for heterozygosity/missing rate 968 
Putative sex chromosome aneuploidy 652 
Sex mismatch 378 




4.1.4.3 Ethnic background for UK Biobank participants 
During the assessment visit, participants were asked to report their ethnic background. 
Although most of them self-reported as white, there were a small fraction of other 
ethnicities (Table 13). With a set of 407,219 unrelated, high quality samples and 
147,604 high quality markers, the top 40 principal components (PCs) were computed 
with fastPCA (262), which is an algorithm performing well on very large datasets like 
UK Biobank. Then PC loadings were computed and all samples were projected onto 
the PCs, forming a set of PC scores for all samples, which was also included in the 
data release. Figure 12 shows results for the first 6 PCs plotted in consecutive pairs. 
Since the effect of population stratification is an issue which should be considered by 
epidemiological or genetic studies, UK Biobank also identified 409,703 white British 
individuals who were all self-reported as British, and who had very similar genetic 
background based on their PCs. 
 
 
Figure 12. Ancestral diversity in the UK Biobank cohort.  
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Plots of consecutive pairs of the first six principal components in a PCA of genotype data for UK 
Biobank participants. Each point represents an individual and is placed according to their principal 
component scores. 
Source: reproduced from Figure 3, reference 261. This figure was slightly different from the original 
figure in article because it came from an online available old version of the paper on biorxiv 
(www.biorxiv.org). This work is licensed under the Creative Commons Attribution 4.0 International 
License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter 
to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA. 
 
Table 13. Self-report ethnic background of the UK Biobank cohort. 
Ethnic group Self-reported ethnic background 
Number (percentage) of UK 
Biobank participants 
White  472837 (94.24%) 
 British 442710 (88.23%) 
 Irish 13215 (2.63%) 
 White 571 (0.11%) 
 Any other white background 16341 (3.26%) 
Asian or Asian British  9882 (1.97%) 
 Indian 5951 (1.19%) 
 Pakistani 1837 (0.37%) 
 Any other Asian background 1815 (0.36%) 
 Bangladeshi 236 (0.05%) 
 Asian or Asian British 43 (0.01%) 
Black or Black British  8066 (1.61%) 
 Caribbean 4520 (0.90%) 
 African 3396 (0.68%) 
 Any other black background 123 (0.02%) 
 Black or Black British 27 (0.01%) 
Chinese  1574 (0.31%) 
 Chinese 1574 (0.31%) 
Mixed  2958 (0.59%) 
 White and Asian 831(0.17%) 
 White and Black Caribbean 620 (0.12%) 
 White and Black African 425 (0.08%) 
 Mixed 49 (0.01%) 
 Any other mixed background 1033 (0.21%) 
Others/Unknown  6439 (1.28%) 
 Do not know 217 (0.04%) 
 Other ethnic group 4560 (0.91%)) 
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 Prefer not to answer 1662 (0.33%) 
Total  501756 (100%) 
 
 
4.1.4.4 Internal relatedness 
Relatedness between individuals could confound the results of epidemiological studies, 
especially when applying general linear models and this familial structure cannot be 
accounted for well in analyses. Thus, genome or phenome wide analyses try to ensure 
that participants are independent (i.e., not related). Participants are not independent in 
the UK Biobank and indeed, many participants are not aware that a close relative is 
also part of the cohort. To explore familial relatedness among UK Biobank participants, 
kinship coefficients were estimated for all pairs of samples to identify related 
individuals. For all pairs of individuals who were inferred to be 3rd degree or closer, 
the coefficients were reported by UK Biobank. Relationship classes were identified 
for each related pair using the kinship coefficient and the fraction of markers for which 
they share no alleles (263). A total of 147,731 individuals (30.3%) were inferred to be 
related (3rd degree or closer) to at least one other person in the cohort, and form a total 
of 107,162 related pairs, with a large proportion (66928, 62.45%) of them being 3rd 
degree related (Table 14).  
 














179 6276 22666 11113 66928 107162 
Source: from Extended Data Table 5, reference 261. This work is licensed under the Creative Commons 
Attribution 4.0 International License. To view a copy of this license, visit 
http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, 
Mountain View, CA 94042, USA. 
 




4.2 Statistical Methods 
The analysis process compromises three parts: 1) creation of the vitamin D score; 2) 
Phenome Wide Association analyses; and 3) Mendelian Randomization analyses. I 
will present details of the 3 major steps and the applied statistical methods in this 
section. All statistical analyses were implemented in R 3.3.2. For the PheWAS by 
phecode system, the R package developed by Carroll et al. (207) was exploited. 
 
4.2.1 Creation of the Vitamin D Score 
I created a genetic risk score for 25(OH)D. In the selection of variants, I used results 
from the most recent and largest GWAS- SUNLIGHT 2018, which was conducted with 
a total of 79,336 individuals of European ancestry (158). This GWAS identified 6 loci 
associated with serum 25(OH)D concentration and these were rs3755967 (GC), 
rs12785878 (NADSYN1/DHCR7), rs10741657 (CYP2R1), rs17216707 (CYP24A1), 
rs10745742 (AMDHD1) and rs8018720 (SEC23A) and they explained a total of 2.84% 
of the variance of the serum 25OHD level (158). I created a genetic score by adding 
the number of effect alleles carried by all 6 SNPs and weighted them based on their 
effect estimates (derived from SUNLIGHT). Imputation data were used in calculation 
of the score, and the risk-score module in software qctool v2.0 was implemented to 
generate the score from imputation data directly. 
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4.2.2 Phenome Wide Association Study Method 
Phenotyping and mapping ICD codes to phecodes 
The “phecode system” was developed by Denny et al. to facilitate the high throughput 
phenotyping process of PheWAS (details gave in Chapter II). In their state-of-art 
PheWAS, EMRs of ICD9 codes were first mapped to phecodes and then analyses were 
performed for predictors on phecodes. As stated in Chapter II, this curating system 
decreases the number of phenotype groups to be tested in a PheWAS and makes each 
group more clinically relevant. However, this version of the “phecode system” worked 
only with the ICD9 clinical modification, an ICD9 version applied in the USA. 
Collaborating with Professor Denny Joshua and his group, we updated the system so 
that it could work with ICD10 as well. In this collaboration, I first sent the ICD10 
summary data from UK Biobank to Denny’s group, under the consent from UK 
Biobank. The summary data sent by me were generated by counting the numbers of 
participants with every unique ICD10 code, which had two columns, i.e. ICD10 code 
and number of participants. On receiving the ICD10 summary data, ICD10 codes were 
mapped to phecodes by Denny’s group either directly or indirectly. If the description 
of an ICD10 code matches the description of a phecode, it was then mapped to that 
phecode directly. Otherwise, ICD10 codes were mapped to phecodes indirectly. They 
used the Unified Medical Language System (UMLS), which integrates and distributes 
key terminology, classification and coding standards, either to mapped an ICD10 code 
to an ICD-9-CM code or mapped the ICD10-code to a Systematized Nomenclature of 
Medicine Clinical Terms (SNOMED CT) code first and then to an ICD-9-CM code. 
Either way, they finally used the previous ICD-9-CM to phecode mapping to link the 
ICD10 code to a phecode indirectly (Figure 13). 
 




Figure 13. Mapping methods between ICD-10 codes and phecodes. 
Abbreviations: SNOMED CT: Systematized Nomenclature of Medical Clinical Terms. UMLS, Unified 
Medical Language System.  
 
Before my PheWAS analyses, I first pooled the hospital inpatient, cancer registry, and 
death registry data together. Then for each participant, every distinctive code he/she 
ever had was aggregated and the number of episodes reporting on that specific code 
was counted. We then applied the phecode algorithm (199) to define the case/control 
status of every participant for every phenotype group in the phecode system. For 
instance, an individual with a record of the ICD10 code M05.2 (rheumatoid vasculitis) 
was coded as a case for the phecode group 714.1 (rheumatoid arthritis). In addition, 
this individual was coded as a case for the phecode groups 714 (inflammatory 
polyarthropathies), 709.7 (Unspecified diffuse connective tissue disease), 716.9 
(Arthropathy, not otherwise specified), and 446.3 (Hypersensitivity angiitis). 
Furthermore, this individual was flagged as an exclusion for phecodes 714-716.0 
(other autoimmune arthritis, except for 714, and 714.1, as these are highly related 
codes and cases for 714.1 and 714 will not be an appropriate controls for these groups), 
and 696-696.99 (psoriasis, as these codes represent diseases also related to the immune 
system). Finally, this individual was coded as a control for all other phecode groups 
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I first explored the distribution of common confounding variables for health-related 
outcomes. Subsequently, genotypes of each variant were tested for Hardy-Weinberg 
equilibrium. In addition, I tested whether genotypes of the 6 SNPs distributed evenly 
across all UK Biobank assessment centres, in order to explore any population 
stratification among the included individuals. Chi square tests were implemented, 
comparing the expected counts to observed counts for the genotypes counts of every 
genotype in every assessment centre. The associations between the genetic risk score 
and common confounding factors, including age, gender, body mass index (BMI), 
physical activity (quantified as outdoor activities), the assessment centre each 
participant attended (approximation for residing area), average household income, 
education qualifications and alcohol intake were tested, since they are considered to 
be associated with many diseases (for the collection and measurement of these 
variables, please see section 4.1). For continuous variables, univariate linear regression 
was conducted with the score as the independent and the confounder of interest as the 
dependent variable. For categorical variables, analysis of variance was conducted. 
 
In the PheWAS analysis I only included disease groups with more than 200 cases based 
on a previous PheWAS simulation study (264). I applied multivariate logistic 
regression with disease outcome as the dependent variable and the 25(OH)D genetic 
risk score as the independent adjusted for gender, age, BMI, the UK Biobank 
assessment centre attended, east and north co-ordinate of home address and the first 5 
genetic PCs. I tested a total of 920 disease groups and thus a P-value of less than 
5.44*10-5 was regarded as statistically significant based on Bonferroni correction 
(0.05/920 = 5.44*10-5). In addition, each of the 6 SNPs (i.e., rs3755967 (GC), 
rs12785878 (NADSYN1/DHCR7), rs10741657 (CYP2R1), rs17216707 (CYP24A1), 
rs10745742 (AMDHD1) and rs8018720 (SEC23A)) were tested on their associations 
with all phenotype groups of more than 200 cases individually, adjusting for the same 
variables. 





4.2.3 Mendelian Randomization Methods 
Outcome selection 
Mendelian Randomization studies are of low power compared with traditional 
observational studies, partly caused by the small variance of biomarker explained by 
the genetic instrumental variable (265). Thus, only phenotypes with sufficient power 
in a Mendelian Randomization context need to be tested in my MR analyses. In my 
study, I considered those phenotypes with more than 80% power for detecting a true 
OR of 1.2 or greater in a Mendelian Randomization study, assuming an explained 
variance of 3%, case/control ratio of 1/5 or smaller (which should always be true with 
a large sample like UK Biobank), at an alpha level of 0.05, as of sufficient statistical 
power. I conducted the power calculation for binary outcomes based on an equation 
published by Burgess S. (265). Phenotypes with enough power which survived 
Bonferroni correction for the PheWAS between the 25(OH)D score and phenotypes 
(the results from single SNP PheWAS are not eligible for MR analyses, since I am 
trying the study the causal association between 25(OH)D as a biomarker and health 
outcomes) or showed probable or suggestive level evidence on association with 
vitamin D from the previous umbrella review on observational studies and RCTs (25) 
or were statistically significantly associated with vitamin D in existing MR studies, or 
those with conflicting results from existing MR studies were selected to be studied in 
my MR analyses (Figure 14). 
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Figure 14. Outcome selection for Mendelian Randomization analysis 
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MR analysis. 
Criteria 2: 1) OR 2) or 3) 
1). Significant in PheWAS. 
2). Significant or conflicting 
evidence from previous MR 
studies. 
3). Classified as probable or 
suggestive by previous 
umbrella review of vitamin D. 
Merge EMR data 
with self-report data. 
MR analyses 
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Merge EMR data and self-reported data 
For outcomes eligible for MR analyses, I merged UK Biobank EMR data with self-
reported medical conditions which were reported by each participant in the baseline 
questionnaire and the subsequent verbal interview with research nurse (details gave in 
section 4.1). By merging the self-reported data in, I aimed to identify cases which were 
missed by EMR data and thus falsely classified as controls in previous PheWAS, and 
to increase the statistical power further. 
 
Mendelian Randomization analyses 
I then ran MR analyses using multiple methods, including: a) two-stage MR, b) inverse 
variance weighted (IVW) MR and c) Egger’s regression MR. 
 
To test the robustness of my risk score as IV, I constructed the identical weighted sum 
score of 6 SNPs in the Study of Colorectal Cancer in Scotland (SOCCS) (266) and 
then tested the variance of 25(OH)D explained by this score and the corresponding F 
statistics. Furthermore, the standard deviation of the log transformed 25(OH)D level 
was also derived from SOCCS, which was used in subsequent calculation of OR values 
using a metric of per standard deviation change of log transformed 25(OH)D level as 
determined by genetic instruments. 
 
The score I used in the PheWAS is a weighted sum score whose weights came from 
SUNLIGHT 2018. In my study, the SUNLIGHT 2018 study represented the first stage 
of two-stage MR, testing the association between SNPs and the selected biomarker, 
vitamin D. The score created was just the predicted vitamin D level, as determined by 
genetic variants. I then ran the second stage of the two-stage MR, a logistic regression 
with the outcome variable (merged EMR and self-reported data) as dependent variable 
and the 25(OH)D score as independent variable, adjusting for gender, participants’ age 
while attending baseline measurements, BMI, the UK Biobank assessment centre 
attended, east and north co-ordinate of home address and the first 5 ancestral PCs. The 
exponential of the coefficient of the regression is the MR estimate of the causal effect 
of 25(OH)D on outcome. 
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I then conducted inverse variance weighted (IVW) MR and Egger’s MR to check the 
consistency of my results between different MR methods and account for any 
unbalanced pleiotropy of individual SNPs. Causal effect estimates from separate SNPs 
as instrumental variables can be pooled together using the IVW method. In brief, 
individual effect estimates are first calculated by the ratio method for every SNP, where 
the coefficient from the regression of outcome on individual SNP is divided by the 
effect estimates of SNP on biomarker exposure. Then, individual effect estimates are 
pooled together by a random-effects meta-analysis (267). The overall causal effect 
from multiple IVs estimated by IVW equals the coefficient from a weighted regression 
of IV-outcome association on IV-exposure association with the intercept constrained 
at zero. However, this method assumes that IVs are not associated with outcomes 
conditional on exposure and confounders (i.e., all the effect of IVs on outcome are 
conducted via the exposure), which is also called “exclusion restriction”. Pleiotropic 
effects of IVs would cause potential violation of this assumption. Egger’s MR employs 
a less strict version of exclusion restriction, the InSIDE, where the correlation between 
the genetic associations with the exposure and the direct effects of the genetic variants 
on the outcome is zero (268). By viewing a MR with multiple IVs as analogous to a 
meta-analysis, the bias caused by pleiotropy is analogous to small study bias in meta-
analysis. Under the InSIDE assumption, applying a regression method for all the 
individual IVs without constraining the intercept to be zero, Egger’s MR tests whether 
there is unbalanced pleiotropy (rejection of the null hypothesis of the intercept value 
equal to zero implies unbalanced pleiotropy, where there are pleiotropic effects with 
IVs and they do not cancel out). It gives a summary effect estimates closer to truth 
compared with IVW, especially under situations of unbalanced pleiotropy (268).  
 
Finally, to test the robustness of the results from my MR analyses, two sensitivity 
analyses were implemented for outcomes in MR analyses. These include leave-one-
out MR analyses and MR analyses excluding variants liable to population stratification. 
In the leave-one-out analyses, I drop one SNP each time, and conduct IVW MR 
analyses involving the other 5 SNPs, which is used to explore the possibility that the 
overall MR result of 6 SNPs is dominated by one single SNP. Then, in the other 
sensitivity analyses, I exclude variants which show evidence of population 
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stratification and conduct IVW MR analyses involving all other SNPs to control the 
influence of population stratification on my results. 
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Chapter V: Results 
5.1 Association between genetic variants and phenotypes 
5.1.1 Descriptive statistics 
A total of 339,256 unrelated British white individuals were included in the analysis of 
this study. Of the included individuals, 182110 (53.86%) were females. The mean age 
was 56.89 years (standard deviation = 7.99), and the mean BMI was 27.40 kg/m2 
(standard deviation = 4.76) (Table 15). 
 
Table 15. Demographic characteristics of the UK Biobank participants.  
Variable Value 
Demographic characteristics (n=339,256)  
Female 182,110 (53.68%) 
Age 56.89 (7.99) years 
BMI 27.40 (4.76) kg/m2 
 
Abbreviations: BMI, body mass index, which is derived by weight (in kg) divided square of height (in 
metres). 
Notes: Continuous variables are presented as mean (standard deviation), while categorical variables are 
presents as N (%).  
 
The participants were of mean standing height of 168.80 cm (standard deviation = 
9.24); mean weight of 78.31 kg (standard deviation = 15.88). As an important 
confounding factor for vitamin D level, outdoor activity was also considered in my 
analyses. Mean time spend outdoors in summer by participant was 3.17 hours/day 
(standard deviation = 3.58). Mean time spend outdoors in winter by participants was 
0.14 hour/day (standard deviation = 4.71). Other confounding factors I explored 
included household income before tax, qualifications and alcohol intake frequency. 
For details, please see Table 16.  
 
Household income before tax is reported as a categorical variable with 7 levels, which 
were “less than £18,000”, “£18,000 to £30,999”, “£31,000 to £51,999”, “£52,000 to 
£100,000”, “greater than £100,000”, “Do not know”, “Prefer not to answer”. A total 
of 1108 participants did not report their income before tax. Among the available data, 
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there were 63806 (18.81%), 75135 (22.15%), 77268 (22.78%), 60478 (17.83%), 
15678 (4.62%), 13027 (3.84%), 32756 (9.66%) for each of the above category. 
Combined with “Do not know” and “Prefer not to answer”, I did not have valid data 
for a total of 46891 (13.82%) participants. 
 
Qualifications were also reported as a categorical variable from the baseline 
touchscreen questionnaire. The eight levels were “College or University degree”, “A 
levels/AS levels or equivalent”, “O levels/GCSEs or equivalent”, “CSEs or 
equivalent”, “NVQ or HND or HNC or equivalent”, “Other professional qualifications 
(eg: nursing, teaching)”, “None of the above”, “Prefer not to answer”. There were 319 
participants who did not select any category, and 107150 (31.58%), 38467 (11.34%), 
74674 (22.01%), 18231 (5.37%), 22411 (6.61%), 17418 (5.13%), 57809 (17.04%) and 
2777 (0.82%) participants who selected each of the above level of education. I did not 
have valid information for 60905 (17.95%) participants. 
 
Alcohol intake frequency was reported as a categorical variable of 7 levels, which were 
“daily or almost daily”, “3 or 4 times a week”, “1 or 2 times a week”, “1 to 3 time a 
month”, “special occasions only”, “never” and “prefer not to answer”. There were 
72786 (21.45%), 82022 (24.18%), 89054 (26.25%), 37492 (11.05%), 35601 (10.49%), 
22065 (6.50%) and 236 (0.07%) participants selecting each of the level above. All 
participants reported data for this variable. However, due to the options of “never” and 
“prefer not to answer”, I still did not have valid data for a total of 22301 (6.57%) 
participants. 
 
Table 16. Characteristics for confounding factors of the UK Biobank participants. 
Variable Name Feature N (%) 
Continuous Mean (S.D.) Number of missingness 
Standing height 168.80 (9.24) cm 730 (0.22%) 
Weight 78.31 (15.88) kg 964 (0.28%) 
Time spend outdoors in 
summer 
3.17 (3.58) hours/day 319 (0.09%) 
Time spend outdoors in winter 0.14 (4.71) hours/day 319 (0.09%) 
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Categorical Levels Number of participants 
Household income  
before tax 
Less than £18,000 63,806 (18.81%) 
£18,000 to £30,999 75,135 (22.15%) 
 £31,000 to £51,999 77,268 (22.78%) 
 £52,000 to £100,000 60,478 (17.83%) 
 Greater than £100,000 15,678 (4.62%) 
 Do not know 13,027 (3.84%) 
 Prefer not to answer 32,756 (9.66%) 
 Missingness 1108 (0.33%) 
Qualifications College or University degree 107,150 (31.58%) 
 A levels/AS levels or 
equivalent 
38,467 (11.34%) 
 O levels/GCSEs or equivalent 74,674 (22.01%) 
 CSEs or equivalent 18,231 (5.37%) 
 NVQ or HND or HNC or 
equivalent 
22,411 (6.61%) 
 Other professional 
qualifications 
(eg: nursing, teaching) 
17,418 (5.13%) 
 None of the above 57,809 (17.04%) 
 Prefer not to answer 2,777 (0.82%) 
 Missingness 319 (0.09%) 
Alcohol intake  
frequency 
Daily or almost daily 72,786 (21.45%) 
3 or 4 times a week 82,022 (24.18%) 
 1 or 2 times a week 89,054 (26.25%) 
 1 to 3 times a month 37,492 (11.05%) 
 Special occasions only 35,601 (10.49%) 
 Never 22,065 (6.50%) 
 Prefer not to answer 236 (0.07%) 
 Missingness 0 
 
Baseline measurements for these participants were taken in 22 UK Biobank 
assessment centres. For the number participants attending each assessment centre, 
please see Table 17. The range of the counts spread from 319 to 31348. Stockport was 
an assessment centre for the pilot part of the study only, thus only 319 (0.09%) 
participants were from Stockport. Leeds recruited the largest number of participants, 
which was 31348 (9.24%). 




Table 17. Number of participants attending each assessment centre. 
Assessment Centre N (%) 
Barts 5,908 (1.74%) 
Birmingham 16,056 (4.73%) 
Bristol 30,830 (9.09%) 
Bury 20,383 (6.01%) 
Cardiff 12,781 (3.77%) 
Croydon 15,076 (4.44%) 
Edinburgh 12,355 (3.64%) 
Glasgow 12,693 (3.74%) 
Hounslow 14,763 (4.35%) 
Leeds 31,348 (9.24%) 
Liverpool 22,685 (6.69%) 
Manchester 9078 (2.68%) 
Middlesborough 15,295 (4.51%) 
Newcastle 26,285 (7.75%) 
Nottingham 24,411 (7.20%) 
Oxford 9,922 (2.92%) 
Reading 21,249 (6.26%) 
Sheffield 21,885 (6.45%) 
Stockport(pilot) 319 (0.09%) 
Stoke 13,824 (4.07%) 
Swansea 1,620 (0.48%) 
Wrexham 490 (0.14%) 
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5.1.2 Genotypes of vitamin D related genetic variants 
 
According to the most recent GWAS on 25(OH)D level at the time of the analysis, six 
SNPs were statistically significantly associated with 25(OH)D level at a GWAS P-
value threshold (P < 10-8) (i.e., rs3755967 (GC), rs10741657 (CYP2R1), rs12785878 
(DHCR7), rs10745742 (AMDHD1), rs8018720 (SEC23A), rs17216707(CYP24A1)). I 
extracted the genotypes of these 6 SNPs from the imputation data, and genotype 









Table 18. Genotype counts of the six vitamin D related SNPs. 
Genotype counts N (%) 
rs3755967 polymorphism (n=338,753)  
CC 169,710 (50.10%) 
CT 140,206 (41.39%) 
TT 28,837 (8.51%) 
Hardy-Weinberg P-value 0.52 
rs10741657 polymorphism (n=339,256)  
AA 55,617 (16.39%) 
AG 163,064 (48.07%) 
GG 120,575 (35.54%) 
Hardy-Weinberg P-value 0.83 
rs12785878 polymorphism (n=339,256)  
TT 211,627 (62.38%) 
TG 112,585 (33.19%) 
GG 15,044 (4.43%) 
Hardy-Weinberg P-value 0.35 
rs10745742 polymorphism (n=336,987)  
TT 47,797 (14.18%) 
TC 158,392 (47.00%) 
CC 130,798 (38.82%) 
Hardy-Weinberg P-value 0.29 
rs8018720 polymorphism (n=339,256)  
GG 10,666 (3.14%) 
GC 98,435 (29.02%) 
CC 230,155 (67.84%) 
Hardy-Weinberg P-value 0.80 
rs17216707 polymorphism (n=324,016)  
TT 216,735 (66.89%) 
TC 96,403 (29.75%) 
CC 10878 (3.36%) 
Hardy-Weinberg P-value 0.78 
 
The frequency for the T allele of rs3755967 (GC) varied from 0.285 (Stockport) to 
0.310 (Wrexham) (Table 19). The P value for the χ2 test for rs3755967 was 0.105, 
suggesting that this variant was distributed evenly across UK Biobank assessment 
centres. 
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Table 19. Genotype distribution for rs3755967 across UK Biobank assessment centres. 
Assessment centre Genotype Value 
Barts   
 CC 2915 
 CT 2475 
 TT 506 
 Frequency of T allele 0.296 
Birmingham   
 CC 8039 
 CT 6676 
 TT 1318 
 Frequency of T allele 0.290 
Bristol   
 CC 15366 
 CT 12751 
 TT 2679 
 Frequency of T allele 0.294 
Bury   
 CC 10216 
 CT 8461 
 TT 1664 
 Frequency of T allele 0.290 
Cardiff   
 CC 6285 
 CT 5406 
 TT 1074 
 Frequency of T allele 0.296 
Croydon   
 CC 7454 
 CT 6299 
 TT 1300 
 Frequency of T allele 0.296 
Edinburgh   
 CC 6251 
 CT 5059 
 TT 1024 
 Frequency of T allele 0.288 
Glasgow   
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 CC 6395 
 CT 5197 
 TT 1074 
 Frequency of T allele 0.290 
Hounslow   
 CC 7301 
 CT 6121 
 TT 1319 
 Frequency of T allele 0.297 
Leeds   
 CC 15849 
 CT 12873 
 TT 2587 
 Frequency of T allele 0.288 
Liverpool   
 CC 11400 
 CT 9325 
 TT 1929 
 Frequency of T allele 0.291 
Manchester   
 CC 4602 
 CT 3686 
 TT 771 
 Frequency of T allele 0.289 
Middlesborough   
 CC 7677 
 CT 6287 
 TT 1308 
 Frequency of T allele 0.291 
Newcastle   
 CC 13330 
 CT 10771 
 TT 2148 
 Frequency of T allele 0.287 
Nottingham   
 CC 12191 
 CT 10072 
 TT 2114 
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 Frequency of T allele 0.293 
Oxford   
 CC 4853 
 CT 4153 
 TT 899 
 Frequency of T allele 0.300 
Reading   
 CC 10646 
 CT 8783 
 TT 1791 
 Frequency of T allele 0.291 
Sheffield   
 CC 10834 
 CT 9077 
 TT 1941 
 Frequency of T allele 0.297 
Stockport (pilot)   
 CC 165 
 CT 123 
 TT 29 
 Frequency of T allele 0.285 
Stoke   
 CC 6904 
 CT 5722 
 TT 1182 
 Frequency of T allele 0.293 
Swansea   
 CC 798 
 CT 691 
 TT 127 
 Frequency of T allele 0.292 
Wrexham   
 CC 239 
 CT 198 
 TT 53 
 Frequency of T allele 0.310 
Overall χ2 test P = 0.105  
 




The frequency for the G allele of rs10741657 (CYP2R1) varied from 0.562 (Wrexham) 
to 0.606 (Barts) (Table 20). The P value for the χ2 test for rs10741657 was 0.003, 
implying that this variant was distributed unevenly across UK Biobank assessment 
centres. I then re-coded assessment centres into two categories (Scotland or 
England/Wales), in order to test the distribution of this SNP across latitude. A total of 
25048 participants (7.38%) were recruited from Edinburgh or Glasgow. However, the 
P value for this χ2 test was 0.878. Thus, there was no difference between genotype of 
rs10741657 in Scotland and genotype of that in England and Wale, which is of lower 
latitude. In χ2 test of participant from Wrexham (n = 490, 0.14%) vs all others, the P 
value was 0.0613. In χ2 test of participant from Wrexham or Cardiff (n = 13271, 3.91%) 
vs all other the P value was 0.001. Participants from Wrexham and Cardiff were of 
lowest level of G allele frequency of rs10741657, and it is significantly different from 
all other assessment centres. 
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Table 20. Genotype distribution for rs10741657 across UK Biobank assessment centres. 
Assessment centre Genotype Value 
Barts   
 AA 942 
 AG 2776 
 GG 2190 
 Frequency of G allele 0.606 
Birmingham   
 AA 2582 
 AG 7749 
 GG 5725 
 Frequency of G allele 0.598 
Bristol   
 AA 4938 
 AG 14635 
 GG 11257 
 Frequency of G allele 0.602 
Bury   
 AA 3354 
 AG 9840 
 GG 7189 
 Frequency of G allele 0.594 
Cardiff   
 AA 2146 
 AG 6277 
 GG 4358 
 Frequency of G allele 0.587 
Croydon   
 AA 2440 
 AG 7280 
 GG 5356 
 Frequency of G allele 0.597 
Edinburgh   
 AA 2028 
 AG 5948 
 GG 4379 
 Frequency of G allele 0.595 
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Glasgow   
 AA 2096 
 AG 6109 
 GG 4488 
 Frequency of G allele 0.594 
Hounslow   
 AA 2394 
 AG 7119 
 GG 5250 
 Frequency of G allele 0.597 
Leeds   
 AA 5106 
 AG 15016 
 GG 11226 
 Frequency of G allele 0.598 
Liverpool   
 AA 3836 
 AG 10925 
 GG 7924 
 Frequency of G allele 0.590 
Manchester   
 AA 1475 
 AG 4377 
 GG 3226 
 Frequency of G allele 0.596 
Middlesborough   
 AA 2516 
 AG 7400 
 GG 5379 
 Frequency of G allele 0.594 
Newcastle   
 AA 4473 
 AG 12658 
 GG 9154 
 Frequency of G allele 0.589 
Nottingham   
 AA 3933 
 AG 11741 
Chapter V: Results 

 
 GG 8737 
 Frequency of G allele 0.598 
Oxford   
 AA 1692 
 AG 4737 
 GG 3493 
 Frequency of G allele 0.591 
Reading   
 AA 3457 
 AG 10132 
 GG 7660 
 Frequency of G allele 0.599 
Sheffield   
 AA 3550 
 AG 10484 
 GG 7851 
 Frequency of G allele 0.598 
Stockport (pilot)   
 AA 52 
 AG 154 
 GG 113 
 Frequency of G allele 0.596 
Stoke   
 AA 2239 
 AG 6730 
 GG 4855 
 Frequency of G allele 0.595 
Swansea   
 AA 269 
 AG 746 
 GG 605 
 Frequency of G allele 0.604 
Wrexham   
 AA 99 
 AG 231 
 GG 160 
 Frequency of G allele 0.562 
Overall χ2 test P = 0.003  




The frequency for the G allele of rs12785878 (DHCR7/NADSYN1) varied from 0.190 
(Glasgow) to 0.223 (Oxford) (Table 21). From the table, I could find a trend that 
participants from centres in the south had a higher G allele frequency compared with 
participants from middle England (e.g., Leeds, Manchester), while participants from 
middle England were of higher G allele frequency compared with participants from 
Scotland (i.e., Edinburgh and Glasgow). The P value for the χ2 test for rs12785878 
was < 2.2*10-16, implying that this variant was distributed unevenly across UK 
Biobank assessment centres. I re-coded assessment centres into two categories 
(Scotland or England/Wales), in order to test the distribution of this SNP across 
region. A total of 25048 participants (7.38%) were recruited from Edinburgh or 
Glasgow. The P value for χ2 test was lower than 2.2*10-16. Thus, the association 
between rs12785878 genotype and assessment centre was caused by the latitudinal 
distribution of rs12785878. 
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Table 21. Genotype distribution for rs12785878 across UK Biobank assessment centres. 
Assessment centre Genotype Value 
Barts   
 TT 3554 
 TG 2077 
 GG 277 
 Frequency of G allele 0.223 
Birmingham   
 TT 9909 
 TG 5360 
 GG 787 
 Frequency of G allele 0.216 
Bristol   
 TT 18872 
 TG 10483 
 GG 1475 
 Frequency of G allele 0.218 
Bury   
 TT 13033 
 TG 6541 
 GG 809 
 Frequency of G allele 0.200 
Cardiff   
 TT 7997 
 TG 4232 
 GG 552 
 Frequency of G allele 0.209 
Croydon   
 TT 9139 
 TG 5155 
 GG 782 
 Frequency of G allele 0.223 
Edinburgh   
 TT 8083 
 TG 3816 
 GG 456 
 Frequency of G allele 0.191 




Glasgow   
 TT 8322 
 TG 3921 
 GG 450 
 Frequency of G allele 0.190 
Hounslow   
 TT 9057 
 TG 4974 
 GG 732 
 Frequency of G allele 0.218 
Leeds   
 TT 19715 
 TG 10317 
 GG 1316 
 Frequency of G allele 0.207 
Liverpool   
 TT 14155 
 TG 7565 
 GG 965 
 Frequency of G allele 0.209 
Manchester   
 TT 5755 
 TG 2934 
 GG 389 
 Frequency of G allele 0.204 
Middlesborough   
 TT 9503 
 TG 5088 
 GG 704 
 Frequency of G allele 0.212 
Newcastle   
 TT 16731 
 TG 8473 
 GG 1081 
 Frequency of G allele 0.202 
Nottingham   
 TT 15050 
 TG 8264 
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 GG 1097 
 Frequency of G allele 0.214 
Oxford   
 TT 5976 
 TG 3462 
 GG 484 
 Frequency of G allele 0.223 
Reading   
 TT 12836 
 TG 7360 
 GG 1053 
 Frequency of G allele 0.223 
Sheffield   
 TT 13789 
 TG 7178 
 GG 918 
 Frequency of G allele 0.206 
Stockport (pilot)   
 TT 209 
 TG 98 
 GG 12 
 Frequency of G allele 0.191 
Stoke   
 TT 8617 
 TG 4589 
 GG 618 
 Frequency of G allele 0.211 
Swansea   
 TT 1007 
 TG 541 
 GG 72 
 Frequency of G allele 0.211 
Wrexham   
 TT 318 
 TG 157 
 GG 15 
 Frequency of G allele 0.191 
Overall χ2 test P < 2.2 *10-16  




The frequency for the C allele of rs10745742 (AMDHD1) varied from 0.610 (Leeds) 
to 0.661 (Swansea) (Table 22). Overall, the P value for the χ2 test was < 2.2*10-16, 
implying that rs10745742 was distributed unevenly across UK Biobank assessment 
centres. Then χ2 test was implemented for participants from Scotland vs all others, 
and the P value was 1.636*10-8. However, participants from Edinburgh (0.628) had a 
relatively low frequency of C allele, which was similar to those from the southern 
centres, compared with those from Glasgow (0.661). This could not be attributed to 
simply a latitude effect. Participants from Cardiff, Glasgow, Wrexham and Swansea 
were of higher C allele frequency compared with other centres. Thus, I tested the 
relevant difference in another χ2 test, and found a P value of lower than 2.2*10-16. 
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Table 22. Genotype distribution for rs10745742 across UK Biobank assessment centres. 
Assessment centre Genotype Value 
Barts   
 TT 824 
 TC 2723 
 CC 2323 
 Frequency of C allele 0.628 
Birmingham   
 TT 2257 
 TC 7581 
 CC 6112 
 Frequency of C allele 0.621 
Bristol   
 TT 4333 
 TC 14357 
 CC 11943 
 Frequency of C allele 0.624 
Bury   
 TT 2991 
 TC 9578 
 CC 7694 
 Frequency of C allele 0.616 
Cardiff   
 TT 1684 
 TC 5802 
 CC 5212 
 Frequency of C allele 0.639 
Croydon   
 TT 2121 
 TC 7075 
 CC 5763 
 Frequency of C allele 0.622 
Edinburgh   
 TT 1666 
 TC 5791 
 CC 4810 
 Frequency of C allele 0.628 
Chapter V: Results 

 
Glasgow   
 TT 1639 
 TC 5729 
 CC 5245 
 Frequency of C allele 0.643 
Hounslow   
 TT 2060 
 TC 6900 
 CC 5699 
 Frequency of C allele 0.624 
Leeds   
 TT 4692 
 TC 14900 
 CC 11576 
 Frequency of C allele 0.610 
Liverpool   
 TT 3022 
 TC 10569 
 CC 8943 
 Frequency of C allele 0.631 
Manchester   
 TT 1269 
 TC 4188 
 CC 3561 
 Frequency of C allele 0.627 
Middlesborough   
 TT 2191 
 TC 6996 
 CC 6010 
 Frequency of C allele 0.626 
Newcastle   
 TT 3624 
 TC 12165 
 CC 10315 
 Frequency of C allele 0.628 
Nottingham   
 TT 3477 
 TC 11499 
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 CC 9283 
 Frequency of C allele 0.620 
Oxford   
 TT 1367 
 TC 4693 
 CC 3796 
 Frequency of C allele 0.623 
Reading   
 TT 3044 
 TC 9901 
 CC 8160 
 Frequency of C allele 0.621 
Sheffield   
 TT 3243 
 TC 10382 
 CC 8094 
 Frequency of C allele 0.612 
Stockport (pilot)   
 TT 47 
 TC 151 
 CC 118 
 Frequency of C allele 0.612 
Stoke   
 TT 2022 
 TC 6437 
 CC 5247 
 Frequency of C allele 0.618 
Swansea   
 TT 166 
 TC 761 
 CC 684 
 Frequency of C allele 0.661 
Wrexham   
 TT 58 
 TC 214 
 CC 210 
 Frequency of C allele 0.658 
Overall χ2 test P < 2.2*10-16  




The frequency for the C allele of rs8018720 varied from 0.817 (Wrexham) to 0.832 
(Stockport) (Table 23). The P value for the χ2 test for rs8018720 was 0.204, supporting 
that this variant distributed evenly across UK Biobank assessment centres. 
 
Table 23. Genotype distribution for rs8018720 across UK Biobank assessment centres. 
Assessment centre Genotype Value 
Barts   
 GG 178 
 GC 1712 
 CC 4018 
 Frequency of C allele 0.825 
Birmingham   
 GG 457 
 GC 4697 
 CC 10902 
 Frequency of C allele 0.825 
Bristol   
 GG 996 
 GC 8903 
 CC 20931 
 Frequency of C allele 0.823 
Bury   
 GG 619 
 GC 6007 
 CC 13757 
 Frequency of C allele 0.822 
Cardiff   
 GG 410 
 GC 3735 
 CC 8636 
 Frequency of C allele 0.822 
Croydon   
 GG 468 
 GC 4316 
 CC 10292 
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 Frequency of C allele 0.826 
Edinburgh   
 GG 421 
 GC 3648 
 CC 8286 
 Frequency of C allele 0.818 
Glasgow   
 GG 403 
 GC 3766 
 CC 8524 
 Frequency of C allele 0.820 
Hounslow   
 GG 457 
 GC 4186 
 CC 10120 
 Frequency of C allele 0.827 
Leeds   
 GG 1017 
 GC 9056 
 CC 21275 
 Frequency of C allele 0.823 
Liverpool   
 GG 739 
 GC 6619 
 CC 15327 
 Frequency of C allele 0.822 
Manchester   
 GG 321 
 GC 2601 
 CC 6156 
 Frequency of C allele 0.821 
Middlesborough   
 GG 492 
 GC 4383 
 CC 10420 
 Frequency of C allele 0.825 
Newcastle   
 GG 806 
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 GC 7794 
 CC 17685 
 Frequency of C allele 0.821 
Nottingham   
 GG 752 
 GC 7014 
 CC 16645 
 Frequency of C allele 0.826 
Oxford   
 GG 286 
 GC 2922 
 CC 6714 
 Frequency of C allele 0.824 
Reading   
 GG 661 
 GC 6132 
 CC 14456 
 Frequency of C allele 0.825 
Sheffield   
 GG 714 
 GC 6267 
 CC 14904 
 Frequency of C allele 0.824 
Stockport (pilot)   
 GG 6 
 GC 95 
 CC 218 
 Frequency of C allele 0.832 
Stoke   
 GG 404 
 GC 3958 
 CC 9462 
 Frequency of C allele 0.828 
Swansea   
 GG 45 
 GC 473 
 CC 1102 
 Frequency of C allele 0.826 
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Wrexham   
 GG 14 
 GC 151 
 CC 325 
 Frequency of C allele 0.817 









The frequency for the C allele of rs17216707 varied from 0.176 (Swansea) to 0.201 
(Wrexham) (Table 24). The P value for the χ2 test for rs17216707 was 0.920, 
suggesting that this variant distributed evenly across UK Biobank assessment centres. 
 
Table 24. Genotype distribution for rs17216707 across UK Biobank assessment centres. 
Assessment centre Genotype Value 
Barts   
 TT 3749 
 TC 1683 
 CC 185 
 Frequency of C allele 0.183 
Birmingham   
 TT 10242 
 TC 4551 
 CC 538 
 Frequency of C allele 0.184 
Bristol   
 TT 19756 
 TC 8719 
 CC 1002 
 Frequency of C allele 0.182 
Bury   
 TT 13120 
 TC 5773 
 CC 642 
 Frequency of C allele 0.181 
Cardiff   
 TT 8242 
 TC 3559 
 CC 409 
 Frequency of C allele 0.179 
Croydon   
 TT 9540 
 TC 4298 
 CC 518 
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 Frequency of C allele 0.186 
Edinburgh   
 TT 7975 
 TC 3454 
 CC 398 
 Frequency of C allele 0.180 
Glasgow   
 TT 8212 
 TC 3575 
 CC 409 
 Frequency of C allele 0.180 
Hounslow   
 TT 9376 
 TC 4177 
 CC 503 
 Frequency of C allele 0.184 
Leeds   
 TT 20076 
 TC 8923 
 CC 987 
 Frequency of C allele 0.182 
Liverpool   
 TT 14549 
 TC 6371 
 CC 727 
 Frequency of C allele 0.181 
Manchester   
 TT 5798 
 TC 2589 
 CC 272 
 Frequency of C allele 0.181 
Middlesborough   
 TT 9739 
 TC 4371 
 CC 490 
 Frequency of C allele 0.183 
Newcastle   
 TT 16853 
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 TC 7485 
 CC 835 
 Frequency of C allele 0.182 
Nottingham   
 TT 15547 
 TC 6941 
 CC 786 
 Frequency of C allele 0.183 
Oxford   
 TT 6267 
 TC 2885 
 CC 316 
 Frequency of C allele 0.186 
Reading   
 TT 13484 
 TC 6092 
 CC 694 
 Frequency of C allele 0.185 
Sheffield   
 TT 13871 
 TC 6295 
 CC 656 
 Frequency of C allele 0.183 
Stockport (pilot)   
 TT 195 
 TC 93 
 CC 10 
 Frequency of C allele 0.190 
Stoke   
 TT 8795 
 TC 3980 
 CC 430 
 Frequency of C allele 0.183 
Swansea   
 TT 1050 
 TC 447 
 CC 49 
 Frequency of C allele 0.176 
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Wrexham   
 TT 299 
 TC 142 
 CC 22 
 Frequency of C allele 0.201 
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5.1.3 Downloading and manipulation of EMRs 
I downloaded the Hospital Episode Statistics in December 2016. The inpatient data I 
downloaded compromised 2,779,598 unique records of hospital inpatient data 
corresponding to 395,978 unique individuals (2,714,364 records had an ICD10 
diagnosis code, 52,123 had an ICD9 diagnosis code and 13,111 records did not have a 
diagnosis code). The inpatient data were organized on an episode basis. Each 
hospitalized episode for a participant generated a unique line in the database. Thus, an 
individual could have several lines of records in the inpatient database based on the 
number of episodes he/she ever had. Not every individual had records in the inpatient 
database.  
 
Cancer registry and death registry were released as separate databases from the 
inpatient data and I downloaded them as well. In the cancer registry data, there were 
233,753 records corresponding to 79,066 unique participants (207,935 records had an 
ICD10 diagnosis code, and 25,818 had an ICD9 diagnosis code). In addition, 14,417 
deaths were recorded in the death registry data. 
 
The phecode system for curating ICD-based phenotyping (ICD10/ICD9 to phecodes) 
was applied in UK Biobank EMRs. A total of 88.6 % (3,106,440 out of 3,504,994) of 
records of unique ICD code per participant were successfully mapped to phecode 
(Figure 15). Among the unmatched records, 86.7% (345,426 out of 398,554 
unmatched records) were ICD10 codes beginning with V (transport accidents) or Z 
(factors influencing health status and contact with health services), which are not 
expected to be directly associated with any genetic factor. In total 1,853 disease 
outcomes were generated with a median number of cases of 309 (range: 0 to 160,512).  
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Figure 15. Manipulation of electronic medical records. 
 
  
Primary diagnosis codes 
ICD 9 = 52,123 
ICD 10 = 2,714,364 
Secondary diagnosis codes 
ICD 9 = 20,178 
ICD 10 = 4,939,760 
 
Pooled together 
A total of 7,997,465 codes 
Number of rows: 
3,504,994 
Cancer registry codes 
ICD 9 = 25,818 
ICD 10 = 207,935 
Counted 
By participant 
Death registry codes 
ICD 10 = 37,287 
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I assessed the electronical medical records of participants in December 2016 and downloaded their primary diagnosis codes (the primary 
cause for admission in every hospitalisation episode, one for each episode), secondary diagnosis codes (other existing medical conditions, 
could be several for each episode) and participants’ cancer registry and death registry codes through linkage with the cancer registry and 
death registry. Then, I treated every presence of codes as a unique line and pooled the four sources of codes we downloaded together and got 
a total of 7,997,465 rows of ICD codes. Subsequently, presences of codes were counted and aggregated by participants (e.g., in the previous 
table, 3 records of the same code for an individual were three different lines, however, after the counting, they were presented by a single line 
with a new column featuring the number of records of the code). I got a table of 3,504,994 rows. Finally, this table were mapped to the 
phecode with the phecode mapping file (https://phewascatalog.org/phecodes) (199). 
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5.1.4 Association between vitamin D genetic score and outcomes 
I created a genetic score of 25(OH)D level by adding the number of effect alleles 
carried in each of the 6 SNPs and weighted based on their effect estimates from the 
most recent SUNLIGHT GWAS (158).  

Associations between the score and potential confounding factors, including age, BMI, 
time spend outdoors in summer, time spend outdoors in winter, sex, UK Biobank 
assessment centre, average household income before tax, qualification and alcohol 
frequency were tested. Only UK Biobank assessment centre was statistically 
significantly associated with the 25(OH)D score (P = 1.30*10-17) (Table 25). This 
might be caused by the unevenly distribution of rs10741657, rs12785878 and 
rs10745742 between assessment centres, as had been explored in Section 5.1.2.  
 




Confounding factors Beta (SE) P-value  F-value P-value 
Age 0.156 (0.202) 0.441    
BMI 0.224 (0.121) 0.063    
Time spend outdoors in summer -0.077(0.091) 0.394    
Time spend outdoors in winter 0.083(0.119) 0.485    
      
Sex    0.455 0.500 
Assessment center    6.164 1.30*10-17* 
Average household income before tax   1.213 0.296 
Qualification    0.490 0.843 
Alcohol intake frequency    1.419 0.203 
 
A total of 920 outcomes had a case size of greater than 200. And hence they were 
tested in our PheWAS analysis. No phenotypes survived Bonferroni correction 
(0.05/920 = 5.43*10-5). There were only two phenotypes with suggestive P values 
smaller than 0.001, which were delirium (517 cases, P = 1.83*10-4) and nephrotic 
syndrome (374 cases, P = 9.75*10-4) (Figure 16). The P value for association between 
the score and vitamin D deficiency was 0.00116 (291 cases), which was the third 
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smallest P value among all tested associations. Although not statistically significant, 
it supported the validity of the instrument and of the method I applied. Finally, 52 
outcomes had P values of lower than 0.05. 
 
The same analysis was implemented after sex stratification (Table 26 and Table 27). 
In females, UK Biobank assessment centre was associated significantly with the score 
with a P value of 9.06*10-10. In males, UK Biobank assessment centre was associated 
significantly with the score with a P value of 1.54*10-6. None of the other confounding 
factors was associated with the 25(OH)D score after sex stratification. 
  








Confounding factors Beta (SE) P-value  F-value P-value 
Age 0.121 (0.273) 0.658    
BMI 0.310 (0.178) 0.082    
Time spend outdoors in summer -0.072 (0.120)         0.550    
Time spend outdoors in winter 0.045 (0.163) 0.781    
      
Assessment center    4.078 9.06*10-10 
Average household income before tax   1.161 0.324 
Qualification    0.321 0.945 
Alcohol intake frequency    0.767 0.600 
 




Confounding factors Beta (SE) P-value  F-value P-value 
Age 0.188 (0.300) 0.532    
BMI 0.109 (0.157)        0.487    
Time spend outdoors in summer -0.100 (0.136) 0.460    
Time spend outdoors in winter 0.103 (0.170) 0.544    
      
Assessment center    3.141 1.54*10-6 
Average household income before tax   0.961 0.450 
Qualification    0.668 0.700 
Alcohol intake frequency    1.460 0.187 
 
 
A total of 680 outcomes were tested in the PheWAS in females. Thus, after applying 
Bonferroni correction, a P value of lower than 7.35*10-5 was considered as statistically 
significant. None of the outcomes survived Bonferroni correction. There was only one 
outcome with P value less than 0.001, which was otitis externa (N of cases = 206; beta 
= -3.373; se = 0.992; P = 6.74*10-4). A total of 26 outcomes had a P values less than 




0.05 (Figure 17).  
 
A total of 628 outcomes were tested in the PheWAS in males. Thus, applying 
Bonferroni correction, a P value of lower than 7.96*10-5 was considered as statistically 
significant. None of the outcomes survived Bonferroni correction. None of the tested 
outcomes had P value less than 0.001. A total of 47 outcomes had a P value less than 
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Figure 16. Manhattan plot for the PheWAS of 25(OH)D score. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 5.44*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction. There were 









Figure 17. Manhattan plot for the PheWAS of 25(OH)D score in females. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.35*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction. There was 









Figure 18. Manhattan plot for the PheWAS of 25(OH)D score in males. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.96*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction or with P 








5.1.5 Association between single genetic variants and outcomes 
Following the PheWAS using score of all 6 SNPs, I also conducted PheWAS for every 
SNP among the 6 25(OH)D level related SNPs. 
 
PheWAS for rs3755967 (GC) 
The genotype of rs3755967 was not associated with any potential confounding factors 
(Table 28). It was not associated with confounding factors in neither females nor males 
after sex stratification (Table 29 and Table 30). 
 
In PheWAS in both genders, none of the tested outcomes survived Bonferroni 
correction. The outcome with the lowest P value was pilonidal cyst (beta = -0.290, se 
= 0.077, P = 1.53*10-4), which was the only outcome with P value less than 0.001. 
Vitamin D deficiency was the outcome with the second lowest P value, which was 
close to 0.001 (beta = 0.286, se = 0.087, P = 0.001). A total of 49 outcomes were with 
P values less than 0.05 (Figure 19). In the PheWAS in females, none of the tested 
outcomes survived Bonferroni correction. The outcome with the lowest P value was 
otitis externa (beta = 0.317, se = 0.103, P = 0.002). There were 28 outcomes with P 
values less than 0.05 (Figure 20). In the PheWAS in males, none of the tested 
outcomes survived Bonferroni correction. The outcome with the lowest P value was 
pilonidal cyst (beta = -0.298, se = 0.090, P = 0.001), which was the only outcome with 
P value less than 0.001. In total, there were 34 outcomes with P value less than 0.05 
(Figure 21).  
 
Table 28. Association of rs3755967 genotype with potential confounding factors. 
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 1.024 0.359     
BMI 1.641 0.194     
Time spend outdoors in summer 0.447 0.640     
Time spend outdoors in winter 0.756 0.469     
       
Sex    5.140 2 0.077 




Assessment center    53.766 42 0.105 
Average household income before tax    7.478 12 0.825 
Qualification    17.384 14 0.236 
Alcohol intake frequency    15.137 12 0.234 
 
 
Table 29. Association of rs3755967 genotype with potential confounding factors in females. 
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.656 0.519     
BMI 0.522 0.594     
Time spend outdoors in summer 0.272 0.762     
Time spend outdoors in winter 0.934 0.393     
       
Assessment center    43.055 42 0.426 
Average household income before tax    10.066 12 0.610 
Qualification    12.285 14 0.583 
Alcohol intake frequency    14.135 12 0.292 
 
 
Table 30. Association of rs3755967 genotype with potential confounding factors in males. 
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.350 0.705     
BMI 2.874 0.056     
Time spend outdoors in summer 0.376 0.686     
Time spend outdoors in winter 0.335 0.716     
       
Assessment center    48.585 42 0.225 
Average household income before tax    5.132 12 0.953 
Qualification    18.541 14 0.183 
Alcohol intake frequency    13.258 12 0.351 
 




Figure 19. Manhattan plot for the PheWAS of rs3755967. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 5.44*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction. There was 
only one phenotype with a P value less than 0.001, which was pilonidal cyst (P=1.53*10-4). Phenotype 








Figure 20. Manhattan plot for the PheWAS of rs3755967 in females. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.35*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction or with P 








Figure 21. Manhattan plot for the PheWAS of rs3755967 in males. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.96*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction. There was 
only one phenotypes with a P value less than 0.001, which was pilonidal cyst (P = 0.001). 
 
  




PheWAS for rs10741657 (CYP2R1) 
The genotype of rs10741657 was associated with BMI (P = 0.038), gender (P = 0.036) 
and assessment centre (P = 0.003) (Table 31). It was not associated with any 
confounding factors, including BMI (P = 0.212 in females; P = 0.156 in males) and 
assessment centre (P = 0.234 in females; P = 0.106 in males) after sex stratification 
(Table 32 and Table 33). 
 
In PheWAS in both genders, none of the tested outcomes survived Bonferroni 
correction. Genotypes of rs10741657 was associated with nephrotic syndrome (beta = 
-0.277, se = .073, P = 1.53*10-4), labyrinthitis (beta = -0.204, se = 0.057, P = 3.82*10-
4), and complications of cardiac/vascular device, implant, and graft (beta = -0.123, se 
= 0.037, P = 9.16*10-4) at P level of lower than 0.001. A total of 52 outcomes were 
with P values less than 0.05 (Figure 22). In the PheWAS in females, none of the tested 
outcomes survived Bonferroni correction. The outcome with the lowest P value was 
diverticulosis (beta = 0.043, se = 0.014, P = 0.002). There were 42 outcomes with P 
values less than 0.05 (Figure 23). In the PheWAS in males, none of the tested 
outcomes survived Bonferroni correction. Premature beats (beta = -0.324, se = 0.094, 
P = 5.84*10-4) and carcinoma in situ of skin (beta = -0.192, se = 0.057, P = 8.34*10-
4) were with P value less than 0.001. In total, there were 41 outcomes with P values of 
lower than 0.05 (Figure 24).  
 
 
Table 31. Association of rs10741657 genotype with potential confounding factors. 
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.276 0.759     
BMI 3.279 0.038     
Time spend outdoors in summer 0.914 0.401     
Time spend outdoors in winter 0.077 0.926     
       
Sex    6.624 2 0.036 
Assessment center    71.099 42 0.003 





Average household income before tax    12.697 12 0.391 
Qualification    15.003 14 0.378 
Alcohol intake frequency    6.838 12 0.868 
 
Table 32. Association of rs10741657 genotype with potential confounding factors in females. 
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.164 0.849     
BMI 1.549 0.212     
Time spend outdoors in summer 0.126 0.882     
Time spend outdoors in winter 0.889 0.411     
       
Assessment center    48.28 42 0.234 
Average household income before tax    9.199 12 0.686 
Qualification    13.02 14 0.525 




Table 33. Association of rs10741657 genotype with potential confounding factors in males.  
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.210 0.811     
BMI 1.857 0.156     
Time spend outdoors in summer 2.188 0.112     
Time spend outdoors in winter 0.653 0.521     
       
Assessment center    53.757 42 0.106 
Average household income before tax    15.616 12 0.210 
Qualification    11.145 14 0.675 
Alcohol intake frequency    10.691 12 0.556 
 
  




Figure 22. Manhattan plot for the PheWAS of rs10741657. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 5.44*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction. There were 
three phenotypes with P value less than 0.001, which were nephrotic syndrome (P = 1.53*10-4), 
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Figure 23. Manhattan plot for the PheWAS of rs10741657 in females. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.35*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction or with P 
value less than 0.001. 
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Figure 24. Manhattan plot for the PheWAS of rs10741657 in males. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.96*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction. There were 
two phenotypes with P value less than 0.001, which were premature beats (P = 5.84*10-4) and carcinoma 
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PheWAS for rs12785878 (DHCR7) 
The genotypes of rs12785878 was association with educational qualifications (P = 
0.046) and UK Biobank assessment centre (P < 2.2*10-16) (Table 34). In females, 
rs12785878 was associated with qualification (P = 0.024) and UK Biobank assessment 
centre (P < 2.2*10-16) (Table 35). In males, rs12785878 was associated with UK 
Biobank assessment centre (P < 2.2*10-16), but not qualifications (P = 0.621) (Table 
36). 
 
In PheWAS in both genders, none of the tested outcomes survived Bonferroni 
correction. The outcome with the lowest P value was visual disturbances (beta = 0.174, 
se = 0.057, P = 0.002). There were 46 outcomes with P value less than 0.05 altogether 
(Figure 25). In the PheWAS in females, none of the tested outcomes survived 
Bonferroni correction. The outcome with the lowest P value was sciatica (beta = -
0.140, se = 0.053, P = 0.009). There were 35 outcomes with P value less than 0.05 in 
total (Figure 26). In the PheWAS in males, none of the tested outcomes survived 
Bonferroni correction. The outcome with the lowest P value was internal derangement 
of the knee (beta = 0.064, se = 0.021, P = 0.002). There were 42 outcomes with P 
value less than 0.05 in total (Figure 27). 
 
Table 34. Association of rs12785878 genotype with potential confounding factors. 
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 1.662 0.190     
BMI 2.822 0.059     
Time spend outdoors in summer 0.625 0.535     
Time spend outdoors in winter 0.040 0.960     
       
Sex    0.498 2 0.780 
Assessment center    338.2 42 < 2.2*10-16 
Average household income before tax    18.47 12 0.102 
Qualification    24.023 14 0.046 
Alcohol intake frequency    14.366 12 0.278 
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Table 35. Association of rs12785878 genotype with potential confounding factors in females. 
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.395 0.673     
BMI 2.684 0.068     
Time spend outdoors in summer 0.333 0.717     
Time spend outdoors in winter 0.527 0.590     
       
Assessment center    192.67 42 < 2.2*10-16 
Average household income before tax    21.038 12 0.050 
Qualification    26.199 14 0.024 
Alcohol intake frequency    14.812 12 0.252 
 
 
Table 36. Association of rs12785878 genotype with potential confounding factors in males.  
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 1.514 0.220     
BMI 0.527 0.590     
Time spend outdoors in summer 0.602 0.548     
Time spend outdoors in winter 0.495 0.610     
       
Assessment center    184.51 42 < 2.2*10-16 
Average household income before tax    12.042 12 0.442 
Qualification    11.814 14 0.621 
Alcohol intake frequency    20.651 12 0.056 
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Figure 25. Manhattan plot for the PheWAS of rs12785878. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 5.44*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction or with P 
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Figure 26. Manhattan plot for the PheWAS of rs12785878 in females. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.35*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction or with P 
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Figure 27. Manhattan plot for the PheWAS of rs12785878 in males. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.96*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction or with P 
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PheWAS for rs10745742 (AMDHD1) 
The genotype of rs10745742 was associated with UK Biobank assessment centre (P < 
2.2*10-16) (Table 37). It was associated with assessment centre in both males and 
female (P = 2.25*10-13 in females; P = 1.18*10-9 in males) after sex stratification 
(Table 38 and Table 39). The genotype of rs10745742 was not associated with any 
other confounding factors.  
 
In PheWAS for both genders, none of the tested outcomes survived Bonferroni 
correction. “Allied disorders of spine” was the outcome with the lowest P value (beta 
= 0.050, se = 0.016, P = 0.001). In total, there were 56 outcomes with P value less than 
0.05 (Figure 28). In the PheWAS in females, none of the tested outcomes survived 
Bonferroni correction. The outcome with the lowest P value was congestive heart 
failure (beta = 0.200, se = 0.067, P = 0.003). There were 34 outcomes with P value 
less than 0.05 (Figure 29). In the PheWAS in males, none of the tested outcomes 
survived Bonferroni correction. “Allied disorders of spine” was the outcome with the 
lowest P value (beta = 0.076, se = 0.024, P = 0.001). There were 28 outcomes with P 
value less than 0.05 (Figure 30). 
 
 
Table 37. Association of rs10745742 genotype with potential confounding factors. 
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.260 0.771     
BMI 0.497 0.609     
Time spend outdoors in summer 0.301 0.740     
Time spend outdoors in winter 0.069 0.933     
       
Sex    4.757 2 0.093 
Assessment center    223.39 42 < 2.2*10-16 
Average household income before tax    10.321 12 0.588 
Qualification    5.947 14 0.968 
Alcohol intake frequency    11.022 12 0.527 





Table 38. Association of rs10745742 genotype with potential confounding factors in females. 
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.797 0.451     
BMI 0.887 0.412     
Time spend outdoors in summer 1.296 0.274     
Time spend outdoors in winter 0.690 0.502     
       
Assessment center    145.75 42 2.25*10-13 
Average household income before tax    8.847 12 0.716 
Qualification    6.617 14 0.949 
Alcohol intake frequency    8.157 12 0.773 
 
 
Table 39. Association of rs10745742 genotype with potential confounding factors in males.  
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.913 0.401     
BMI 0.350 0.705     
Time spend outdoors in summer 0.599 0.550     
Time spend outdoors in winter 0.909 0.403     
       
Assessment center    121.5 42 1.18*10-9 
Average household income before tax    9.022 12 0.701 
Qualification    7.367 14 0.920 
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Figure 28. Manhattan plot for the PheWAS of rs10745742. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 5.44*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction or with P 
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Figure 29. Manhattan plot for the PheWAS of rs10745742 in females. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.35*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction or with P 
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Figure 30. Manhattan plot for the PheWAS of rs10745742 in males. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.96*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction or with P 
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PheWAS for rs8018720 (SEC23A) 
The genotype of rs8018720 was not associated with any confounding factors in general 
(Table 40). It was not associated with any confounding factors in either females nor 
males after sex stratification (Table 41 and Table 42). 
 
In PheWAS in both genders, none of the outcomes survived Bonferroni correction. 
The genotype was associated with “myalgia and myositis” (beta = 0.331, se = 0.094, 
P = 4.02*10-4) and “rheumatic disease of the heart valves” (beta = -0.225, se = 0.064, 
P = 4.21*10-4) at P value less than 0.001. In total, there were 50 outcomes with a P 
value less than 0.05 (Figure 31). In the PheWAS in females, none of the tested 
outcomes survived Bonferroni correction. The outcome with the lowest P value was 
“rheumatic disease of the heart valves” (beta = -0.318, se = 0.101, P = 0.002). There 
were 29 outcomes with P value less than 0.05 (Figure 32). In the PheWAS in males, 
none of the tested outcomes survived Bonferroni correction. The outcome with the 
lowest P value was “staphylococcus infections” (beta = -0.151, se = 0.047, P = 0.001). 
All outcomes were associated with rs8018720 at P levels of greater than 0.001. There 
were 30 outcomes with P value less than 0.05 (Figure 33). 
 
  




Table 40. Association of rs8018720 genotype with potential confounding factors. 
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.567 0.567     
BMI 0.732 0.481     
Time spend outdoors in summer 1.379 0.252     
Time spend outdoors in winter 1.556 0.211     
       
Sex    5.476 2 0.065 
Assessment center    49.326 42 0.204 
Average household income before tax    13.237 12 0.352 
Qualification    10.316 14 0.739 
Alcohol intake frequency    10.097 12 0.608 
 
 
Table 41. Association of rs8018720 genotype with potential confounding factors in females. 
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.569 0.566     
BMI 0.173 0.841     
Time spend outdoors in summer 1.677 0.187     
Time spend outdoors in winter 2.146 0.117     
       
Assessment center    45.241 42 0.338 
Average household income before tax    6.746 12 0.874 
Qualification    10.207 14 0.747 










Table 42. Association of rs8018720 genotype with potential confounding factors in males.  
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.128 0.880     
BMI 1.323 0.266     
Time spend outdoors in summer 0.424 0.654     
Time spend outdoors in winter 0.415 0.660     
       
Assessment center    44.61 42 0.363 
Average household income before tax    13.448 12 0.337 
Qualification    10.124 14 0.753 
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Figure 31. Manhattan plot for the PheWAS of rs8018720. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 5.44*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction. There were 
two phenotypes with P value less than 0.001, which were myalgia and myositis (P = 4.02*10-4) and 
rheumatic disease of the heart valves (P = 4.21*10-4). 
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Figure 32. Manhattan plot for the PheWAS of rs8018720 in females. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.35*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction or with P 
value less than 0.001. 
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Figure 33. Manhattan plot for the PheWAS of rs8018720 in males. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.96*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction or with P 
value less than 0.001. 
 
  




PheWAS for rs17216707 (CYP24A1) 
The genotype of rs17216707 was not associated with any confounding factors in 
general (Table 43). It was associated with alcohol intake frequency in males after sex 
stratification (P = 0.022) (Table 45). It was not associated with any others confounding 
factors in females or males after sex stratification (Table 44 and Table 45). 
 
In PheWAS in both genders, associations between the genotype of rs17216707 and 
“calculus of ureter” (beta = -0.219, se = 0.045, P = 1.14*10-6), “urinary calculus” (beta 
= -0.129, se = 0.027, P = 1.31*10-6), “alveolar and parieto-alveolar pneumonopathy” 
(beta = 0.418, se = 0.101, P = 3.53*10-5) survived Bonferroni correction. In addition, 
“calculus of kidney” (beta = -0.139, se = 0.038, P = 2.98*10-4) was associated with 
rs17216707 at P level less than 0.001. There were 62 outcomes with P value less than 
0.05 (Figure 34). In PheWAS in females, none of the tested outcomes survived 
Bonferroni correction. The genotype of rs17216707 was associated with “calculus of 
kidney” (beta = -0.270, se = 0.071, P = 1.39*10-4), “urinary calculus” (beta = -0.175, 
se = 0.050, P = 4.35*10-4) and “calculus of ureter” (beta = -0.333, se = 0.096, P = 
5.51*10-4) at a P level less than 0.001. There were 37 outcomes with a P value less 
than 0.05 (Figure 35). In PheWAS in males, none of the tested outcomes survived 
Bonferroni correction. Genotype of rs17216707 was associated with “calculus of 
ureter” (beta = -0.185, se = 0.051, P = 2.75*10-4) and “urinary calculus” (beta = -0.110, 
se = 0.032, P = 5.08*10-4) at P level less than 0.001. There were 48 outcomes with a 
P value less than 0.05 (Figure 36). 
 
Table 43. Association of rs17216707 genotype with potential confounding factors. 
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.827 0.437     
BMI 1.095 0.335     
Time spend outdoors in summer 0.180 0.835     
Time spend outdoors in winter 0.458 0.632     
       
Sex    1.778 2 0.411 
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Assessment center    29.873 42 0.920 
Average household income before tax    11.128 12 0.518 
Qualification    16.363 14 0.292 
Alcohol intake frequency    18.887 12 0.091 
 
Table 44. Association of rs17216707 genotype with potential confounding factors in females. 
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 1.971 0.139     
BMI 0.619 0.539     
Time spend outdoors in summer 0.329 0.720     
Time spend outdoors in winter 0.281 0.755     
       
Assessment center    35.515 42 0.750 
Average household income before tax    14.897 12 0.247 
Qualification    9.656 14 0.787 
Alcohol intake frequency    9.60 12 0.651 
 
 
Table 45. Association of rs17216707 genotype with potential confounding factors in males.  
 Continuous  Categorical 
Confounding factors F-value P-value  X
2 df P-value 
Age 0.154 0.857     
BMI 0.579 0.561     
Time spend outdoors in summer 0.017 0.983     
Time spend outdoors in winter 0.138 0.871     
       
Assessment center    22.043 42 0.995 
Average household income before tax    5.633 12 0.933 
Qualification    21.546 14 0.088 
Alcohol intake frequency    23.678 12 0.022 
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Figure 34. Manhattan plot for the PheWAS of rs17216707. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 5.44*10-5, 
and the blue line indicates a P level of 0.001. Three phenotypes survived Bonferroni correction, which 
were calculus of ureter (P = 1.14*10-6), urinary calculus (P = 1.31*10-6) and alveolar and parieto-
alveolar pneumonopathy (P = 3.53*10-5). In addition, there was one phenotype with P value less than 
0.001, which was calculus of kidney (P = 2.98*10-4). 
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Figure 35. Manhattan plot for the PheWAS of rs17216707 in females. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.35*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction. There were 
three phenotypes with P value less than 0.001, which were calculus of kidney (P = 1.39*10-4), urinary 
calculus (P = 4.35*10-4) and calculus of ureter (P = 5.51*10-4). 
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Figure 36. Manhattan plot for the PheWAS of rs17216707 in males. 
 
Phenotypes aggregated on International Classification of Disease (ICD) codes were plotted with the –
log10 P value of each association. The red line indicates a Bonferroni corrected P level of 7.96*10-5, 
and the blue line indicates a P level of 0.001. No phenotype survived Bonferroni correction. There were 
two phenotypes with P value less than 0.001, which were calculus of ureter (P = 2.75*10-4) and urinary 
calculus (P = 5.08*10-4). 
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Finally, for a summary of all outcomes which was associated with the score or any 
SNPs at P < 0.001 level and the related P value level comparison, please see Table 46, 
Table 47 and Table 48. 
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Table 46. Comparison of the P values for all outcomes associated with score or SNPs at P < 0.001 level. 
Outcome Score rs3755967 rs10741657 rs12785878 rs10745742 rs8018720 rs17216707 
alveolar and parieto-alveolar pneumonopathy >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 Bonferroni 
calculus of kidney <0.05 >0.05 >0.05 >0.05 >0.05 >0.05 <0.001 
calculus of ureter <0.05 >0.05 >0.05 >0.05 >0.05 >0.05 Bonferroni 
carcinoma in situ of skin >0.05 >0.05 <0.05 >0.05 >0.05 >0.05 >0.05 
complications of cardiac/vascular device, 
implant, and graft 
>0.05 >0.05 <0.001 >0.05 >0.05 >0.05 >0.05 
Delirium <0.001 <0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
labyrinthitis >0.05 >0.05 <0.001 >0.05 >0.05 >0.05 >0.05 
myalgia and myositis >0.05 >0.05 >0.05 >0.05 >0.05 <0.001 >0.05 
nephrotic syndrome <0.001 >0.05 <0.001 >0.05 >0.05 >0.05 <0.05 
Otitis externa <0.05 <0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
pilonidal cyst <0.05 <0.001 >0.05 >0.05 >0.05 >0.05 >0.05 
premature beats >0.05 >0.05 <0.05 >0.05 >0.05 >0.05 >0.05 
rheumatic disease of the heart valves >0.05 >0.05 >0.05 >0.05 >0.05 <0.001 >0.05 
urinary calculus <0.05 >0.05 >0.05 >0.05 >0.05 >0.05 Bonferroni 
Levels of P values were shown in the table and shaded. P values > 0.05 were shaded with grey; 0.05 to 0.001 were shaded with blue; 0.001 to Bonferroni significance 
were shaded with yellow; exceeded Bonferroni corrected threshold were shaded with red. 
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Table 47. Comparison of the P values for all outcomes associated with score or SNPs at P < 0.001 level in females. 
Outcome Score rs3755967 rs10741657 rs12785878 rs10745742 rs8018720 rs17216707 
alveolar and parieto-alveolar pneumonopathy NA NA NA NA NA NA NA 
calculus of kidney >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 <0.001 
calculus of ureter >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 <0.001 
carcinoma in situ of skin >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
complications of cardiac/vascular device, 
implant and graft 
>0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
Delirium NA NA NA NA NA NA NA 
labyrinthitis >0.05 >0.05 <0.05 >0.05 >0.05 <0.05 >0.05 
myalgia and myositis >0.05 >0.05 <0.05 >0.05 >0.05 <0.05 >0.05 
nephrotic syndrome NA NA NA NA NA NA NA 
Otitis externa <0.001 <0.05 >0.05 >0.05 >0.05 >0.05 NA 
pilonidal cyst NA NA NA NA NA NA NA 
premature beats NA NA NA NA NA NA NA 
rheumatic disease of the heart valves >0.05 >0.05 >0.05 >0.05 <0.05 <0.05 >0.05 
urinary calculus >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 <0.001 
Levels of P values were shown in the table and shaded. P values > 0.05 were shaded with grey; 0.05 to 0.001 were shaded with blue; 0.001 to Bonferroni significance 
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Table 48. Comparison of the P values for all outcomes associated with score or SNPs at P < 0.001 level in males. 
Outcome Score rs3755967 rs10741657 rs12785878 rs10745742 rs8018720 rs17216707 
alveolar and parieto-alveolar pneumonopathy NA NA NA NA NA NA NA 
calculus of kidney <0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 
calculus of ureter <0.05 >0.05 >0.05 <0.05 >0.05 >0.05 <0.001 
carcinoma in situ of skin >0.05 >0.05 <0.001 >0.05 <0.05 >0.05 >0.05 
complications of cardiac/vascular device, 
implant and graft 
>0.05 >0.05 <0.05 >0.05 >0.05 >0.05 >0.05 
Delirium <0.05 <0.05 >0.05 <0.05 >0.05 >0.05 >0.05 
labyrinthitis >0.05 >0.05 <0.05 >0.05 >0.05 >0.05 >0.05 
myalgia and myositis >0.05 >0.05 >0.05 >0.05 >0.05 <0.05 >0.05 
nephrotic syndrome <0.05 >0.05 <0.05 >0.05 >0.05 >0.05 >0.05 
Otitis externa >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 NA 
pilonidal cyst <0.05 <0.001 >0.05 >0.05 >0.05 >0.05 <0.05 
premature beats >0.05 >0.05 <0.001 >0.05 >0.05 >0.05 >0.05 
rheumatic disease of the heart valves >0.05 >0.05 >0.05 >0.05 >0.05 <0.05 >0.05 
urinary calculus <0.05 >0.05 >0.05 <0.05 >0.05 >0.05 <0.001 
Levels of P values were shown in the table and shaded. P values > 0.05 were shaded with grey; 0.05 to 0.001 were shaded with blue; 0.001 to Bonferroni significance 
were shaded with yellow; exceeded Bonferroni corrected threshold were shaded with red. 
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5.2 Causal association between 25(OH)D level and health outcomes 
5.2.1 Power calculation and outcome selection 
Table 49 shows statistical power for MR studies of binary outcome under different 
parameters. If the IV explained 3% of the variance of 25(OH)D level and the case: 
control ratio was 1:5 or larger, which was always true with such a large cohort as UK 
Biobank, a binary outcome with 9445 cases or larger would have a power or greater 
than 80% for detecting a true effect of no less than 1.2 at type I error rate of 0.05. Thus, 
I considered outcomes with more than 9445 cases as having sufficient statistical power. 
According to the criteria given in section 4.2.3 (Figure 14), a total of 9 outcomes were 
eligible for subsequent MR analyses (Table 50). 
 
Table 49. Case number required in a Mendelian Randomization analysis with a binary outcome with 5% 
significance level varying effect size (odds ratio) and required statistical power. 
Power OR=1.05 OR=1.10 OR=1.15 OR=1.20 OR=1.25 OR=1.30 
70% 103,711 27,177 12,639 7,427 4,958 3,587 
75% 116,621 30,561 14,212 8,352 5,575 4,033 
80% 131,887 34,561 16,073 9,445 6,305 4,561 
85% 150,867 39,535 18,386 10,804 7,213 5,217 
90% 176,560 46,268 21,517 12,644 8,441 6,106 
95% 218,354 57,220 26,610 15,637 10,439 7,551 
Numbers of cases required were calculated assuming 5% significance level, case to control ratio of 1:5, 
and a 3% explained variance of exposure by instrumental variable, with the equation published by 




Table 50. Selective conditions met by the MR included outcomes. 
 PheWAS a MR studies b umbrella review c Power d 
SBP No Yes No Yes 
DBP No Yes No Yes 
Hypertension No Yes Yes Yes 
T2D No Yes Yes Yes 
IHD No No Yes Yes 
BMI No No Yes Yes 




Depression No No Yes Yes 
Non-vertebral 
fracture 
No No Yes Yes 
All-cause 
mortality 
No Yes No Yes 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; T2D, type 2 diabetes; IHD, 
ischemic heart disease; BMI, body mass index. 
a Phenotype survived Bonferroni correction in the phenome wide association study for weighted score 
of 6 SNPs. 
b Phenotype had significant or conflicting evidences from published Mendelian Randomization studies. 
c Phenotype was classified as probable or suggestive by the published umbrella review of observational 
studies and RCTs (25). 
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6.2.2 Incorporation of self-reported medical conditions 
I integrated EMR data with self-reported medical condition data for the final MR 
analysis. The outcomes that I selected were systolic blood pressure (SBP), diastolic 
blood pressure (DBP), risk of hypertension, risk of type 2 diabetes (T2D), risk of 
ischemic heart disease (IHD), body mass index (BMI), risk of depression, risk of non-
vertebral fracture and all-cause mortality. This merged phenotype dataset increased the 
number of cases, re-assigned spurious controls, thus increasing the power of our 
analysis (Table 51). 
 
For hypertension, self-reported data included 42317 cases (39.8% of the final case 
number) which were not captured by the EMR data. The number of hypertension cases 
was eventually 106,405. For T2D, 671 cases missed by EMR were reported by the 
self-reported data (4.2%). Incorporating the self-reported data formed a case size of 
15,958 for T2D. For IHD, the final case size was 28,337, while 2,566 (9.0%) were 
missed by EMR but captured by self-reported data. For depression, the final case size 
was 23,294, a large proportion of which were missed by EMR (13628 cases, 58.5%). 
For non-vertebral fracture, I finally got 23,603 cases, 6,382 (27.0%) of which were 
missed by EMR. I got a total of 9830 cases for all-cause mortality, all of which came 
from the death registry data. SBP, DBP and BMI were measured at baseline 




Table 51. Numbers of cases in Mendelian Randomization analysis. 
Outcomes N total a N, EMR b N, SR c N, both d 
SBP e 319778 (100%) NA NA NA 
DBP e 319779 (100%) NA NA NA 
Hypertension 106405 (100%) 16905 (15.9%) 42317 (39.8%) 47183 (44.3%) 
T2D 15958 (100%) 13692 (85.8%) 671 (4.2%) 1595 (10.0%) 
IHD 28337 (100%) 13062 (46.1%) 2556 (9.0%) 12719 (44.9%) 
BMI e 338172 (100%) NA NA NA 
Depression 23294 (100%) 5382 (23.1%) 13628 (58.5%) 4284 (18.4%) 
Non-vertebral fracture 23603 (100%) 15811 (67.0%) 6382 (27.0%) 1410 (6.0%) 
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All-cause mortality f 9830 (100%) 9830 (100%) NA NA 
Notes: a) Total number of cases; b) Number of cases captured by electronic medical records data only; 
c) Number of cases captured by self-reported medical data only; d) Number of cases captured by both 
electronic medical records and self-reported data; e) continuous variable, data came from baseline 
anthropometric measurement data; f) mortality data, data came from death registry solely. 
Abbreviations: EMR, electronic medical records; SR, self-reported medical conditions; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; T2D, type 2 diabetes; IHD, ischemic heart disease; BMI, 
body mass index. 
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6.2.3 Mendelian Randomisation results 
I conducted a linear regression of the score on 25(OH)D level in controls from the 
SOCCS study (n = 2821). The R2 value was 1.61%, and the F statistic was 45.96, 
indicating that the score is a strong IV for MR (269).
 
I did not observe any statistically significant associations in our MR analyses for all 
the tested outcomes and the results from the three different MR methods (two-stage 
MR, IVW MR and Egger’s MR) were consistent (Table 52, Figure 37). For 
continuous outcomes, the effect estimates I got for SBP, DBP and BMI were -0.648 
mmHg (se = 0.451, P = 0.210), -0.117 mmHg (se = 0.251, P = 0.661) and 0.130 kg/m2 
(se = 0.121, P = 0.329) per standard deviation increase of the natural log transformed 
25(OH)D level. The risk of hypertension decreased by 0.027 (OR = 0.973, 95% CI: 
0.911 to 1.040, P = 0.340) by every standard deviation increase of the natural log 
transformed 25(OH)D level. The risk of T2D decreased by 0.029 (OR = 0.971, 95% 
CI: 0.845 to 1.117, P = 0.617) by every standard deviation increase of the natural log 
transformed 25(OH)D level. The OR for IHD risk was 1.020 (OR = 1.020, 95% CI: 
0.917 to 1.135, P = 0.647), for depression was 0.913 (OR = 0.913, 95% CI: 0.816 to 
1.022, P = 0.093), for non-vertebral fracture was 0.969 (OR = 0.969, 95% CI: 0.867 to 
1.083, P = 0.495) and for all-cause mortality was 1.030 (OR = 1.030, 95% CI: 0.869 
to 1.222, P = 0.671) by every standard deviation increase of the natural log transformed 
25(OH)D level. For all the above outcomes, due to the substantial power, I reached 
effect estimates close to null with very narrow confidence interval (i.e., high precision 
of the estimates). 
 
Additionally, I implemented the Egger’s MR. The intercept item of Egger’s MR tests 
for the existence of unbalanced pleiotropy. If there are no pleiotropic effects among all 
the instruments, or there are pleiotropic effects of several instruments in opposite 
directions and they cancelled out, the intercept item would not be statistically 
significant (P > 0.05). This means that the effect estimates derived from two-stage MR 
and IVW MR are valid and precise. In my MR Egger’s regressions, the P values of the 
intercept term for all outcomes were greater than 0.05, indicating no evidence of 
unbalanced pleiotropy among the variants I used (Table 53). 




Table 52. Mendelian Randomization causal effect estimates. 
Method beta se P-value OR 95% CI N total/N cases Power 
Systolic blood pressure      319778 NA 
two-stage MR -0.669 0.449 0.137 NA NA   
IVW MR -0.648 0.451 0.210 NA NA   
Egger's regression -0.180 1.086 0.876 NA NA   
Diastolic blood pressure      319779 NA 
two-stage MR -0.121 0.251 0.629 NA NA   
IVW MR -0.117 0.251 0.661 NA NA   
Egger's regression 0.491 0.530 0.407 NA NA   
Hypertension      339256/106405 1.00 
two-stage MR -0.056 0.059 0.343 0.976 0.928-1.026   
IVW MR -0.063 0.060 0.340 0.973 0.911-1.040   
Egger's regression 0.084 0.175 0.657 1.037 0.841-1.278   
Type 2 Diabetes      339256/15958 0.97 
two-stage MR -0.060 0.126 0.632 0.974 0.876-1.083   
IVW MR -0.067 0.126 0.617 0.971 0.845-1.117   
Egger's regression 0.242 0.244 0.377 1.110 0.829-1.485   
Ischaemic Heart Disease      339256/28337 1.00 
two-stage MR 0.049 0.096 0.611 1.021 0.942-1.107   
IVW MR 0.047 0.096 0.647 1.020 0.917-1.135   
Egger's regression 0.109 0.219 0.645 1.048 0.807-1.360   
Body mass index      338172 NA 
two-stage MR 0.128 0.120 0.288 NA NA   
IVW MR 0.130 0.121 0.329 NA NA   
Egger's regression -0.099 0.213 0.665 NA NA   
Depression      339256/23294 1.00 
two-stage MR -0.216 0.102 0.034 0.911 0.837-0.993   
IVW MR -0.212 0.102 0.093 0.913 0.816-1.022   
Egger's regression -0.311 0.180 0.158 0.875 0.706-1.084   
Non-vertebral fracture      339256/23603 1.00 
two-stage MR -0.068 0.101 0.497 0.971 0.892-1.057   
IVW MR -0.074 0.101 0.495 0.969 0.867-1.083   
Egger's regression -0.092 0.265 0.747 0.961 0.700-1.320   
All-cause mortality      339256/9830 0.87 
two-stage MR 0.073 0.154 0.634 1.032 0.907-1.175   
IVW MR 0.069 0.154 0.671 1.030 0.869-1.222   
Egger's regression 0.192 0.272 0.520 1.086 0.785-1.503   
        
Abbreviations: MR, Mendelian Randomisation; IVW, inverse variance weighted; OR, odds ratio. 
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Notes: MR effect estimates were done with three different MR methods. OR was calculated as 
exponential of beta*sd (the standard deviation of log transformed 25(OH)D level in an independent 
British population, SOCCS, which was 0.430), whose unit was per sd increase of log transformed 
25(OH)D level. The upper/lower 95% CI was calculated similarly; with the same unit as OR. Power 
was calculated assuming a R square of 0.03, OR of 1.2 and significance level at 0.05.  
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Figure 37. Scatter plots for Mendelian Randomization on nine outcomes 
 
   
 
 































X axis represents SNPs’ effects on 25(OH)D level. Y axis represents SNPs’ effects on outcomes. The 
green line represents the regression line from inverse variance weighted Mendelian Randomization. 
The yellow line represents the regression line from two-stage Mendelian Randomization. The red line 
represents the regression line from Egger’s Mendelian Randomization. 
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Table 53. Results for intercept items of Egger’s regressions. 
Phenotype beta s.e. P value 
SBP -0.026 0.049 0.628 
DBP -0.033 0.024 0.236 
Hypertension -0.008 0.008 0.366 
T2D -0.017 0.011 0.198 
IHD -0.003 0.010 0.748 
BMI 0.013 0.010 0.260 
Depression 0.019 0.012 0.203 
Non-vertebral fracture 0.002 0.011 0.879 
All-cause mortality -0.007 0.012 0.614 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; T2D, type 2 diabetes; IHD, 
ischemic heart disease; BMI, body mass index; s.e., standard error. 
 
Beta, standard error and P values for intercept items of Egger’s regression for every outcome. 
Significance (P<0.05) of the intercept item indicates existence of unbalanced pleiotropy. 
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6.2.4 Sensitivity analyses 
Leave-one-out analyses 
I conducted leave-one-out sensitivity analyses for the 9 selected outcomes with the 
IVW MR. For each single outcome, I dropped one SNP at a time, and conducted IVW 
MR involving the other five SNPs as IVs. For all the nine outcomes, leaving any SNP 
out did not change the results, which indicates that the results were not due to effects 
of a specific SNP (Table 54 to Table 62). 
 
Table 54. Leave-one-out sensitivity analysis for systolic blood pressure. 
SNP beta se P-value 
rs3755967 -1.440 0.843 0.163 
rs10741657 -0.399 0.475 0.449 
rs12785878 -0.522 0.473 0.332 
rs10745742 -0.704 0.457 0.199 
rs8018720 -0.567 0.455 0.281 
rs17216707 -0.794 0.460 0.160 
 
Table 55. Leave-one-out sensitivity analysis for diastolic blood pressure. 
SNP beta se P-value 
rs3755967 -0.833 0.471 0.151 
rs10741657 0.0803 0.265 0.777 
rs12785878 -0.101 0.264 0.723 
rs10745742 -0.118 0.255 0.667 
rs8018720 -0.067 0.254 0.805 
rs17216707 -0.155 0.257 0.578 
 
Table 56. Leave-one-out sensitivity analysis for risk of hypertension. 
SNP beta se P-value OR 95% CI 
rs3755967 -0.246 0.112 0.092 0.782 0.573-1.066 
rs10741657 -0.006 0.063 0.930 0.994 0.835-1.184 
rs12785878 -0.051 0.063 0.465 0.951 0.799-1.131 
rs10745742 -0.055 0.061 0.414 0.946 0.800-1.120 
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rs8018720 -0.056 0.060 0.404 0.945 0.800-1.117 
rs17216707 -0.088 0.061 0.220 0.915 0.773-1.084 
 
Table 57. Leave-one-out sensitivity analysis for risk of type 2 diabetes. 
SNP beta se P-value OR 95% CI 
rs3755967 -0.472 0.236 0.117 0.624 0.324-1.203 
rs10741657 0.004 0.133 0.979 1.004 0.693-1.454 
rs12785878 -0.034 0.133 0.810 0.967 0.668-1.398 
rs10745742 -0.035 0.128 0.798 0.965 0.676-1.379 
rs8018720 -0.086 0.128 0.537 0.917 0.644-1.308 
rs17216707 -0.058 0.129 0.677 0.944 0.659-1.351 
 
Table 58. Leave-one-out sensitivity analysis for risk of ischemic heart disease. 
SNP beta se P-value OR 95% CI 
rs3755967 -0.151 0.180 0.449 0.860 0.522-1.417 
rs10741657 0.076 0.101 0.496 1.079 0.814-1.430 
rs12785878 0.110 0.101 0.337 1.116 0.843-1.478 
rs10745742 0.050 0.098 0.635 1.051 0.802-1.378 
rs8018720 0.032 0.097 0.756 1.033 0.789-1.352 
rs17216707 0.030 0.098 0.774 1.031 0.785-1.354 
 
Table 59. Leave-one-out sensitivity analysis for body mass index. 
SNP beta se P-value 
rs3755967 0.438 0.226 0.124 
rs10741657 0.071 0.127 0.607 
rs12785878 0.106 0.127 0.451 
rs10745742 0.126 0.122 0.362 
rs8018720 0.126 0.122 0.358 
rs17216707 0.126 0.123 0.364 
 
Table 60. Leave-one-out sensitivity analysis for risk of depression. 
SNP beta se P-value OR 95% CI 
rs3755967 -0.186 0.191 0.387 0.831 0.488-1.413 
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rs10741657 -0.197 0.108 0.141 0.821 0.609-1.107 
rs12785878 -0.205 0.107 0.128 0.815 0.605-1.097 
rs10745742 -0.227 0.104 0.093 0.797 0.598-1.062 
rs8018720 -0.222 0.103 0.097 0.801 0.602-1.066 
rs17216707 -0.213 0.104 0.110 0.808 0.605-1.079 
 
Table 61. Leave-one-out sensitivity analysis for risk of non-vertebral fracture. 
SNP beta se P-value OR 95% CI 
rs3755967 0.069 0.189 0.735 1.071 0.634-1.810 
rs10741657 -0.131 0.106 0.285 0.877 0.653-1.178 
rs12785878 -0.076 0.106 0.512 0.927 0.691-1.243 
rs10745742 -0.034 0.102 0.754 0.966 0.727-1.284 
rs8018720 -0.083 0.102 0.462 0.921 0.694-1.221 
rs17216707 -0.093 0.103 0.419 0.912 0.685-1.213 
 
Table 62. Leave-on-out sensitivity analysis for risk of all-cause mortality. 
SNP beta se P-value OR 95% CI 
rs3755967 0.113 0.289 0.716 1.119 0.502-2.498 
rs10741657 0.012 0.163 0.945 1.012 0.644-1.590 
rs12785878 0.065 0.162 0.709 1.067 0.680-1.674 
rs10745742 0.115 0.157 0.504 1.122 0.726-1.733 
rs8018720 0.076 0.156 0.649 1.079 0.700-1.663 
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Analyses excluding variants associated with UK Biobank assessment centres 
Since three SNPs (rs10741657, rs12785878 and rs10745742) were significantly 
associated with UK Biobank assessment centre I implemented a sensitivity analysis 
with the IVW MR, only including the other 3 SNPs (rs3755967, rs8018720 and 
rs17216707).  
 
Similar to the results of the MR of all 6 SNPs, I did not find any statistically significant 
association in this sensitivity analysis. All outcomes had effect estimates similar with 
the 6-SNP MR, but wider confidence intervals (Table 63). 
 
Table 63. Inverse variance weighted Mendelian Randomization with 3 SNPs. 
Phenotype beta se P-value OR 95% CI 
SBP -0.280 0.512 0.639 NA NA 
DBP 0.130 0.286 0.694 NA NA 
Hypertension 0.027 0.068 0.724 1.012 0.893-1.147 
T2D 0.094 0.144 0.579 1.041 0.798-1.359 
IHD 0.159 0.109 0.284 1.071 0.875-1.310 
BMI 0.027 0.137 0.861 NA NA 
Depression -0.206 0.116 0.217 0.915 0.739-1.134 
Non-vertebral fracture -0.093 0.114 0.504 0.961 0.778-1.188 
All-cause mortality 0.054 0.175 0.786 1.024 0.740-1.416 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; T2D, type 2 diabetes; IHD, 
ischemic heart disease; BMI, body mass index; s.e., standard error. 
Analyses were done with inverse variance weighted MR, using rs3755967, rs8018720 and rs17216707 
as instrumental variables. OR was calculated as exponential of beta*sd (the standard deviation of log 
transformed 25(OH)D level in an independent British population, SOCCS, which was 0.430), whose 
unit was per sd increase of log transformed 25(OH)D level. The upper/lower 95% CI was calculated 
similarly; with the same unit as OR. 
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Chapter VI DISCUSSION 
6.1 Introduction 
In the first chapter of this thesis, multiple aspects of vitamin D were introduced. I first 
gave a brief introduction on vitamin D, its synthesis and metabolism, its biological 
functions and the severity of vitamin D deficiency and insufficiency worldwide. Then, 
I updated an umbrella review, which summarized evidence on vitamin D and health 
outcomes from previously published meta-analyses of observational studies and RCTs, 
by searching for articles published between 2014 and 2018. In addition, I searched 
PubMed and the GWAS catalogue for all published GWAS on 25-hydroxyvitamin D 
25(OH)D concentration and summarized all the loci/genes which have been found to 
be associated with 25(OH)D. Finally, I conducted a systematic literature review for all 
previously published Mendelian Randomization studies on association between 
25(OH)D level and health outcomes, which had not been covered by the umbrella 
review of meta-analyses of observational studies and RCTs. In chapter two, I presented 
a systematic literature review on published PheWAS studies and summarized the 
methodology that was applied and the main findings from the included studies. I also 
presented a general pipeline on how to conduct and report PheWAS studies and 
discussed its advantages, disadvantages and future developments. In chapter three, I 
presented the aims and objectives and in chapter four, I described the UK Biobank 
cohort and the specific methods I used. All relevant results were reported in chapter 
five. 
 
In this chapter, I will discuss the main issues, which emerged in this study. In the first 
part of the discussion, issues regarding the methodological and analytical aspects of 
this study are presented. In particular, I discuss the strengths and limitations of the 
study design, population, and statistical methods I used. In the second part of this 
chapter, the most important findings from this study are discussed and compared with 
findings from previous published studies.  
 
6.2 Methodological and analytical issues 
In this part of the chapter, I will first discuss the strengths and limitations of the UK 
Biobank population. Then strengths and limitations of the PheWAS method and the 
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MR method, which arose in my thesis, will be discussed. 
 
6.2.1 The UK Biobank cohort 
6.2.1.1 Strengths of the UK Biobank 
The large sample size 
As described in chapter IV, the UK Biobank is a British cohort that recruited 
participants across the UK. With a sample size of ~500,000, the UK Biobank provides 
a very big population for studies on various topics. For outcomes of large sample size 
the statistical power is improved, which can be a significant challenge for a MR study 
(265). As presented in Table 49, I had an estimated statistical power of 90% for 
outcomes with more than 46,268 cases at OR of 1.10, and for outcomes with more 
than 12,644 cases at OR of 1.20. Therefore, in this cohort, there should be sufficient 
power for detecting moderate to large effect sizes for common diseases (e.g., 
hypertension, cardiovascular diseases). In contrast, eleven out of the 27 identified MR 
studies in the systematic literature review (Table 7, 11/27 = 40.7%) were of sample 
size less than 10,000 (182, 184, 185, 188, 190, 192, 193, 196, 270-272).  
 
This also holds true for the phenome wide analysis, which used logistic regression. 
From my systematic literature review for PheWAS studies, 24 out of the 45 PheWAS 
studies (Table 8, 10/20 = 50.0%) were of sample size less than 10,000 (Table 8) (199, 
201, 203-205, 207, 210, 216, 236, 237). However, since large number of phenotypes 
are tested, multiple testing burden is substantial for PheWAS. A PheWAS of 10,000 
individuals is not sufficient for surviving the multiple testing correction, especially for 
moderate to small effect outcomes. Among the studies with sample size greater than 
10,000, only five of them were of sample size larger than 100,000, ranging from 
521,000 to 1,749,400 (212, 217, 226, 228, 241). In addition, although hundreds or 
thousands of distinct phenotypes could be defined through linkage with EMR, many 
PheWAS only analyses phenotypes with more than 20 or 25 cases (due to power 
consideration). Consequently, the number of phenotypes which are selected to go to 
statistical analysis will be small for PheWAS study of limited sample size. 
 
Therefore, this study had larger statistical power for common outcomes of moderate 
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to large effects compared to previous PheWAS and MR studies of vitamin D. 
 
Comprehensive data collection 
The UK Biobank collected a wide variety of variables, covering demographic factors, 
environmental exposures, psychosocial factors, environmental factors, lifestyle 
information, health status and physical and functional measurements (e.g., blood 
pressure, cognitive functions and hearing threshold). In addition, the UK Biobank also 
acquired hospital inpatient data, cancer and death registry data and asked for the health 
status and medical history in baseline assessment and verbal interviews with 
participants. This expanded the number of phenotypes, which could be tested in a 
PheWAS or MR, making my study even more comprehensive than previous studies.  
 
In addition, most previous studies used only EMR data in defining case-control status, 
which can lead to misclassification (will be further discussed in 6.2.1.2). By 
incorporating the self-reported medical data, medication history and serum/urine 
biomarkers, the UK Biobank cohort allows a better definition for cases and controls. 
 
Relative homogeneity of UK Biobank study population 
Participants of UK Biobank were recruited exclusively in the UK. They were recruited, 
measured, and interviewed according to the same protocol in all 22 assessment centres. 
Moreover, I restricted my analysis in white British participants based on their self-
reported ethnic background and ancestral PCs calculated from their genetic data. 
Therefore, the set of participants I studied was homogenous in recruitment, 
genotype/phenotype measurement, and genetic ancestry. This is expected to be 
advantageous since it is known that heterogeneity and population stratification cause 
bias and affect the implications of epidemiological studies, as discussed below.  
 
First, humans vary at both geographical and individual level (273). Populations of 
different races may vary in their physiological pathways and associations which exist 
in one ethnic group are not necessarily true in another (i.e., population differentiation). 
For example, in a study of Chinese participants, which explored the associations 
between BMI-related loci identified by GWAS from white population and BMI or 
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obesity in Chinese population, few of the loci were successfully replicated. From their 
allele frequency calculations, evidence of population stratification was shown between 
Chinese individuals and Europeans (274). Specifically for my study, the associations 
between vitamin D and health outcomes may not be universally identical for 
Europeans residing in different areas. Since European-ancestral individuals residing in 
different countries have greatly differing sun exposures, they can be expected to have 
different 25(OH)D levels. At different 25(OH)D levels, associations dominant in 
countries of lower latitude may not exist in the UK population. For example, I failed 
to replicate observed causal associations between 25(OH)D and MS (180, 181). 
Although the results from my study could be criticised for lack of power for the MS 
outcome, since there were only 986 cases, I also noticed that the inferred OR reported 
by a previous MR study was 2.0 (95%CI: 1.7-2.5, P = 7.7*10-12) (180), which was a 
large effect. With a case number of 986 and a true OR of 2.0, the estimated power for 
my analyses was nearly 100%. However, it should be acknowledged that the OR of 
2.0 originally reported by Mokry and colleagues was vulnerable to winner’s curse, 
where newly discovered true associations often have inflated effects compared to true 
effects (275). This inflation may be caused by crossing predefined P threshold in an 
underpowered sample, flexible analyses and selective reporting, which was not 
investigated in the original paper by Mokry and colleagues (180, 275). Thus, the 
difference between my result for MR and previous studies could be possibly due to 
actual biological differences between UK population and other white populations in 
lower latitude. The findings and the reason underlying them need to be investigated by 
other large studies of UK population.  
 
Secondly, in a meta-analysis of different studies, which is similar to a crude pooled 
analysis for participants from different ancestral backgrounds and geographically 
locations, it is essential to check that effect estimates from individual studies are 
similar enough (i.e., homogeneous). In a meta-analysis, the presence of heterogeneity 
may affect the statistical validity of the summary estimated effect (276). We can test 
whether there is more variation between studies than would be expected by chance 
alone. Rejection of the null hypothesis indicates the existence of heterogeneity. 
Heterogeneity could be quantified by I2, which represents the fraction of the total 




variance in the meta-analysis estimate that is due to intrinsic variability in the effect 
size, as distinct from variability arising from measurement error (277). When there is 
relative homogeneity a fixed-effect model is used in meta-analysis. Alternatively, 
when heterogeneity exists, a random-effects meta-analysis should be conducted, which 
takes the between-study variation into consideration (278). However, a valid random-
effects model depends on the assumption that effect estimates from individual studies 
follow a certain distribution pattern, such as a normal distribution. Establishing the 
validity of distributional assumptions is hard, especially for meta-analysis of small 
number of studies (279). Therefore, compared to meta-analysis or consortia with a 
similar pooled sample size, the UK Biobank provides a large prospective cohort of a 
relatively homogeneous population, which is less vulnerable to problems caused by 
heterogeneity. Conversely, it should be acknowledged that homogeneity can also limit 
statistical power, because there may be less population variability in phenotype values. 
For example it is expected that 25(OH)D levels of UK Biobank participants would 
vary less compared to the global population. 
 
There are several previous PheWAS and MR studies with sample sizes larger than 
100,000, which were comparable to the UK Biobank cohort in size but based on 
consortia data (179, 180, 186, 195, 279). For instance, the MR study on multiple 
sclerosis published by Mokry et al. had a total sample size of 14,498 multiple sclerosis 
cases and 24,091 controls from the International Multiple Sclerosis Genetics 
Consortium study (IMSGC). The MS cases of IMSGC were collected in 12 countries 
across the world, including Australia, New Zealand, Belgium, Denmark, Finland, 
France, Germany, Italy, Norway, Sweden, UK and the US, and cases from different 
sites varied in female/male rate and mean age of disease onset (280). Large study 
populations generated by pooling samples from different studies within research group 
consortia have two potential problems: differences in phenotype measurements, and 
heterogeneity/population stratification. Each study has its own study protocol, in most 
cases, and thus measure and record different phenotypes. Meanwhile, the same 
phenotype is measured by different methods (outcomes defined according to different 
criteria) and employ different quality control procedures. Thus, harmonisation of 
phenotypes from different individual studies can be problematic. Phenotype 
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heterogeneity, in both outcomes and covariates across studies, represents a major 
challenge to successful meta-analysis of common traits (281). If stark difference exists 
in phenotype definition, an effort at harmonization is essential (282). Although tools 
such as PhenX Toolkit of standardized, high priority measures is available to 
investigators planning new studies, most current consortia involve existing studies 
whose phenotypes and data collection instruments are already defined (281). This is 
the reason why some previous PheWAS manually created phenotype classes and 
categorized the various phenotypes from individual study sites into predefined classes 
(233, 234, 236). Even though they can be harmonized, this process of binning lost 
some information (234). In addition, in the situation where samples were collected 
from broad geographical areas, population stratification can be a problem as has been 
discussed above. Especially in MR analyses, population stratification violates the IV 
assumption, and it can bias the results. Therefore, studying associations between 
exposure and health outcome in a world-wide population should be implemented and 
interpreted carefully, and the issue of heterogeneity between population of individual 
studies and population stratification should be considered and tested. In their MS paper, 
Mokry and colleagues did test for heterogeneity and found an increased I2 (I2 = 63%, 
95% CI: 0% to 88%). Therefore, they compared the fixed effect model estimates with 
the random-effects model estimates. However, they did not test whether effect 
estimates from different centres complied with the random-effects model assumption. 
In addition, since they used only 4 SNPs as their IVs, they claimed that the 
heterogeneity of their study could not be accurately measured by I2 only (180). 
 
6.2.1.2 Limitations of the UK Biobank 
Misclassification of case/control status 
The phenotyping method I applied may have misclassified the case/control status. The 
UK Biobank has only released inpatient, death registry and cancer registry data, and 
therefore my phenotyping was based on those three data sources. However, in the NHS 
health care system, diseases which are less life threatening (e.g., non-vertebral fracture, 
depression, hypertension, vitamin D deficiency) are usually not monitored in hospitals, 
and thus will not be captured by the EMR data. Thus, the precision of phenotyping 
varies by phenotype. For instance, cases of depression and non-vertebral fracture were 
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mistakenly classified as controls as be seen from Table 51. A total of 13628 cases for 
depression (58.5% of the total case number in EMR plus self-reported data) and 6382 
cases for non-vertebral fracture (27.0% of the total case number in EMR plus self-
reported data) were not captured by the inpatient EMR data. Even for outcomes which 
were normally monitored in the inpatient department, cases occurred outside of the 
NHS-funded hospitals would not be captured by the UK Biobank data and thus may 
also be misclassified as controls.  
 
Although UK Biobank has the self-reported medical data collected from the baseline 
questionnaire and a verbal interview with a trained research nurse, it is impossible to 
use this data in PheWAS. The coding of the self-reported health outcomes followed a 
customized tree-structure system defined by the UK Biobank, which was different 
from the ICD coding used by EMR data. Due to this difference of coding structures, 
automatic merging of the EMR data and self-reported data for all outcomes is not 
feasible with standard computation tools. In the MR analysis of nine outcomes I 
manually merged those two sources of data. This substantially increased the number 
of cases for some outcomes, as shown in the results section (Table 51). For example, 
the merged data identified 106,405 cases for hypertension (42,317 (39.8%) from self-
reported data), 23,294 cases for depression (13,628 (58.5%) from self-reported data) 
and 23,603 for non-vertebral fracture (6,382 (27.0%) from self-reported data). Other 
outcomes, like type 2 diabetes and ischemic heart disease, were captured more 
accurately by EMR data and only 4.2% and 9.0% of the total number of cases were 
exclusively captured by self-reported data.  
 
However, self-reported medical conditions are blamed for their accuracy. In a 
systematic literature review by the UK Biobank group, which included 17 studies 
comparing patient self-reported stroke against reference standard, authors found that 
the positive predictive values of self-reported stroke varied from 22% to 87%. The 
positive predictive value increased with stroke prevalence. Hence, they concluded that 
in population-based studies, such as the UK Biobank, a large proportion of self-
reported strokes may be false positives (283). In a study of self-reported data accuracy 
for fractures in elderly women, the false positive rate of self-reported fractures was 
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11%, and it varied by fractured sites and education level (284). The issue of over 
reporting holds true for other outcomes, and the rate of false positives may vary by 
outcomes. 
 
Moreover, limitations of the phenotyping method I used may also be caused by the 
lack of access to other data, such as clinical text (e.g., medical notes, discharge 
summary, etc.). If clinical text were to be incorporated in case-control definitions (e.g., 
by natural language processing algorithm), classification accuracy would be improved 
(216). In a systematic review of 19 studies, the median of sensitivity for case definition 
increased to 78.1% by ICD coding plus text phenotyping algorithms (including 
keyword searches, machine learning algorithm and rule-based algorithm) in 
comparison with ICD coding alone definition, whose median sensitivity was 61.7% 
(285). In addition, Li and colleagues identified a total of 2609 cases, while a natural 
language procession system found 1253 cases which were not captured by the ICD 
coding system (286); Baus and colleagues found that combined use of ICD-9-CM 
codes with text significantly increases the total case number compared with ICD-9-
CM coding alone (mean = 1256.1 for ICD-9-CM plus text vs mean = 1174 for ICD-9-
CM alone) for case definition of essential hypertension (287). Therefore, fully use of 
structured and unstructured data (including billing codes, clinical notes, medications 
and lab and test results) in EMR in phenotyping algorithm is recommended by 
previous study (288).  
 
Lack of individual vitamin D data 
A valid instrumental variable must be strongly associated with the exposure of interest, 
which is serum 25(OH)D concentration in my study. Although the SNPs I selected 
came from the largest GWAS of white ancestry, which should be associated with 
25(OH)D level in the UK Biobank population as well, it would have been desirable to 
test this MR assumption in the UK Biobank sample. UK Biobank has measured several 
serum biochemical markers, including 25(OH)D. However, they have not yet released 
the data. If these data were available, in addition to testing the association between IV 
and exposure, I could also have studied the observational associations between 
25(OH)D level and outcomes by PheWAS. In addition, with individual 25(OH)D level 
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data, a GWAS for 25(OH)D in the UK Biobank can also be considered. Since its 
sample size is much larger than the recently published GWAS of vitamin D, novel 
vitamin D related loci could possibly be identified. Once the biomarker data is released 
by the UK Biobank, all the above points can be considered by future studies. 
 
Generalizability 
The previous GWAS on vitamin D included participants of white ancestry but from a 
number of different regions across the world. However, all UK Biobank participants 
reside in the UK, a high latitude country with low sun exposure on average especially 
during winter. Due to the weather conditions in the UK and the large impact of sun 
exposure on vitamin D synthesis, UK population could be of possibly lower 25(OH)D 
than populations in lower latitude areas, especially during the winter. However, as 
mentioned above, serum biomarker data has not been released, so the magnitude of 
this difference remains unknown. As indicated by the difference of R2 value between 
SOCCS individuals and previous GWAS samples (1.61% vs 2.84%), the proportion of 
25(OH)D variance explained by genetic variants in UK population might not be the 
same as that in the original GWAS. Hence the effect size for each variant might also 
diverge. Therefore, the accuracy of the application of genetic variant effects sizes from 
the SUNLIGHT GWAS to UK Biobank population is not certain, but it cannot be 
explored without the individual level 25(OH)D data. 
 
Furthermore, whether the findings from the UK population can be generalized to the 
broader white population is also a question. Previous studies suggested that the 
relationship between vitamin D concentration and health outcomes may be nonlinear. 
Reid and colleagues observed an interaction between 25(OH)D and treatment effect 
from a 2-year trial data of 452 participants. For participants with baseline 25(OH)D 
level of no more than 30 nmol/L, body mass mineral change was observed between 
treatment group and placebo group at spine and femoral sites. But when they analysed 
all participant irrespective of baseline 25(OH)D level, body mass mineral changes at 
spine and femoral sites were not statistically significant (289). Similarly, Macdonald 
and colleagues analysed other trial data of 305 postmenopausal women, and found that 
vitamin D supplementation only increased bone mineral density at spine and hip 
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among individuals with serum 25(OH)D of no more than 30 nmol/L level (290). Thus, 
the effect of 25(OH)D on health outcomes may differ by baseline serum 25(OH)D 
level. Considering the limited diversity of 25(OH)D levels of the UK population, my 
study might lack power in detecting true effect of 25(OH)D at certain levels. In 
addition, the limited diversity of 25(OH)D levels in the UK Biobank might cause a 
lower R2 level as shown above from the SOCCS sample (i.e., a lower level of the 
variance in vitamin D level is explained by genetic factors), which further decrease the 
statistical power of analysis dramatically. 
 
Finally, the recruitment policy of UK Biobank might potentially bring several 
problems. Since UK Biobank participants were invited by mail, there may be selection 
bias in the UK Biobank, which makes it an unrepresentative sample of the general UK 
population. In fact, the UK Biobank mailed 9.2 million invitations, and only 503,325 
participants responded (response rate, 5.47 %) (291). Fry and colleagues compared the 
sociodemographic, physical, lifestyle and health-related characteristics of UK Biobank 
participants with those from UK national surveys. They found that UK Biobank 
participants were more likely to be older, to be female, and to live in less 
socioeconomically deprived areas compared with UK general population. In addition, 
UK Biobank participants were less likely to be obese, to smoke or to drink and were 
of fewer self-reported health conditions (292). Their study suggested that the UK 
Biobank participants differed from the general UK population with regards of their 
social economic status, lifestyle, and disease prevalence. This selection bias could 
potentially cause invalid results (293).  
 
Selection bias is especially true for observational studies. In a MR design, values of 
instrumental variables are not expected to be associated with socio-economic status or 
lifestyle factors. My analysis for the association between the genetic score of the 6 
SNPs or individual SNPS and age/ BMI/ time spend outdoors/ income/ qualification/ 
alcohol intake frequency confirmed this. 
 
In addition, participants can withdraw the cohort without any reason at any time. When 
I first downloaded the UK Biobank data, data from 502,655 participants were available. 
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However, in the final genetic data release, only 487,411 were still available. Among 
them, 39 individuals withdrew their participation. The others were caused by low 
quality of genotyping data. As the follow up goes on, there would possibly be more in 
the future. It would be crucial to check the characteristics of withdrawn individuals in 
order to study whether drop off happens at random. Therefore, when results from the 
UK Biobank cohort are to be generalized to the general population of the UK, the 
above discussed points should be taken into consideration. 
 
6.2.2 Strengths and limitations of the PheWAS methodology 
6.2.2.1 Strengths of the PheWAS methodology 
Taking advantage of EMR record, PheWAS tests associations between selected genetic 
variants or exposure and a wide range of phenotypes, diagnoses, traits or outcomes. In 
contrast with GWAS, which tests association between genetic variants and a single or 
a small selection of outcomes (e.g., blood pressure, BMI), PheWAS focuses on the 
broad associations between predetermined exposure and a comprehensive range of 
outcomes. As a reverse GWAS, which is hypothesis generating as well, PheWAS is an 
important tool for identifying new biomarkers, elucidating genetic architecture of 
complex traits, and uncovering pleiotropy (294). Previous PheWAS studies have 
successfully validated known associations, and identified novel associations as well 
(section 2.2.1). In addition, Moore and colleagues implemented a PheWAS for 
associations with 5,954,294 polymorphisms and 27 laboratory phenotypes in 2,547 
individuals from human immunodeficiency virus clinical trial data. They found 10,963 
nominal genotype-phenotype associations (P < 0.01), and 29 possibly novel 
association (e.g., rs10494326 with neutrophil counts and rs2201841 with plasma 
chloride concentration) (236). A limitation of their study might be that although they 
tested ~1.6 million associations, they defined their statistical significance threshold as 
P < 0.01 in both datasets and consistent direction between the two datasets (they split 
4 trials into two comparable datasets to seek internal replication), rather than 
implementing any statistical process controlling for multiple testing burden. However, 
their study did suggest the possibility of PheWAS for identifying pharmacogenomic 
associations. Moreover, when applied in trial data, PheWAS can also be used to 
identify side/adverse effects of treatment factor (e.g., medication) effectively, without 
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any prior assumptions.  
 
In this study, I comprehensively studied the association between 6 vitamin D related 
SNPs, a score of 6 SNPs and 920 outcomes. In fact, I used it in combination with 
Mendelian Randomisation, forming a MR-PheWAS design as the study published by 
Millard and colleagues (235). Compared with traditional single outcome MR studies, 
this design can simultaneously explore causal associations between selected predictor 
and great number of phenotypes.  
 
Previous studies were mainly for establishing methods and workflow for PheWAS of 
different types. But they have successfully demonstrated the value of PheWAS for 
genomic research, including replicating known associations and identifying suggestive 
novel associations. It is possible that PheWAS will become a powerful tool used by 
both clinicians and basics scientists. Studies conducted in trial data were good 
examples for this (236, 243). In addition, PheWAS is also useful for clinicians in real-
word environment. Since EMRs have large numbers of individuals, who were exposed 
to multiple drug across their lifetime, important relationships between genetic 
variation and pharmacological responses as well as the factor of time and age could be 
highlighted (295). Moreover, as the cost of developing new drugs increasing over the 
past 60 years, PheWAS provides attractive opportunities for drug repurposing through 
its high-throughput computational analysis (296). For basic physiologist, PheWAS 
will complement experimental research and help validate insight gained from studying 
genes and gene variants in model organisms (297). 
 
In the near future, the construction of large Biobanks linked with EMRs, which also 
collect broad range of epidemiological phenotypes (e.g., the UK Biobank), could help 
generate promising findings from PheWAS. Despite its good potential, PheWAS is still 
in its early age. It has several limitations as listed below, which should be conquered 
by methodological improvements. 
 
6.2.2.2 Limitations of the PheWAS Methodology 
PheWAS heavily relies on the phenotyping method/algorithm it applied. In my study, 
Chapter VI: Discussion 

 
I employed a phecode system developed by Denny and colleagues (207). This 
algorithm defines cases and controls with ICD codes, which included hospital inpatient 
ICD codes, cancer and death registry codes. As it has been discussed in section 6.2.1.2, 
this phenotyping method might cause substantial issues with misclassification. It 
should be acknowledged that the algorithm for phenotyping is yet to be fully developed. 
To make the algorithm perform better, the following efforts could be considered. 
Firstly, incorporate self-reported data in phenotype definition. In the subsequent MR 
analyses, I merged EMR data with self-reported data for a selection of outcomes. The 
UK Biobank group is also conducting similar work as well. They adjudicate 
phenotypes for individuals based on their hospital in-patient data, cancer/death registry 
and self-reported data by algorithm. Cases were reported as prevalent cases or incident 
cases. Prevalent cases were reported as identified by EMR (with or without self-report) 
or identified by self-reported only. Incident cases were reported as identified by EMR 
or identified by register data. They have released adjudicated outcomes for myocardial 
infarction and stroke outcomes, and outcomes on more common diseases will be 
released in the future. In addition, leverage clinical text in case/control definition. 
Although large amounts of medical notes were generated, they were not fully exploited 
in PheWAS. With the development of deep neural networks, clinical text processing 
programmes are expected which manipulate text and can assign case/control status for 
health outcomes effectively in a high throughput way. Moreover, a good classifier 
could take data from multiple sources (e.g., EMR codes, clinical texts, lab data, 
imaging data), integrate them and give reliable judgements on the case/control status 
for diseases. There have been several medical information extraction algorithms based 
on natural language processing, for instance cTAKES and MedLEE (298). In addition, 
Denny and colleagues developed 13 algorithms which incorporate EMR codes with 
clinical text, medication and lab data (for phenotypes cataract, dementia, type 2 
diabetes, diabetic retinopathy, resistant hypertension, peripheral arterial disease, 
primary hypothyroidism, low levels of high-density lipoprotein cholesterol and 
baseline lipid values, red blood cell indices, white blood cell indices, normal cardiac 
conduction and height) (202). However, the information extraction algorithms are 
criticized as being unable to capture subtle relationships hidden in clinical notes, since 
the language is complex and algorithms lack explicit semantic resources describing 
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the relationships between clinical concepts (298). The algorithms developed by Denny 
and colleagues focused on selected diseases, which were determined on clinical 
priority and their research interest. Therefore, extra efforts are still needed in algorithm 
development, especially in making a complex algorithm, which integrates multiple 
source data and defines case/control status for all diseases comprehensively.  
 
As mentioned above, the statistical power of genotype-phenotype association depends 
on the number of cases for each health outcome. Although a total of 1853 phenotypes 
were defined through EMR data by the phecode system, only 920 outcomes had more 
than 200 cases and were included in the analysis. This threshold of 200 cases was 
based on a previous simulation for PheWAS power (299). The reasons for employing 
a case number threshold was to exclude low power phenotypes, release multiple testing 
burden, and meanwhile, to comprehensively explore associations for as many 
outcomes as possible. 
 
Since large number of phenotypes are tested simultaneously in a PheWAS, there is a 
great multiple testing burden. In GWAS, a total of 1 million independent variants 
across the whole genome is examined, so applying a Bonferroni correction, a P value 
of smaller than 5*10-8 is considered as statistically significant. To guarantee the 
repeatability of the results, replication in independent samples is usually conducted. 
However in a PheWAS, phenotypes are usually correlated. Applying Bonferroni 
correction, which divide 0.05 by the number of tested phenotypes, is over conservative. 
In my study, the phecode system first binned ICD codes according to their clinical 
relationship, and then I applied Bonferroni correction. However, this did not guarantee 
that all the phecode groups were independent, so the application of Bonferroni 
correction in my study also had the problem of being over conservative. Alternatively, 
false discovery rate (FDR) could be considered in controlling for multiple testing 
burden. In a conventional hypothesis testing, the P threshold of 0.05 controls the false 
positive rate of being lower than 5%, which means that if one implemented 100 
independent tests, there would be at most 5 false positives. FDR is the expected 
fraction of tests declared statistically significant in which the null hypothesis is true 
(300). The Benjamini and Hochberg procedure is a common choice in FDR correction. 




It first ranks all P values in ascending order, then it finds the largest P value where Pi 
< d * i/n (i denotes the rank of P value, d denotes the significance level (e.g., 0.05), n 
denotes the total number of tests). All associations with P values of less than this P 
value (including this value) are declared as statistically significant (301). FDR retains 
more statistical power compared to Bonferroni correction, but it does not take the 
correlation of phenotypes into consideration. Recently, a new Bayesian algorithm, 
which implements a Markov process, has been developed by Cortes and colleagues. 
They have shown that their Bayesian framework could increase statistical power by 
20% and identified novel associations in the UK Biobank cohort (302). The strength 
of their approach is that it analyses the association between exposure and all ICD codes 
of every coding level (i.e., I21 (acute myocardial infarction) and I21.0 (acute 
transmural myocardial infarction of anterior wall) are analysed as independent codes) 
while the relationships between codes can be handled by the Markov process. On the 
other hand, this Bayesian framework is more computationally intensive compared with 
traditional general linear models. 
 
GWAS has proved its good replicability, however, the replicability for PheWAS may 
be lower. As has been discussed above, the current algorithm for high-throughput 
phenotyping is imperfect (problem of misclassification). So case-control status of 
different populations collected by different studies/clinical centres might be biased in 
different directions, causing associations observed in one population not replicated in 
another one. There are not many previous PheWAS which use different populations or 
split one cohort into two parts for discovery and replication in one study. Three 
previous studies analysed genotype-phenotype associations in different populations, 
and defined associations which were consistent and significant in more than one 
populations as statistically significant (233, 234, 236). However, these studies only 
reported the associations which met their criteria of cross-population statistical 
significance. It could be not estimated from their study that how many associations 
were significant only in one population. In 2015, Bolland and colleague conducted a 
PheWAS in a population of 1,749,400 from the Columbia University Medical Centre. 
They studied association between birth month and 1688 diseases and found that 55 
diseases were significantly associated with birth month (212). In their study, nine 
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cardiovascular related outcomes were significant, including atrial fibrillation, essential 
hypertension, congestive cardiac failure, angina, coronary arteriosclerosis, 
cardiomyopathy, pre-infarction syndrome, chronic myocardial ischemia and mitral 
valve disorder. In 2016, Li and colleague tried to replicate their findings from an 
independent population of 1,169,599 individuals from the Mount Sinai Hospital (217). 
Among the nine significant cardiovascular outcomes in the previous study by Bolland 
and colleagues, four outcomes (coronary arteriosclerosis, essential hypertension, 
angina, and pre-infarction syndrome) were significant and three outcomes (atrial 
fibrillation, cardiomyopathy, and chronic myocardial ischemia) were of consistent 
pattern but not significant. Association for congestive cardiac failure and mitral valve 
disorder were not replicated by the latter study. As the convention for GWAS, 
independent replication is vital for study findings drawn from EMRs (217). In addition, 
future developments in better phenotyping algorithms as discussed above could help 
in implementing PheWAS of better replicability. In my thesis, I did not have another 
cohort of comparable size to the UK Biobank. However, splitting the UK Biobank into 
different sub-populations according to the assessment centre (or genotyping array) and 
seeking replication is a potential choice. 
 
6.2.3 Strengths and Limitations of Mendelian Randomization Method 
6.2.3.1 Strengths of Mendelian Randomization Method 
MR study is a cost-effective analogy to trials by using genetic variants as instrumental 
variables in testing causal associations between exposures and outcomes. In 
observational studies, statistically significant association could possibly exist between 
independent exposure and outcome variables if a confounding factor is associated with 
both exposure and outcome. Thus, associations identified from observational studies 
should not be interpreted as causal. However, genotypes of individuals are not affected 
by most confounding factors (e.g., social economic status, environmental exposure), 
since they are determined randomly at conception. By using genetic variants as 
instrumental variables, Mendelian Randomization is able to explore the putative causal 
association between exposure (e.g., 25(OH)D) and health outcomes.  
 
Compared to RCTs, MR studies are easier to implement in large samples. The process 
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of randomization for a MR study happens at conception for every participant when 
alleles are randomly allocated into gametes, rather than as a step in the experimental 
design of the RCT. MR study is more cost-effective by omitting the randomization and 
following up steps which are essential in a trial. It can recruit population based samples 
and study the causal association between life-long exposure of specific factor and 
health outcome retrospectively. If used in large biobanks with biorepository (e.g., UK 
Biobank cohort), it is feasible to be implemented in very large population.  
 
6.2.3.2 Limitations of Mendelian Randomization Method 
Although MR is generally not influenced by the common confounding factors and 
not seriously affected by reverse causality, it does rely on several assumptions that 
can be hard to identify and control and has several crucial issues that need to be 
noted when interpreting their results. I will discuss these issues in this section. 
 
MR assumptions 
The three main assumptions that underpin the MR method are: 1) the instrumental 
variable is associated with exposure; 2) the instrumental variable is not associated with 
any confounder of the exposure-outcome association; 3) the instrumental variable is 
conditionally independent of the outcome given the exposure and confounders (267). 
 
Assumption 1: 
Genetic variants should be statistically significantly associated with the exposure 
variable to be a valid instrumental variable. Furthermore, if the variance of exposure 
variable explained by the instrumental variable is small, it could reduce the statistical 
power of MR (265). Thus, a weak instrument is an issue that should be explored by 
MR studies. This can be measured by the F statistic. F statistic depends on sample size, 
number of instruments, and R2 (proportion of variance of exposure explained by 
instruments). The bias induced by weak instrument is shown to be 100/F percent of 
the observational association between exposure and outcome. Thus, instruments with 
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F statistic of larger than 10 (i.e., bias is around 10% of the observational estimate) are 
generally considered to be robust (269). However, as criticized by Burgess and 
colleagues, estimating bias simply on F statistics measured from data is not enough 
(303). In their study, they spilt a cohort into 16 equally sized substudies, implemented 
two-stage MR for each of them, and then derived the summarized causal effect 
estimate by fixed-effect meta-analysis. As shown by their data, F statistics of the 16 
substudies varied from 3.4 to 22.6. Substudies with larger F statistics were of higher 
causal effect estimate values and tighter CIs, while the causal effect estimate was near 
0 when the whole cohort is analysed in MR. Although strong instruments are desirable, 
any guidance that relies on providing a threshold, such as excluding instruments or 
studies if F < 10, may introduce more bias than it prevents (303). Therefore, issues of 
weak instruments should ideally be pre-specified before data collection, by specifying 
sample sizes, instruments and genetic models based on the best prior evidence 
available. In addition, adjusting for covariates in models also helps reducing weak 
instrument bias (303). 
 
This issue is especially important for vitamin D, since it is highly affected by 
environmental factors, such as sun exposure, when compared to other traits (e.g., 
height, body mass index). From previous twin studies, the hereditability of 25(OH)D 
concentration was estimated to be ~70% (304, 305). However, the largest GWAS 
conducted by SUNLIGHT consortium identified 6 GWAS significant SNPs, and they 
explained only 2.84% of the variance of 25(OH)D. I judged the adequacy of my 
instruments based on the fact that the SNPs were significantly association with 
25(OH)D level from GWAS and that the F statistic for the score was 45.96 (calculated 
from SOCCS sample). Since F statistics is correlated with sample size, the F statistics 
calculated from UK Biobank would be larger. In addition, the wide application of the 
4 loci (DHCR7, CYP2R1, GC, CYP24A1) as IVs in previous MR on vitamin D and the 
strong associations of all 6 loci with 25(OH)D level in GWAS provide prior evidence 
supporting the validity of the IVs in my study. Despite this, it should be acknowledged 
that the very low percentage of variance explained is a major limitation of my study.  





This assumption would be violated if subgroups in the study population have both 
different genotype frequencies and different distributions of the outcome (population 
stratification), or if there is an association between the genetic instruments and 
confounders. In my study, the genotype distributions of 3 SNPs were statistically 
significantly different across UK Biobank assessment centres, which is an indication 
of population stratification. The polymorphism rs12785878 showed a clear pattern of 
genotype changing with latitude, while the other two (rs10741657 and rs10745742) 
did not show a clear pattern. I included UK Biobank assessment centre, longitude and 
latitude of home address and the first 5 ancestral principle components as covariates 
in my MR analyses to adjust for the potential bias induced by population stratification. 
The cause of associations between rs10741657, rs10745742 and UK Biobank 
assessment centers should be further explored. This could possibly be caused by 
genotyping error or biased sampling, but I cannot explore this with my current data. 
This issue can be checked with another independent sample collected from the whole 
UK, or just the affected geographical areas, whose minor allele frequencies are 
different from other areas. 
 
Assumption 3: 
This assumption is likely to be violated when the genotype has multiple (pleiotropic) 
effects, and there is another pathway other than the targeted exposure (i.e., vitamin D) 
through which instrument can affect outcomes. PheWAS is a good way to explore 
pleiotropy since associations between score or SNP and all disease outcomes were 
tested. From my PheWAS results, only associations between rs107216707 and kidney 
outcomes or alveolar and parietoalveolar pneumonopathy survived Bonferroni 
correction, which suggested possible pleiotropic effect of rs107216707. My results did 
not suggest pleiotropic effect of the other 5 SNPs or the score.  
 
When pleiotropy is present significant associations found from MR between targeted 
exposures and outcomes might be false positives, which are actually caused by the 
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causal association between another exposure and outcome. Sensitivity analysis can be 
considered to explore and control the existence of pleiotropy. This can be performed, 
as in my study, by dropping one variant in turn and implementing MR with the other 
variants. If the observed association in MR with all variants were dominant by any 
single variant of pleiotropic effect, the result excluding that variant would differ. In 
addition, Egger’s regression could be considered in testing the existence of pleiotropy 
and get an unbiased effect estimate, which will be discussed below. 
 
In order to examine the assumptions and to obtain robust causal estimates, several MR 
statistical methods have been proposed, including two-stage MR, MR IVW and MR 
Egger. I will discuss these MR methods in the following sections. 
 
Two Stage Mendelian Randomization 
The score of 6 SNPs which I constructed was a sum score, weighted by the SNPs effect 
estimates from the largest-published GWAS (158). In a two-stage MR, the first stage 
is to fit a model for the association between the IV and the exposure, which had already 
been done by the SUNLIGHT GWAS (158). Afterwards, the second stage is to fit the 
level of exposure predicted by the IV for each participant (i.e., the process of 
calculating the score of 6 SNPs in my study), and run a logistic regression between the 
genetic determined exposure level and health outcomes. Therefore, in this way, my 
PheWAS for the score of 6 SNPs equals the second stage in a two-stage MR. The 
causal estimate is the second-stage regression coefficient that is explained as the 
change in the outcome caused by a unit change in the exposure and the estimator is 
expressed as a causal relative risk or odds ratio (306, 307). However, a drawback of 
conducting a two-stage MR in this way is that the standard error in the first stage 
(association between genetic variants and exposure) is not considered, and the 
estimated standard error of coefficients and P values would be inflated. Despite this, 
the two-stage estimator with a logistic regression second-stage model still provides a 
valid test for the null hypothesis. 
 
Inverse Variance Weighted Mendelian Randomization 
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Inverse variance weighted (IVW) Mendelian Randomization is a combination of the 
ratio method and meta-analysis. The causal estimate for a single instrument could be 
calculated by the ratio method, which is the coefficient of the regression of outcome 
on the variant divided by the coefficient of the regression of exposure on the variant. 
If multiple instruments are employed, the ratio estimate from each instrument is then 
pooled with an inverse-variance weighted meta-analysis. In an IVW MR, the IV-
specific causal estimates are equivalent to the study-specific estimates in meta-analysis, 
and the weights are the inverse-variance weights (267). The causal effect estimate is 
derived by a weighted linear regression, where the residual standard error is set to one 
and the intercept is constrained to zero. This equals to a fixed-effect meta-analysis. It 
is assumed that there is no heterogeneity between individual effect estimates for each 
SNP when applying a fixed-effect model. When substantial heterogeneity presents, 
IVW MR is not recommended. In addition, IVW also relies on the three MR 
assumptions as listed above. If all three are met, the causal effect estimate from IVW 
MR is robust and unbiased. However, assumptions 2 and 3 might be violated when 
using multiple genetic variants as instruments. To check these assumptions, I thus 
applied the MR Egger method to assess whether the genetic variants have any 
pleiotropic effects (directional pleiotropy). 
 
Egger’s Mendelian Randomization 
The Egger’s MR method is developed to provide robustness against misspecification 
of the MR assumption 3 (268). Egger’s MR assumes that the correlation between the 
genetic associations with the exposure and the direct effect of the genetic variants on 
the outcome is zero, termed the InSIDE assumption, rather than using the original 
assumption 3 (268). In Egger’s MR, the intercept term is no longer restricted to zero 
as in IVW MR. If the intercept is zero (referred as ‘balanced pleiotropy’), the InSIDE 
assumption is satisfied, and the estimates from Egger’s MR should be similar to 
estimates from IVW MR. If the intercept differs from zero (rejection of the null 
hypothesis), the InSIDE assumption is violated (referred as ‘directional pleiotropy’). 
In this situation, the IWW MR estimates are biased, but Egger’s MR provides effect 
estimates closer to true effect compared with IVW MR (268). Hence, testing the 
intercept from the MR Egger analysis provides an assessment of the validity of the IV 
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assumption. Although the Egger’s MR is more robust in dealing with pleiotropy, this 
method also has some limitations, which include the precision of the estimate, the 
influence of outlying variants, and the limited statistical power. These limitations 
should be noted when interpreting results from Egger’s MR. 
 
Accurate effect estimate from Egger’s MR requires the consistency of the effects 
across the genetic variants. When pleiotropic variants were employed as IVs, 
heterogeneity between the causal estimate of individual variant would be observed. 
This would result in over-dispersion in the MR Egger regression, in which a random-
effects model is preferred. Therefore, the standard error of the causal estimate from 
the MR Egger method (random-effects model) is typically larger than that from the 
MR IVW method (fixed-effect model) and accordingly the 95%CI of the causal 
estimate from the MR Egger method is also wider than that from the MR IVW, which 
would result in an imprecise estimate (308). 
 
In addition, the MR Egger estimate is easily influenced by an outlying variant (268). 
If one variant has a much stronger association with the exposure than others, this 
variant would have a larger influence on the coefficients in the Egger’s MR compared 
with other variants. Thus, the causal effect estimate from Egger’s MR would be 
dominated by this outlying variant. Among the 6 variants I employed, rs3755967 (GC) 
had a much larger effect on 25(OH)D concentration than other variants (shown in 
figure 37). This implied that the Egger’s MR results might be biased by this variant. 
Hence, I implemented sensitivity analyses afterwards in which I excluded rs3755967 
and only used the other 5 variants. But the results were not changed by excluding 
rs3755967. 
 
Finally, Egger’s MR is of limited power, which is a common issue shared by all MR 
methods. The statistical power of MR methods depends on variance of exposure 
explained by the IVs, estimated effect size, number of cases, case/control ratio and the 
P-value threshold. The number of cases impacts the statistical power a lot. In my study, 
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I analysed 920 outcomes in the PheWAS using a score of 6 SNPs. This was based on 
a rough power estimation for PheWAS, rather than a power estimation for an MR. If I 
assumed a R2 of 0.03 and a control/case ratio of 5 or larger, phenotypes with more than 
9000 cases would have a power of more than 80% for detecting an OR of 1.2 or larger 
at a 0.05 alpha level. Based on this calculation, only 9 outcomes had sufficient power 
in MR analysis, including systolic blood pressure, diastolic blood pressure, risk of 
hypertension, risk of type 2 diabetes, risk of ischaemic heart disease, body mass index, 
risk of depression, risk of non-vertebral fracture, and all-cause mortality. Although the 
PheWAS for the score equalled a two-stage PheWAS, the high P values for outcomes 
with small sample size did not necessarily mean that there is not causal association 
between 25(OH)D concentration and the outcome due to the limited statistical power 
for low-sample-size phenotypes.  
 
6.3 Findings from the thesis 
In this part of the chapter, the following results from my thesis will be presented and 
discussed: 1) Genotypic distribution; 2) Confounding factors; 3) PheWAS results; 4) 
MR results. 
 
6.3.1 Genotypic distribution 
I first checked whether genotype frequencies of the selected variants distribute evenly 
across different assessment centres. A significant difference might imply population 
stratification, which violate the MR assumption. The frequencies of rs3755967, 
rs8017720 and rs17216707 were distributed evenly across all UK Biobank recruitment 
centres. However, for the other three SNPs, including rs10741657, rs12785878 and 
rs10745742, genotypes from UK Biobank assessment centre differ significantly. For 
the rs12785878, participants recruited from Edinburgh and Glasgow had a G allele 
frequency of 0.191 and 0.190, respectively. However, participants from middle 
England had a slightly higher allele frequency. The frequencies for G allele from Leeds 
and Manchester were 0.207 and 0.204, respectively. Centres from south UK had even 
higher frequencies. For instance, the G allele frequencies for participants from Oxford 
and Bristol were 0.223 and 0.218, respectively. When I pooled participants from 
Scotland together (i.e. Edinburgh centre and Glasgow centre), and tested the genotype 
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counts of Scotland versus all other centres, the P value for difference was lower than 
2.2*10-16. This showed an uneven distribution of genotype across latitudes, which was 
consistent with data reported by a previous study (309). In this study with 6,877 
participants from the 1958 British birth cohort, authors tested the associations between 
five vitamin D related SNPs (rs4588 (GC), rs12785878 (DHCR7/NADSYN1), 
rs10741657 (CYP2R1), rs6013897 (CYP24A1), rs10877012 (CYP27B1)) and multiple 
confounding factors, including region, sun cover, time spent outside, physical activity, 
oily fish intake, socioeconomic class at age of 42 years (309). In their study, the 
geographical region of residence was based on Government Office Regions, and were 
classified into South (South East, South West, and Greater London), Middle (East 
Anglia, Midlands, and Wales), North (North, North West, and Yorkshire and the 
Humber), and Scotland. When used as an outcome in the analysis, region was 
dichotomized into South/Middle vs North/Scotland. From their analyses, rs12785878 
(DHCR7/NADSYN1) was statistically significantly associated with geographical 
region (P = 3.0*10-5). This genotype difference is an indication of population 
stratification. This may be caused by various reasons, including drift and selection. 
Drift and selection are evolutionary processes which would affect genetic variation 
within and among populations (310). The actual cause and implication of this allele 
frequency difference across latitude needs to be explored by further population 
genetics studies. 
 
Although rs10741657 was associated with assessment centre, it did not show any 
association with region or location. It seemed that only participants from Wrexham 
(Wales, n = 490, 0.562) and Cardiff (Wales, n = 12,781, 0.587) were of lower G allele 
frequencies compared with participants from other assessment centres (P value for chi 
square test was 0.001). When I pooled participants from Edinburgh and Glasgow 
together, the P value for participants from Scotland vs England/Wales was 0.878, 
suggesting that the distribution of rs10741657 genotype does not differ by latitude. 
This is consistent with the results from the 1958 British birth cohort study. In their 
study, rs10741657 was not associated with region either (311). From another MR study 
of Scottish sample, the G allele frequency for rs10741657 was 0.608, which was 
similar to the allele frequency of Scottish participants in this study (190). Alternatively, 




this difference was not well explained by population stratification (Wales population 
vs all others) or genotype distribution across longitude. The third assessment centre in 
Wales was Swansea, whose allele G frequency was 0.604 (n = 1,620), even higher than 
those centres in England and Scotland. Meanwhile, Swansea is the most western centre, 
which is of higher allele frequency, while Wrexham and Cardiff locate between 
Swansea and all other centres but were of relative low allele frequencies. The genotype 
distribution of this polymorphism needs to be further explored by other studies of 
independent samples.  
 
In addition, rs10745742 (AMDHD1) was also found to be associated with assessment 
centre in this analysis. The distribution of its genotype did not show any gradient 
across geographical region either. Participants from Edinburgh had similar genotype 
frequency to those from southern centres (C allele frequency 0.628), which was a large 
difference from those participants from Glasgow centre (C allele frequency 0.643). In 
fact, participants from Cardiff (Wales, n = 12,698, 0.639), Glasgow (Scotland, n = 
12,613, 0.643), Wrexham (Wales, n = 482, 0.658) and Swansea (Wales, n = 1,611, 
0.661) were of higher C allele frequency compared with participants in other centres. 
The P value for Cardiff/Glasgow/Wrexham/Swansea vs other centres were smaller 
than 2.2*10-16. HapMap and 1000 Genomes have reported its C allele frequencies to 
be 0.58 (n = 1,006, 1000 Genomes, EUR) and 0.55 (n = 104, HapMap, CEU) in 
European ancestry, respectively, which were close to the majority of assessment 
centres except for Cardiff, Glasgow, Wrexham and Swansea. I did not find any other 
previous studies reporting the allele frequency of this SNP in human of European 
ancestry. The genotype distribution of rs10745742 in the UK need to be further studied 
by other studies. 
 
The polymorphism rs12785878 is the only SNP showing clear evidence of population 
stratification, which might invalidate the variants as a IV and bias the results. In my 
PheWAS and MR analysis the first 5 PCs, assessment centre and latitude/longitude of 
home address were included in the analysis. Thus, the effect of population stratification 
should be controlled. Furthermore, I also conducted sensitive analysis excluding 
rs12785878. Relevant results will be further discussed in section 6.3.3. 
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6.3.2 Confounding factors 
In addition to UK Biobank assessment centre, I also investigated whether the score or 
individual SNPs were associated with other common confounding factors, including 
age, BMI, time spend outdoors in summer, time spend outdoors in winter, average 
household income, educational qualification and alcohol intake frequency. 
 
The score was not associated with any confounding factors except for assessment 
centre, implying that the score was a good instrumental variable for MR analyses. 
Since first 5 PCs, assessment centre, and home address was adjusted in my analysis 
models, the PheWAS and MR results for the score should be free from these common 
confounding factors. 
 
The variant rs10741657 (CYP2R1) was associated with BMI (P = 0.038) and sex (P = 
0.036) in general. This shows that the genotype frequency diverges in different genders. 
However, since the P value is close to 0.05, this association is only nominal significant. 
The difference in genotype frequency might be brought about by sampling bias. When 
stratified by sex, this variant is not associated with BMI (P = 0.212 in females; P = 
0.156 in males).  
 
The variant rs12785878 (DHCR7) is associated with educational qualifications in both 
genders and females (P = 0.046 in both genders; P = 0.024 in females). Through 
literature search on PubMed and search on the GWAS catalogue, I did not find 
previous studies reporting any association between rs12785878 and educational 
qualifications. It was only reported by GWAS to be associated with 25(OH)D level. 
The variant rs17216707 is associated with alcohol intake frequency in males (P = 
0.022). Through a literature search, rs17216707 was reported to be associated with 
glomerular filtration rate and vitamin D level by previous studies. There has not been 
any study reporting its association with alcohol intake. Since the P values for 
rs12785878 with educational qualifications and for rs17216707 with alcohol intake in 
males were only nominal from my results, my thesis merely provided any evidence 
supporting these associations. 
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At last, the variant rs3755967 (GC), rs10745742 (AMDHD1), rs8018720 (SEC23A) 
was not associated with any common confounding factor except for assessment centre. 
 
6.3.3 Findings from PheWAS analyses 
I first implement PheWAS for each of the 6 variants individually. Single-variant 
phenome wide analyses might reveal health outcomes associated with each variant, 
and evidence of pleiotropy. In addition, it might identify associations between single 
variant and outcomes which is independent of the vitamin D pathway. In these single-
variant PheWAS, I did not find any significant or suggestive association for 
rs12785878 (DHCR7) and rs10745742 (AMDHD1). Results for the other 4 SNPs will 
be further discussed below.

Results of the PheWAS for rs3755967 (GC) 
None of the phenotypes were statistically significantly associated with rs3755967 at a 
P-value of 5.44*10-5 (i.e., after applying Bonferroni correction). It was found to be 
suggestively associated with pilonidal cyst (overall and in males), and with otitis 
externa (in females) at P level of smaller than 0.001. Pilonidal cyst is a type of cyst 
filled with hair and skin debris, which always occurs in the lower back. There is not 
any previous study which has reported an association between GC or rs3755967 and 
pilonidal cyst. Otitis externa is caused by inflammation of the ear canal, which often 
presents with ear pain, swelling of the ear canal, and sometimes decreased hearing. I 
did not find any previous study exploring association between GC or rs3755967 and 
otitis externa. In addition, by searching the GWAS catalogue, there have not been any 
outcomes reported to be associated with rs3755967 other than vitamin D level. Since 
my MR analysis did not support any association between 25(OH)D level and pilonidal 
cyst or otitis externa, the suggestive association observed by me was unlikely to be 
caused by vitamin D levels. This might be caused by other biological pathways linked 
with GC gene or other nearby mutation or genes which are correlated with rs3755967 
in surrounding area. Future studies with sequencing data or fine mapping of 
surrounding area may be helpful to explore the reason of this observed associations.  
 
Results of PheWAS for rs10741657 (CYP2R1) 
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In a pooled PheWAS including both sexes, rs10741657 was not statistically associated 
with any outcome. However, its associations with nephrotic syndrome, labyrinthitis 
and complications of cardiac/vascular device, implant, and graft were suggestive at a 
P < 0.001 level. Nephrotic syndrome refers to excessive proteinuria, with associated 
hypoalbuminemia, edema and hyperlipidemia (312). Labyrinthitis is an inner ear 
infection, which causes labyrinth to be inflamed and affects hearing and balance. 
CYP2R1 is involved in the synthesis of cholesterol, steroids and other lipids.  The 
mechanism linking CYP2R1 to the above three outcomes is unknown, and there have 
not been studies reporting associations between CYP2R1 and those three outcomes. 
Through a GWAS catalogue search, this variant has only been reported to be 
associated with vitamin D level and vitamin D deficiency by previous GWAS (158, 
159). 
 
In males, none of the tested outcomes survived Bonferroni correction, but associations 
with premature cardiac beats and carcinoma in situ of skin were suggestive at a P < 
0.001 level. A premature beat is an extra heartbeat resulting from abnormal electrical 
activation originating in the ventricles before a normal heartbeat would occur. 
Similarly, there is not any previous evidence (including any published GWAS) linking 
CYP2R1 with premature beats or carcinoma in situ of skin in either gender. These 
associations suggested by my study may need to be further explored by other studies. 
Future cross-sectional studies with sequencing data or fine mapping of the surrounding 
region, or cell/animal studies may help to unravel the true biological pathways causing 
these associations. 
 
Results of PheWAS for rs8018720 (SEC23A) 
The polymorphism rs8018720 was not statistically significantly associated with any 
outcome. However, the results suggested associations with “myalgia and myositis” 
and “rheumatic disease of the heart valves” at P < 0.001 level. There have not been 
any previous publications reporting associations between rs8018720 or gene SEC23A 
and myalgia, myositis or rheumatic disease of the heart valves. There is not any 
previous GWAS studies reporting association between rs8018720 and outcomes other 
than vitamin D level. The encoded protein SEC23A was suggested to be involved in 
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ER-Golgi protein trafficking (313). The mechanisms linking SEC23A with the above 
three outcomes, if any, may need to be elucidated by future studies. 
 
Results of PheWAS for rs17216707 (CYP24A1) 
The associations between rs17216707 and “calculus of ureter”, “urinary calculus”, 
“alveolar and parieto-alveolar pneumonopathy” survived Bonferroni correction in the 
analysis including participants of both sexes. Associations between rs17216707 and 
“calculus of kidney” were suggested in both sexes and females, and associations with 
“urinary calculus” and “calculus of ureter” were suggested in females and males at a 
P level of less than 0.001.  
 
As described in section 1.3, the gene CYP24A1 encodes 25(OH)D-24-hydroxylase 
which hydroxylase the side chain of 1,25(OH)2D and degrade it to 24,25(OH)2D (165). 
In addition, 1,25(OH)2D can be finally transformed into calcitroic acid, which is 
secreted in bile. Thus, it plays an important role in calcium homeostasis. There have 
been previous studies reporting associations between mutations in CYP24A1 and 
hypercalcemia, hypercalciuria, and kidney diseases (e.g., nephrolithiasis and 
nephrocalcinosis) (314, 315). Previous studies were case reports, so my study observed 
the association between CYP24A1 and renal stones at population level for the first time 
with a very large sample size. My results suggest that the association between 
CYP24A1 and renal outcomes might not be caused by the causal effect of 25(OH)D. 
Gene GC explained a larger variance of 25(OH)D concentration compared to 
CYP24A1, but the associations between GC variant and renal outcomes were at a P 
value of greater than 0.001 level. In addition, in the MR analysis, when I combined all 
6 SNPs together, the association between vitamin D and renal outcomes was not 
statistically significant. In a previous study it was suggested that in chronic kidney 
disease patients, elevated serum phosphate and fibroblast-like growth factor 23 levels 
would increase CYP24A1 expression, which causes downstream vitamin D deficiency 
and contributes to other complications of renal disease (316). The role of CYP24A1 in 
risk of kidney stones and other related outcomes, which is independent of 25(OH)D 
level, deserves further study by future laboratory, animal and other population level 
studies. 




In short, by single-variant phenome wide analyses, novel associations for the 4 SNPs 
were suggested, which provide evidences for future studies. 
 
6.3.4 Findings from MR analyses 
Following the single-variant phenome wide analyses for each of the 6 SNPs 
individually, I explored causal associations between 25(OH)D level as an exposure 
and broad health outcomes with a PheWAS for score of 6 SNPs and further MR 
analyses. Since the PheWAS used a score of 6 SNPs weighted by their effect estimates 
from previous GWAS, which equals the 25(OH)D level predicted by genetic variants, 
the results from the PheWAS equalled a two-stage MR. In the PheWAS, none of the 
phenotypes survived Bonferroni correction. Therefore, the PheWAS implied that there 
was no causal effect of vitamin D on all the 920 outcomes tested. 
 
Although with a limited cases number (n=291), vitamin D deficiency came out as the 
outcome with the third smallest P value among all the phenotypes I tested (P=0.00116) 
in the PheWAS of score, suggesting the validity of the instrument and methodology I 
applied. Since the EMR data I used in the PheWAS was from hospital inpatient data, 
cancer registry and death registry, I suspect that a large number of cases for vitamin D 
deficiency were missed by the EMR dataset. Because this condition is largely under-
detected and not normally treated in hospital, and participants would not commonly 
be aware of its presence.  
 
At last, in the final MR analyses, I merged the EMR data I used in PheWAS with self-
reported medical conditions in case/control classification, in order to capture cases 
missed by EMR data. I merged phenotype data for nine outcomes, and conduct MR 
analyses of three different methods (Table 52). Results from the MR analyses will be 
discussed and compared with previous MR studies below. 
 
Evidence from a previous MR study by Kunustor et al. did not find any significant 
association between vitamin D (instrument of 4 SNPs) and SBP or DBP in a sample 
of 69,395 individuals (176). Another study by Skabby et al. also did not observe 
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significant association (178). However, in a MR study using summary data, involving 
up to 50 individual studies, DBP and risk of hypertension were found to be statistically 
significantly associated with vitamin D in a sample of more than 140k participants 
(DBP: -0.29 mmHg, 95% CI: -0.52 to -0.07, P = 0.01; risk of hypertension: OR = 0.92, 
95% CI: 0.87 to 0.97, P = 0.002) (179). In my study, by merging the self-reported data, 
I had SBP and DBP values for 319,778 participants, and 106,405 cases of hypertension. 
The estimated power for detecting an effect with an odds ratio of 1.2, assuming 
explained variance of 0.03 of 25(OH)D level, is 1.00. However, the effect estimates 
from my analysis were -0.648 mmHg (s.e.=0.451, P=0.210) for SBP, -0.117 mmHg 
(s.e.=0.251, P=0.661) for DBP, and 0.973 (95% CI: 0.911-1.040, P=0.340) for risk of 
hypertension per standard deviation increase of log transformed vitamin D level by 
IVW MR. Since I used participants from the same study, the phenotype collections 
(blood pressure measurement, and hypertension diagnosis and coding) were measured 
consistently across the whole cohort. As noted above due to the study design 
characteristics of UK Biobank data from this study might be expected to be less 
vulnerable to the problem of population stratification, which may be an issue for MR 
based on summary statistics and may cause false positives. In accordance to two 
previous MR studies (176, 178), my study suggests that there is no moderate to large 
causal effect (greater than 1.2) of vitamin D on blood pressure outcomes and risk of 
hypertension. 
 
Type 2 diabetes has a high global prevalence and the association between vitamin D 
and T2D was summarized as suggestive by evidence from previous observational 
studies and RCTs (25). Most of the previous MR studies did not support any causal 
effect of vitamin D on risk of T2D (170, 173, 317), except for one (171). In my study, 
I had 15,958 cases for T2D and a 97% estimated power of detecting an effect of 1.2. 
However, the observed OR estimation for risk of T2D was 0.971 (95% CI: 0.845-1.117, 
P=0.971) per standard deviation increase of log transformed vitamin D level. 
Comparing results from the present study and results from previous MR studies, I 
provided evidence arguing a null causal effect of vitamin D and T2D. 
 
Similarly, the association between vitamin D and cardiovascular diseases was also 
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suggestive by the previous umbrella review (25). However, none of the previous MR 
studies observed any causal effect (175, 177). In my phenotype data incorporating 
EMR and self-reported data, I had 28,337 cases for ischemic heart disease and 1.00 
power of detecting an OR of 1.2. The estimated OR from my study was 1.020 (95% 
CI: 0.971-1.135, P=0.647) per standard deviation increase of log transformed vitamin 
D level for IHD. Thus, my study did not support any causal effect of vitamin D on 
IHD.  
 
From the previous umbrella review summarizing evidence from observational studies 
and RCTs, the association between 25(OH)D level and BMI was suggestive (25). 
However, two previous MR studies did not find any statistically significant association 
(173, 195). In my sample of UK Biobank cohort, the estimated effect was 0.130 
(SD=0.121, P=0.329) kg/m2 per SD increase of log transformed vitamin D level. Thus, 
current evidence from MR analyses does not support a causal effect of vitamin D on 
BMI. 
 
From the previous umbrella review summarizing evidence from observational studies 
and RCTs, the association between 25(OH)D level and risk of depression was 
suggestive (25). However, to the best of my knowledge this association has never been 
tested in a MR study. My study is the first one to explore the effect of vitamin D on 
risk of depression in a large prospective cohort. In the merged dataset of EMR data 
and self-reported data, I had 23,294 cases for depression, and 1.00 power of detecting 
a true effect of 1.2. However, the estimated causal OR from IVW MR was 0.913 (95% 
CI: 0.816-1.022, P=0.093). My study does not support any causal association between 
vitamin D and risk of depression. 
 
The first biological function vitamin D was found to be involved in was calcium 
absorption and metabolism (318) and it is widely believed vitamin D would be causally 
associated with bone related outcomes. According to the previous umbrella review, the 
association between vitamin D and non-vertebral fractures was concluded as 
suggestive (25). From my systematic literature review of previous MR studies on 
vitamin D, I did not find any MR study on non-vertebral fracture. However, I found 
Chapter VI: Discussion 

 
one on bone mineral density (BMD) and bone metabolism biomarkers. Li et al. 
explored associations between 25(OH)D level and BMD at the lumbar spine, BMD at 
femoral neck, total hip BMD, parathyroid hormone and procollagen type 1 N-terminal 
pro-peptide in 1,824 postmenopausal Chinese women with four 25(OH)D related 
variants as IVs. In their observational analysis, individual vitamin D levels showed a 
statistically significant association with all the above outcomes. However, when they 
used the four SNPs as IVs and conducted MR analyses with two-stage least square 
model, none of the association retained statistical significance (193). I tested the causal 
association between vitamin D IVs and risk of non-vertebral fracture with 23,603 cases 
in UK Biobank data (power = 1.00, for an OR of 1.2). The OR estimation by IVW MR 
from my study was 0.969 (95% CI: 0.867-1.083, P=0.495). The results from my study 
do not support any role of vitamin D in risk of non-vertebral fractures. To investigate 
the effect of calcium, vitamin D or combination of calcium and vitamin D on incidence 
of fracture, Zhao et al. conducted a systematic literature review. They included 33 
randomized trials with a total of 51,145 participants, which compared calcium, vitamin 
D or combined calcium and vitamin D supplements with a placebo or no treatment for 
fracture incidence in community-dwelling adults older than 50 years. Specific 
outcomes they tested included hip fracture, non-vertebral fracture, vertebral fracture 
and total fracture. However, they did not find statistically significant associations for 
most of the fracture outcomes. From their meta-analyses, the RR was 0.95 (95% CI: 
0.82-1.11, P=0.54), 1.10 (95% CI: 1.00-1.21, P=0.05) and 0.88 (95% CI: 0.75-1.03, 
P=0.10) for calcium, vitamin D and calcium plus vitamin D supplementation on 
incidence of non-vertebral fracture, respectively (319). To summarise, results from my 
MR study with UK Biobank did not show any causal link between vitamin D and the 
risk of non-vertebral fractures, and similarly a recent systematic review summarizing 
the evidence from previous trials did not support effect of calcium or vitamin D on 
incidence of fractures.  
 
Finally, all-cause mortality was tested in MR analyses. In a previous MR, Afzal et al. 
created a score of 4 SNPs as IV and studied its association with mortality outcomes in 
95,766 white Danish (10,349 cases for all-cause mortality). For all-cause mortality, the 
OR estimation was 1.3 (1.05-1.61) per 20 nmol/L lower 25OHD level (187). In UK 
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Biobank cohort, I had a total of 9,830 deaths in my post QC white British sample, and 
an 87% power detecting a true OR of 1.2. From the IVW MR, the estimated OR was 
1.030 (95% CI: 0.907-1.175, P=0.671). Although previous MR found a statistically 
significant effect of vitamin D for all-cause mortality with an OR of 1.3, I have shown 
that I have enough power at an OR of 1.2 with the UK Biobank sample. The 
inconsistency between the two studies could be further explored by future studies. 
 




Chapter VII. Conclusions and Recommendations 
In this last chapter, I will draw the main conclusions of my thesis. In addition, 




The work I have done in this thesis was comprised of three parts. A systematic 
literature review of previous studies; a PheWAS analysis, which explores the 
association between genetic variants and hundreds of outcomes; and a MR analysis, 
which explored the causality between 25(OH)D level and selective outcomes. From 
systematic literature reviews (updated umbrella review for vitamin D, review for 
PheWAS studies and review for MR studies on vitamin D), I showed that vitamin D 
have been associated with numerous outcomes, but with conflicting evidence from 
previous studies. The PheWAS suggest possible novel associations between single 
variants and outcomes, and identify significant associations between CYP24A1 and 
renal outcome, which is independent of the vitamin D pathway. The MR analyses did 
not support causal associations between vitamin D level and any health outcomes with 
large sample size and good statistical power. 
 
7.1.1 Main conclusions from systematic literature reviews 
The first vitamin D umbrella review was published in 2013. Since then there have been 
95 new meta-analyses of observational studies or RCTs. The research area of studying 
the association between vitamin D and non-skeletal outcomes keeps growing fast. For 
the systematic literature review on MR, there have been only 29 studies, which met 
my inclusion criteria. Although associations between vitamin D and several health 
outcomes were probable or suggestive based on evidence from observational studies 
or RCTs, the associations were poorly replicated by MR studies. Considering the 
consistency of evidence from observational studies, MR studies and RCTs, convincing 
evidence on causal associations between vitamin D and outcomes is still lacking. In 
addition, only a small number of outcomes have been studied by MR. As a method to 
establish causal relationship, it is still not widely used in vitamin D studies. 
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7.1.2 Main conclusions for PheWAS analysis 
Although around 900 outcomes were tested for a weighted score of 6 SNPs and 
individual SNPs, there were no statistically significant associations, except for the 
associations between rs17216707 (CYP24A1) and kidney stone related outcomes. My 
results implicate that gene CYP24A1 may be associated with stone formation in kidney, 
and this association is independent of effect of 25(OH)D level. 
 
7.1.3 Main conclusions for MR analysis 
The results from MR analyses suggested that there was no evidence of large to 
moderate (OR>1.2) causal associations of vitamin D on a very wide range of health 
outcomes. I provided evidence of greater power for nine outcomes, including SBP, 
DBP, risk of hypertension, risk of type 2 diabetes, risk of ischemic heart disease, body 
mass index, risk of depression, risk of non-vertebral fracture, risk of all-cause mortality, 
for which I merged the EMR data and self-reported medical data. Results from 
different MR methods were consistent. Egger’s regression shows that there is no 
evidence of unbalanced pleiotropy. Excluding any single SNP or using only 3 SNP 
which were not associated with UK Biobank assessment centre did not change the 
results. These all supported that the results of null finding are robust. 
 
Furthermore, even larger studies, probably involving the joint analysis of data from 
several large biobanks with extra IVs that explain a higher proportion of the trait 
variance, will be required to exclude smaller causal effects, which could have public 
health importance because of the high prevalence of low vitamin D levels in some 
populations. 
 
Although MR assumes a linear model in general, methods which can deal with non-
linear effects are in development. Silverwood and colleagues proposed a method based 
on estimating local average treatment effects for discrete levels of exposure ranges, 
then testing for a linear trend in those effects (320). Future MR on vitamin D which 
exploit non-linear models are needed. 
 




When the UK Biobank releases the general practice data in near future, it will be 
valuable to merge general practice data with inpatient data and registry data. This will 
help identify more cases and meanwhile allow inclusion of diseases that are rarely 
admitted to hospital. Since the general practice data use a different system from that 
of inpatient data, extra efforts will be needed to harmonise those data. In addition, an 
algorithm which could deal with the different coding structure of EMR data and self-
reported data and merge them automatically for all outcomes would be helpful. As the 
UK Biobank follow up goes on, more incident cases will occur, which will increase 
statistical power for outcomes. With all the efforts above, more cases will be identified 
in the future which should result in increasing statistical power over time. Thus, 
another future PheWAS on vitamin D with the UK Biobank cohort may reveal novel 
findings or give more certainty about the lack of associations with health outcomes. 
 
My study studied only white British individuals. To study the effect of vitamin D more 
comprehensively, PheWAS and MR study in cohorts of comparable size but with 
different populations (e.g., residing at lower latitude areas, having different lifestyles, 
sun exposure, diets ) is needed, since vitamin D exposure is highly related to latitude, 
sun exposure and other factors. By comparing results from populations of distinct 
geographical regions, the differentiation of 25(OH)D effect and its underlying 
biological pathway can be understood.  
 
Future genetic studies are also needed, since a big proportion of the heritability of 
25(OH)D is still missing. Missing heritability has been an issue for GWAS of all traits. 
Firstly, GWAS of larger sample size is needed (e.g., GWAS of 25(OH)D in the UK 
Biobank cohort). GWAS of larger sample is of greater power, which can identify loci 
of tiny effects which could not be found by smaller GWAS. In addition, the missing 
heritability might also be explained by rare variants or gene-environment interaction. 
Hence, sequencing studies and interaction studies are also needed. When more loci 
associated with 25(OH)D level are discovered, stronger IV explaining larger 
proportion of 25(OH)D variance can be constructed. Then more powerful MR study 
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